Cover page
Cover page | 12 Months Ended |
Dec. 31, 2021shares | |
Entity Information [Line Items] | |
Document Type | 20-F |
Document Registration Statement | false |
Document Annual Report | true |
Document Period End Date | Dec. 31, 2021 |
Current Fiscal Year End Date | --12-31 |
Document Transition Report | false |
Document Shell Company Report | false |
Entity File Number | 001-39777 |
Entity Registrant Name | NANOBIOTIX S.A. |
Entity Incorporation, State or Country Code | I0 |
Entity Address, Address Line One | 60 rue de Wattignies |
Entity Address, Postal Zip Code | 75012 |
Entity Address, City or Town | Paris |
Entity Address, Country | FR |
Title of 12(b) Security | Ordinary shares, nominal value €0.03 per share |
Security Exchange Name | NASDAQ |
Entity Common Stock, Shares Outstanding | 34,825,872 |
Entity Well-known Seasoned Issuer | No |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Accelerated Filer |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
ICFR Auditor Attestation Flag | false |
Document Accounting Standard | International Financial Reporting Standards |
Entity Shell Company | false |
Entity Central Index Key | 0001760854 |
Document Fiscal Year Focus | 2021 |
Document Fiscal Period Focus | FY |
Amendment Flag | false |
No Trading Symbol Flag | true |
Business Contact | |
Entity Information [Line Items] | |
Entity Address, Address Line One | 60 rue de Wattignies |
Entity Address, Postal Zip Code | 75012 |
Entity Address, City or Town | Paris |
Entity Address, Country | FR |
Contact Personnel Name | Mr. Bart van Rhijn |
City Area Code | 33 |
Local Phone Number | (0)1 40 26 04 70 |
Contact Personnel Fax Number | 33 (0)1 40 26 04 44 |
American depositary shares, each representing one ordinary share, nominal value €0.03 per share | |
Entity Information [Line Items] | |
Title of 12(b) Security | American depositary shares, each representing one ordinary share, nominal value €0.03 per share |
Trading Symbol | NBTX |
Security Exchange Name | NASDAQ |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2021 | |
Auditor Information [Abstract] | |
Auditor Name | ERNST & YOUNG et Autres |
Auditor Firm ID | 1704 |
Auditor Location | Paris-La Défense, France |
STATEMENTS OF CONSOLIDATED FINA
STATEMENTS OF CONSOLIDATED FINANCIAL POSITION - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Non-current assets | ||
Intangible assets | € 4 | € 21 |
Property, plant and equipment | 8,186 | 8,256 |
Non-current financial assets | 519 | 505 |
Total non-current assets | 8,709 | 8,782 |
Current assets | ||
Trade receivables | 0 | 62 |
Other current assets | 9,139 | 6,035 |
Cash and cash equivalents | 83,921 | 119,151 |
Total current assets | 93,060 | 125,248 |
TOTAL ASSETS | 101,769 | 134,030 |
Shareholders’ equity | ||
Share capital | 1,045 | 1,033 |
Premiums related to share capital | 255,767 | 255,735 |
Accumulated other comprehensive income | 643 | 555 |
Treasury shares | (202) | (196) |
Reserve | (183,459) | (153,069) |
Net loss for the period | (47,003) | (33,590) |
Total shareholders’ equity | 26,790 | 70,468 |
Non-current liabilities | ||
Non-current provisions | 318 | 414 |
Non-current financial liabilities | 37,816 | 44,107 |
Total non-current liabilities | 38,134 | 44,522 |
Current liabilities | ||
Current provisions | 110 | 40 |
Current financial liabilities | 8,204 | 4,872 |
Trade payables and other payables | 6,482 | 7,106 |
Other current liabilities | 5,531 | 7,022 |
Deferred revenues and contract liabilities | 16,518 | 0 |
Total current liabilities | 36,845 | 19,041 |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | € 101,769 | € 134,030 |
STATEMENTS OF CONSOLIDATED OPER
STATEMENTS OF CONSOLIDATED OPERATIONS - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Revenues and other income | |||
Revenues | € 10 | € 50 | € 68 |
Other income | 2,637 | 2,462 | 2,473 |
Total revenues and other income | 2,647 | 2,512 | 2,541 |
Research and development expenses | (30,378) | (24,330) | (30,411) |
Selling, general and administrative expenses | (19,434) | (14,611) | (18,909) |
Other operating income and expenses | (5,414) | 0 | 0 |
Total operating expenses | (55,226) | (38,941) | (49,320) |
Operating income (loss) | (52,579) | (36,428) | (46,779) |
Financial income | 6,360 | 201 | 837 |
Financial expenses | (780) | 2,646 | (4,970) |
Financial income (loss) | 5,580 | 2,847 | (4,133) |
Income tax | (5) | (9) | (3) |
Net loss for the period | € (47,003) | € (33,590) | € (50,915) |
Basic loss per share (in euro per share) | € (1.35) | € (1.38) | € (2.35) |
Diluted loss per share (in euro per share) | € (1.35) | € (1.38) | € (2.35) |
STATEMENTS OF CONSOLIDATED COMP
STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of comprehensive income [abstract] | |||
Net loss for the period | € (47,003) | € (33,590) | € (50,915) |
Actuarial gains and losses on retirement benefit obligations (IAS 19) | 182 | (4) | 88 |
Tax impact | 0 | 0 | 0 |
Other comprehensive loss that will not be reclassified subsequently to income or loss | 182 | (4) | 88 |
Currency translation adjustment | (94) | 125 | (36) |
Tax impact | 0 | 0 | 0 |
Other comprehensive income that may be reclassified subsequently to income or loss | (94) | 125 | (36) |
Total comprehensive loss | € (46,915) | € (33,469) | € (50,863) |
STATEMENTS OF CONSOLIDATED CHAN
STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS’ EQUITY - EUR (€) | Total | Share capital Ordinary shares | Premiums related to share capital | Accumulated other comprehensive income (loss) | Treasury shares | Reserve | Net loss for the period |
Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2018 | 19,633,373 | ||||||
Equity at beginning of period at Dec. 31, 2018 | € 14,243,000 | € 589,000 | € 122,799,000 | € 381,000 | € (124,000) | € (79,057,000) | € (30,345,000) |
Net loss for the period | (50,915,000) | (50,915,000) | |||||
Currency translation adjustments | (36,000) | (36,000) | |||||
Actuarial gains and losses (IAS 19) | 88,000 | 88,000 | |||||
Total comprehensive loss | (50,863,000) | 52,000 | (50,915,000) | ||||
Allocation of prior period loss | 0 | (30,345,000) | 30,345,000 | ||||
Capital increase, net (in shares) | 2,566,666 | ||||||
Capital increase, net | 28,079,000 | € 77,000 | 28,002,000 | ||||
BSPCE exercise (in shares) | 215,000 | ||||||
BSPCE exercise | 1,306,000 | € 6,000 | 1,300,000 | ||||
Subscription of warrants | 21,000 | 8,000 | 13,000 | ||||
Share based payment | 4,320,000 | 4,320,000 | |||||
Treasury shares | (45,000) | (45,000) | |||||
U.S. Initial public offering costs offset | 1,030,000 | 1,030,000 | |||||
Number of shares outstanding at end of period (in shares) at Dec. 31, 2019 | 22,415,039 | ||||||
Equity at end of period at Dec. 31, 2019 | (1,908,000) | € 672,451.17 | 153,139,000 | 433,000 | (169,000) | (105,070,000) | (50,915,000) |
Net loss for the period | (33,590,000) | (33,590,000) | |||||
Currency translation adjustments | 125,000 | 125,000 | |||||
Actuarial gains and losses (IAS 19) | (4,000) | (4,000) | |||||
Total comprehensive loss | (33,469,000) | 121,000 | (33,590,000) | ||||
Allocation of prior period loss | 0 | (50,915,000) | 50,915,000 | ||||
Capital increase, net (in shares) | 12,017,083 | ||||||
Capital increase, net | 102,942,000 | € 361,000 | 102,591,000 | (10,000) | |||
Subscription of warrants | 5,000 | 5,000 | |||||
Share based payment | 2,924,000 | 2,924,000 | |||||
Treasury shares | (27,000) | € (27,000) | |||||
U.S. Initial public offering costs offset | (10,700,000) | ||||||
Number of shares outstanding at end of period (in shares) at Dec. 31, 2020 | 34,432,122 | 12,970 | |||||
Equity at end of period at Dec. 31, 2020 | 70,468,000 | € 1,032,963.66 | 255,735,000 | 555,000 | € (196,000) | (153,070,000) | (33,590,000) |
Net loss for the period | (47,003,000) | (47,003,000) | |||||
Currency translation adjustments | (94,000) | (94,000) | |||||
Actuarial gains and losses (IAS 19) | 182,000 | 182,000 | |||||
Total comprehensive loss | (46,915,000) | 88,000 | (47,003,000) | ||||
Allocation of prior period loss | 0 | (33,590,000) | 33,590,000 | ||||
Capital increase, net (in shares) | 393,750 | ||||||
Capital increase, net | 0 | € 12,000 | (12,000) | ||||
Subscription of warrants | 43,000 | 32,000 | 11,000 | ||||
Share based payment | 3,201,000 | 3,201,000 | |||||
Treasury shares | (6,000) | € (6,000) | |||||
Number of shares outstanding at end of period (in shares) at Dec. 31, 2021 | 34,825,872 | 15,456 | |||||
Equity at end of period at Dec. 31, 2021 | € 26,790,000 | € 1,044,776.16 | € 255,767,000 | € 643,000 | € (202,000) | € (183,460,000) | € (47,003,000) |
STATEMENTS OF CONSOLIDATED CASH
STATEMENTS OF CONSOLIDATED CASH FLOWS - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Cash flows used in operating activities | |||
Net loss for the period | € (47,003) | € (33,590) | € (50,915) |
Elimination of other non-cash, non-operating income and expenses | |||
Depreciation and amortization | 1,560 | 1,754 | 1,767 |
Provisions | 152 | (48) | 164 |
Expenses related to share-based payments | 3,201 | 2,924 | 4,320 |
Cost of net debt | 2,224 | 2,115 | 1,940 |
Loss on disposals | 0 | 0 | 45 |
U.S. Initial public offering 2018 costs reversal | 0 | 0 | 201 |
Impact of deferred income related to financial liabilities discounting effect | (1,554) | (6,463) | 2,833 |
Other charges with no impact on cash | 8 | 7 | (5) |
Cash flows used in operations, before tax and changes in working capital | (41,412) | (33,300) | (39,647) |
(Increase) / Decrease in trade receivables | 62 | (51) | (85) |
Decrease in Research tax credit receivable | 1,927 | 5,688 | 0 |
Increase in other receivables | (5,034) | (721) | (4,640) |
Increase / (Decrease) in trade and other payables | (281) | (995) | 2,057 |
Increase / (Decrease) in other current liabilities | (1,652) | 1,840 | 1,146 |
Increase in deferred income and contract liabilities | 16,518 | 0 | 0 |
Changes in operating working capital | 11,540 | 5,762 | (1,522) |
Net cash flows used in operating activities | (29,872) | (27,538) | (41,169) |
Cash flows from (used in) investing activities | |||
Acquisitions of intangible assets | (5) | (11) | (353) |
Acquisitions of property, plant and equipment | (228) | (96) | (1,091) |
Addition in non-current financial assets | (9) | (4) | (16) |
Net cash flows from (used in) investing activities | (242) | (112) | (1,459) |
Cash flows from financing activities | |||
Capital increases | 0 | 113,650 | 29,517 |
Warrants subscription | 43 | 5 | 1,327 |
Transaction costs | (349) | (10,359) | (1,438) |
Increase in loans and conditional advances | 0 | 10,350 | 14,000 |
Loans repayments | (2,833) | (250) | (500) |
Payment of lease liabilities | (909) | (928) | (1,067) |
Interest paid | (1,132) | (700) | (350) |
Net cash flows from financing activities | (5,180) | 111,769 | 41,489 |
Effect of exchange rates changes on cash | 64 | (63) | 29 |
Net increase (decrease) in cash and cash equivalents | (35,230) | 84,056 | (1,109) |
Net cash and cash equivalents at beginning of period | 119,151 | 35,094 | 36,203 |
Net cash and cash equivalents at end of period | € 83,921 | € 119,151 | € 35,094 |
Company information
Company information | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure Of Information Related To The Company [Abstract] | |
Company information | Company information Presentation of the Company Nanobiotix S.A. was incorporated in 2003 as a spin-off from the State University of New York (SUNY) in Buffalo. Nanobiotix S.A. (together with its subsidiaries, the “Company”), is headquartered in Paris, France. The Company is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, as well as the utility and efficacy of radiotherapy. Its lead product candidate, NBTXR3, is an aqueous suspension of functionalized crystalline metallic nanoparticles approximately 50 nanometers (50 billionths of a meter) in diameter, designed for injection directly into a malignant tumor. When exposed to ionizing radiation, NBTXR3 amplifies the localized, intratumor killing effect of that radiation. NBTXR3 is designed to enhance the overall efficacy of radiotherapy without resulting in additional side effects on the surrounding healthy tissues. Alongside the Company’s core NBTXR3 development program, the Company is also pursuing a development program to explore the use of radiotherapy-activated NBTXR3 in combination with immune checkpoint inhibitors across several solid tumor indications. The Company is listed on the Euronext regulated market in Paris (under the ticker symbol “NANO”; Code ISIN: FR0011341205, Bloomberg code: NANO:FP) and on the Nasdaq Global Select Market (under the ticker symbol “NBTX”). Significant events of the period Nanobiotix and PharmaEngine mutually agree to terminate their collaboration In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, Nanobiotix and PharmaEngine mutually agreed to terminate the licensing and collaboration agreement entered into in August 2012. Accordingly, on March 4, 2021, Nanobiotix and PharmaEngine entered into a termination and release agreement (the “ Termination Agreement ”). Under the Termination Agreement, Nanobiotix retained all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. Nanobiotix agreed to make total termination payments to PharmaEngine of up to $12.5 million in the aggregate as described below. PharmaEngine was eligible for and received in March 2021 a $2.5 million payment following the announcement of Nanobiotix’s collaboration with LianBio for the Asia-Pacific region. In May 2021, PharmaEngine received an additional $4.0 million in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration. PharmaEngine will be eligible to receive an additional $1.0 million in administrative fees and a final payment of an additional $5.0 million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive a low-single digit tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region. As of December 31, 2021, these future payments were not accrued because the triggering events have not occurred. As part of the Termination Agreement, PharmaEngine re-assigned to Nanobiotix rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated. Nanobiotix and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates. Nanobiotix partners with LianBio for the development and commercialization of NBTXR3 in several oncology indications and in combination with several anti-cancer therapies, in China and other Asian markets In May 2021, Nanobiotix entered into a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix’s lead product candidate, NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy. LianBio will also support the expansion of global phase III registrational study in head and neck cancer into Greater China with longer term strategic alignment across multiple tumor indications and therapeutic combinations. Under the terms of the agreement, the Company received a $20 million upfront payment and is entitled to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. The Company will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. LianBio will fund all development and commercialization expenses in the collaboration territory, and the Company will continue to fund all development and commercialization expenses in all other geographies. Nanobiotix announces the appointment of Dr. Gary Phillips as Chairman of the Supervisory Board In May 2021, Dr. Gary Phillips was appointed Chairman of the Company's supervisory board of the Company (“the “ Supervisory Board ”). Dr Phillips succeeded Laurent Condomine, who retired from the Supervisory Board after 11 years of leadership. Nanobiotix announces the appointment of Bart Van Rhijn as Chief Financial Officer and member of the executive board of the Company to support its international expansion On June 1, 2021, the Company announced the appointment of Bart Van Rhijn, MBA, as Chief Financial Officer and member of the executive board of the Company (the “ Executive Board ”). Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeded Philippe Mauberna, who stepped down from his roles as Chief Financial Officer and Executive Board member after 8 years of service to the Company. |
General Information, Statement
General Information, Statement of Compliance and Basis of Presentation | 12 Months Ended |
Dec. 31, 2021 | |
General Information, Statement of Compliance and Basis of Presentation [Abstract] | |
General Information, Statement of Compliance and Basis of Presentation | General Information, Statement of Compliance and Basis of Presentation General principles The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders’ equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management’s supervision and were approved by the Executive Board of the Company (the “Executive Board”) and reviewed by the Supervisory Board of the Company (the “Supervisory Board”) on March 30, 2022. All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items. The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (‘‘IFRS’’) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information). The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company’s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of €83,921 thousand as of December 31, 2021, as compared to €119,151 thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication. Statement of Compliance and Basis of Presentation The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union. Those are available on the European Commission website: https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002 The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021. Application of New or Amended Standards and Interpretations The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021: • Amendments to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and • Amendments to IFRS 16 - Covid-19 Related rent concession. The application of these standards had no impact on the consolidated financial statements of the Company. Application of New or Amended Standards and Interpretations early adopted by the Company The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. Application of New or Amended Standards and Interpretations not yet applied by the Company The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 : • IFRS 17 - Insurance contracts and related amendments. No impact expected on the financial statements. • Amendment to IAS 1 - Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality”. No significant impact expected on the financial statements. • Amendment to IAS 37 - Onerous Contracts - Cost of Fulfilling a Contract. No significant impact expected on the financial statements. • Amendment to IFRS 3 - Conceptual framework . No significant impact expected on the financial statements. • Amendment to IAS 8 - Definition of an accounting estimate . No significant impact expected on the financial statements. • Amendments to IAS 16 - Property, Plant and Equipment: Proceeds before Intended Use . No significant impact expected on the financial statements. |
Consolidation principles and me
Consolidation principles and methods | 12 Months Ended |
Dec. 31, 2021 | |
Significant Accounting Policies [Abstract] | |
Consolidation principles and methods | Consolidation principles and methods 3.1 Basis of consolidation Accounting policy In accordance with IFRS 10 – Consolidated Financial Statements , an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company’s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control. All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full. The accounting methods of the Company’s subsidiaries are aligned with those of the Company. The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $1.1326 as of December 31, 2021 and an average of $1.1835 for the year ended December 31, 2021 (source: Banque de France) compared with $1.2271 and $1.1413, for 2020 and $1.1234 and $1.1196 for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment. Consolidated entities As of December 31, 2021, the Company involves one parent entity, “Nanobiotix S.A.,” and five wholly owned subsidiaries: • Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014; • Nanobiotix Germany GmbH, incorporated in Germany in October 2017; • Nanobiotix Spain S.L.U., incorporated in Spain in December 2017; • Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and • Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. The consolidated financial statements as of and for the year ended December 31, 2019 include the operations of each of these subsidiaries from the date of their incorporation, excluding Curadigm Corp which was created in 2020. 3.2 Use of judgement, estimates and assumptions The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. Measurement of share-based payments The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants ( e.g. , vesting terms) and market data ( e.g. , expected share volatility) (see Note 17). Deferred tax assets Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19). The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position. Clinical trial accruals Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly. See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020. Revenue recognition In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio. See Note 15 for additional detail regarding the Company’s accounting policies for its additional sources of revenue. Fair value of financial assets and liabilities The fair value measurement of the loan granted by European Investment Bank (“EIB”) requires the Company to assess the amount of additional interest (“royalties”, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company’s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied). |
Significant transactions
Significant transactions | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of transactions between related parties [abstract] | |
Significant transactions | Significant transactions 4.1 LianBio In May 2021, Nanobiotix announced a partnership with LianBio Oncology Limited a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations. LianBio will also support the expansion of the global phase III registrational study in head and neck cancer into Greater China, while supporting longer term strategic alignment across multiple tumor indications and therapeutic combinations. As of December 31, 2021, a non-refundable upfront payment of $20 million has been collected by the Company at the signature of the LianBio Agreement. The Company is entitled to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. See Note 15 Revenues and other income for further details on this new partnership. 4.2 PharmaEngine In August 2012, the Company entered into an Exclusive License and Collaboration Agreement (as amended in 2014, the ‘‘License and Collaboration Agreement’’) with PharmaEngine, a biopharmaceutical company specializing in the development of new drugs for the treatment of cancer in Asia. Under the terms of the License and Collaboration Agreement, PharmaEngine will receive the exclusive right to further develop NBTXR3 to obtain regulatory approval, leverage the data generated by the Company’s development activities and commercialize NBTXR3 in multiple countries throughout the Asia-Pacific region. Under the same Agreement, PharmaEngine is responsible for developing (non-clinical and clinical research) and commercializing NBTXR3 throughout the contractual territory and making certain development and minimum commercial milestone payments to the Company. Key provisions of the License and Collaboration Agreement include: • An exclusive perpetual license granted to PharmaEngine, with the right to sublicense the Company’s technology in order to exploit or have NBTXR3 exploited and use the Company’s trademark in connection with the exploitation of NBTXR3 in the contractual territory (with exploitation including among others developing, obtaining and maintaining regulatory approval, commercializing, distributing, promoting and marketing); • The Company’s commitment to furnish PharmaEngine with know-how necessary and useful to develop and commercialize NBTXR3 in the contractual territory, know-how meaning any results of experimentation and pre-clinical, clinical and non-clinical trial data by providing PharmaEngine with access to an electronic data platform; and • The Company’s commitment to supplying or having supplied PharmaEngine with all quantities of NBTXR3 required and used by PharmaEngine for clinical testing and subsequent commercialization if and when regulatory approvals are obtained. In return, PharmaEngine commits to use commercially reasonable efforts to develop NBTXR3 in the contractual territory at PharmaEngine’s cost. Under the License and Collaboration Agreement, the Company has received and/or is entitled to receive: • A $1.0 million up-front payment on signature of the contract, fully received in 2012; • Payments upon the achievement of development milestones, including key stages of product development, first filing for regulatory approval, and first regulatory approval in the contractual territory; • Payments upon the achievement of commercial milestones based on specified sales thresholds; • Up to double-digit royalties based on net product sales in the Asia-Pacific region; and • Payments for the supply of NBTXR3. Potential development and commercial milestone payments, including those paid to date, amount to an aggregate of up to $56 million. The Company and PharmaEngine amended the agreement in October 2014, as part of which PharmaEngine agreed: • To join the global pivotal clinical trial of NBTXR3 for the treatment of Soft Tissue Sarcoma initiated by the Company in the Asia-Pacific area, with each party committing itself to share clinical trial results in order to increase the tested population and to accelerate growth and value creation; • To pay the first development milestone ($1 million, received by the Company in 2014) and share external clinical research organization costs charged to the Company in proportion to its contribution in recruiting the patient population included in the clinical trial; and • To pay the development milestone ($1 million, received by the Company in 2016) related to the launch of the first Phase II of the pivotal study. As of December 31, 2020, $3.0 million has been received since the signature of the License and Collaboration Agreement. The next potential milestone payment under the agreement will become payable only if PharmaEngine files a commercialization authorization of NBTXR3 in their region. In November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. While both Nanobiotix and PharmaEngine believe in the potential of NBTXR3 to improve treatment outcomes for patients with cancer, the parties have had disagreements regarding the optimal strategy for development in the Asia-Pacific region. As such, after discussion between the two parties, Nanobiotix and PharmaEngine have mutually agreed to discontinue the collaboration. This agreement to terminate the License and Collaboration agreement represents a full resolution of outstanding disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region. See Note 15 for additional detail regarding the accounting policy applied to the License and Collaboration Agreement. In March 2021, the Company and PharmaEngine mutually agreed to terminate the License and Collaboration agreement. As of December 31, 2021, the Company paid a cumulative amount of $6.5 million to PharmaEngine in accordance with the termination agreement signed between the parties. PharmaEngine will receive additional payments of $1 million upon receipt by the Company of certain clinical study reports and of $5 million upon the second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region. These future payments were not accrued because the triggering events have not occurred. 4.3 Financing Agreement with the European Investment Bank (“EIB”) In July 2018, the Company signed a non-dilutive financing agreement with the EIB to borrow up to €40 million in order to fund its research, development and innovation activities related to NBTXR3 in various therapeutic indications, subject to achieving a set of agreed-upon performance criteria. This financing is divided in three tranches: • a first tranche of €16 million, received in October 2018, subject to a 6% fixed rate and that will be fully repaid in 2023 at the latest; • a second tranche of €14 million, received in March 2019, subject to a 5% fixed rate, with repayments beginning in 2021 and continuing into 2024; and, • a last tranche of €10 million, subject to a 4% fixed interest rate, that will be fully repaid after a period of five years, which begins within one year of obtaining it. The Company has not yet met the criteria to request this tranche. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, was delayed by 12 months to July 31, 2021. As the conditions have not been met by July 31, 2021, the Company will not request the final tranche of the EIB loan. In connection with this financing agreement, the Company also entered into a royalty agreement with EIB pursuant to which the Company is required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) royalties to EIB. The amount of royalties payable is calculable based on low single-digit royalty rates, which vary according to the number of tranches that have been drawn, and indexed on the Company’s annual sales turnover. The €14 million second tranche, which was received in March 2019, was disbursed on the basis of achieving the following criteria: • Determination of the recommended dose at 22% of the tumor volume for head and neck cancers treatment following the end of the Phase I clinical trial with NBTXR3; and • Positive evaluation of the clinical benefit/risk ratio of NBTXR3 in the Phase II/III clinical trial in soft tissue sarcomas by the clinical expert mandated by the French notified body covering medical devices, GMED. See Note 22 for discussion of royalties that may be due in the case of early repayment or change of control after repayment of the loan. 4.4 Collaboration Agreement with the University of Texas MD Anderson Cancer Center In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration. The collaboration will support multiple new Phase I/II clinical trials involving around 340 patients with Nanobiotix’s product NBTXR3 for use in treating several cancer types –, including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11 million for those clinical trials during the collaboration, and made an initial $1.0 million payment at the commencement of the collaboration and a second $1.0 million payment on February 3, 2020. Additional payments were made in the six months following patients enrollment, with the balance payable upon enrollment of the final patient for all studies. Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $2.2 million to $16.4 million. As of December 31, 2021 and 2020, the Company recognized prepaid expenses for €1.0 million and €1.6 million respectively. Expenses will be recorded during the course of the collaboration in the statement of consolidated operations based on the patients enrolled during the relevant period. See Note 8.2 for further details on other current assets. |
Intangible assets
Intangible assets | 12 Months Ended |
Dec. 31, 2021 | |
Intangible assets other than goodwill [abstract] | |
Intangible assets | Intangible assets Accounting policies In accordance with IAS 38 – Intangible Assets , intangible assets are carried at their acquisition cost. Research and Development costs Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 – Intangible Assets , development costs may only be capitalized as intangible assets if the following criteria are met: • it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale; • the Company intends to complete the development of the intangible asset and use or sell it; • the Company has the ability to use or sell the intangible asset; • it is probable that the intangible asset will generate future economic benefits; • adequate technical, financial and other resources are available to complete the development of the intangible asset; and • the Company is able to reliably measure the expenditures attributable to the development of the intangible asset. The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods. Patents Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36. Software The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license. Recoverable amount of intangible assets Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount. Detail of intangible assets The change in intangible assets breaks down as follows: (in thousands of euros) As of As of January 1, 2021 Increases Decreases Transfer Currency As of December 31, 2021 Patents 65 — — — — 65 Software 651 5 — — — 657 Intangible assets in progress — — — — — — Gross book value of intangible assets 717 5 — — — 722 Patents (65) — — — — (65) Software (630) (22) — — — (652) Accumulated depreciation of intangible assets (1) (695) (22) — — — (717) Net book value of intangible assets 21 (17) — — — 4 (1) Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses (in thousands of euros) As of January 1, 2020 Increases Decreases Transfer Currency As of December 31, 2020 Patents 65 — — — — 65 Software 584 11 (5) 61 — 651 Intangible assets in progress 61 — — (61) — — Gross book value of intangible assets 710 11 (5) — — 717 Patents (65) — — — — (65) Software (483) (152) 5 (0) (0) (630) Accumulated depreciation of intangible assets (1) (548) (152) 5 — — (695) Net book value of intangible assets 163 (141) — (0) (0) 21 (1) Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses |
Property, plant and equipment
Property, plant and equipment | 12 Months Ended |
Dec. 31, 2021 | |
Property, plant and equipment [abstract] | |
Property, plant and equipment | Property, plant and equipment Accounting policies Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company’s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred. Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets. The depreciation periods used are as follows: • General fixtures and fittings, building work: 5 to 10 years; • Technical installations, equipment and industrial tooling: 3 to 10 years; and • Office and IT equipment and furniture: 1 to 10 years. Recoverable amount of property, plant and equipment Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use. Detail of property, plant and equipment The change in property, plant and equipment is as follows: (in thousands of euros) As of January 1, 2021 Increases Decreases Transfer Currency As of December 31, 2021 Fixtures, fittings and installations 3,313 5 — — — 3,318 Right of use – Buildings 7,171 1,362 (139) — — 8,393 Technical equipment 2,061 73 — 1 — 2,135 Office and IT equipment 988 53 (35) — 4 1,010 Transport equipment 31 — — — 3 33 Right of use – Transport equipment 65 — (38) — 1 28 Tangible assets in progress 1 97 — (0) — 98 Prepayments on tangible assets — — — (0) — — Gross book value of tangible assets 13,630 1,590 (212) — 8 15,017 Fixtures, fittings and installations (1,320) (320) — — — (1,641) Right of use – Buildings (1,739) (901) 30 — — (2,610) Technical equipment (1,466) (178) — — — (1,644) Office and IT equipment (783) (124) 34 — (3) (875) Transport equipment (31) — — — (3) (33) Right of use – Transport equipment (36) (12) 20 — (1) (28) Accumulated depreciation of tangible assets (1) (5,374) (1,534) 84 — (6) (6,831) Net book value of tangible assets 8,256 56 (129) — 3 8,186 In 2021, the €1,362 thousand increase in Right of use – Buildings mainly relates to the extension of Villejuif leases for 4 years for €1,390 thousand reduced by approximately €25 thousand related to rent indexation impact. The €139 thousand decrease in Right of use – Buildings relates to the termination of a lease contract in Faubourg Saint-Antoine in Paris, France. (in thousands of euros) As of January 1, 2020 Increases Decreases Other movements & transfer. Currency As of December 31, 2020 Fixtures, fittings and installations 3,297 16 — — — 3,313 Right of use – Buildings 6,766 418 (14) — — 7,171 Technical equipment 2,019 42 — — — 2,061 Office and IT equipment 957 37 (1) — (4) 988 Transport equipment 34 — — — (3) 31 Right of use – Transport equipment 115 — (41) (5) (4) 65 Tangible assets in progress 11 1 — (11) — 1 Prepayments on tangible assets — — — — — — Gross book value of tangible assets 13,197 515 (57) (15) (11) 13,630 Fixtures, fittings and installations (1,001) (320) — — — (1,320) Right of use – Buildings (829) (911) — 2 — (1,739) Technical equipment (1,272) (194) — — — (1,466) Office and IT equipment (629) (157) 1 — 2 (783) Transport equipment (34) — — 1 3 (31) Right of use – Transport equipment (45) (35) 42 — 1 (36) Accumulated depreciation of tangible assets (1) (3,811) (1,616) 43 4 6 (5,374) Net book value of tangible assets 9,386 (1,101) (14) (12) (4) 8,256 (1) Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses In 2020, the €418 thousand increase in Right of use – Buildings mainly relates to: • Two new lease contracts: one in Rue Oberkampf in Paris, France for €155 thousand, the other in Rue du Faubourg Saint-Antoine in Paris, France for €140 thousand, • The termination of a lease contract by Curadigm SAS for €43 thousand; • The addition of a parking for the Villejuif facility for €30 thousand, and |
Non-current financial assets
Non-current financial assets | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of financial assets [abstract] | |
Non-current financial assets | Non-current financial assets Accounting policies Non-current financial assets are recognized and measured in accordance with IFRS 9 – Financial Instruments. No non-current financial assets are estimated at fair value through other comprehensive income (OCI). Pursuant to IFRS 9 – Financial Instruments , financial assets are classified in three categories according to their nature and the intention of management: • Financial assets at fair value through profit and loss; • Financial assets at fair value through other comprehensive income; and • Financial assets at amortized cost. All regular way purchases and sales of financial assets are recognized at the settlement date. Financial assets at fair value through profit or loss This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable. Financial assets at amortized cost This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents. They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15. After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met: • The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired. IFRS 9 – Financial Instruments requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case–by–case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements. Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released. Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations. Detail of non-current financial assets The change in non-current financial assets breaks down as follows: (in thousands of euros) Liquidity contract - Cash account (1) Other Security Total Net book value as of December 31, 2019 131 — 399 529 Additions — — 9 9 Decreases (27) — (5) (31) Currency translation adjustments — — (2) (2) Net book value as of December 31, 2020 105 — 401 505 Additions — — 9 9 Decreases (6) — — (6) Transfer — — 8 8 Currency translation adjustments — — 3 3 Net book value as of December 31, 2021 98 — 421 519 (1) See note 10.2 Treasury shares In 2021, non-current financial assets increased by €14 thousand compared to 2020. In 2020, non-current financial assets decreased by €24 thousand compared to 2019. In 2021, the security deposits paid increased by €20 thousand, mainly due to a €9 thousand deposit paid in connection with a new Nanobiotix Corp headquarters’ lease contract in Cambridge, Massachusetts, United States. The decrease of the liquidity contract – cash account corresponds to treasury shares transactions whose counterpart is recorded as capital on the "treasury shares" line in the statement of change in shareholders’ equity. |
Trade receivables and other cur
Trade receivables and other current assets | 12 Months Ended |
Dec. 31, 2021 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Trade receivables and other current assets | Trade receivables and other current assets Accounting policies for trade receivables and other current assets are described in Note 7. 8.1 Trade receivables In 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled. As of December 31, (in thousands of euros) 2021 2020 Trade receivables — 62 Trade receivables — 62 Trade receivables break down as follows: As of December 31, (in thousands of euros) 2021 2020 Due in 3 months or less — 62 Due between 3 and 6 months — — Due between 6 and 12 months — — Due after more than 12 months — — Trade receivables — 62 8.2 Other current assets Other current assets break down as follows: As of December 31, (in thousands of euros) 2021 2020 Research tax credit receivable 2,490 1,927 VAT receivable 1,058 971 Prepaid expenses 2,213 2,217 Other receivables 3,378 920 Other current assets 9,139 6,035 As of December 31, 2021, prepaid expenses mainly relate to: • research agreements related to the MD Anderson agreement (see Note 4.4 – Collaboration Agreement with the University of Texas MD Anderson Cancer Center ) for €1.0 million, and • insurance related to the Directors & Officers for €0.6 million. As of December 31, 2020, prepaid expenses mainly relate to research agreements related to MD Anderson agreement (see Note 4.4 – Collaboration Agreement with the University of Texas MD Anderson Cancer Center ) for €1.6 million. Other receivables mainly comprised advances paid to suppliers in the amounts of €3,043 thousand as of December 31, 2021 as compared to €805 thousand as of December 31, 2020. This advance payment is mainly related to the new ICON contract signed in 2021 in conjunction with the launch of the 312 study. Research tax credit The Company receives a research tax credit (Crédit d’Impôt Recherche, or ‘‘CIR’’) from the French tax authorities. See Note 15 for additional details on the CIR research tax credit. The research tax credit for 2021 was €2.5 million (€2.3 million for Nanobiotix S.A. and €218 thousand for Curadigm SAS), while the amount for 2020 was €1.9 million (€1.9 million for Nanobiotix S.A. and €69 thousand for Curadigm SAS). The 2020 research tax credit was collected by the Company in November 2021, while the 2019 research tax credit was collected in July 2020. The change in research tax credit receivables breaks down as follows: (in thousands of euros) Receivable as of December 31, 2019 5,688 Refund of 2018 research tax credit – Nanobiotix SA (3,251) Refund of 2019 research tax credit – Nanobiotix SA (2,374) Refund of 2019 research tax credit – Curadigm SAS (64) 2020 research tax credit – Nanobiotix SA 1,858 2020 research tax credit – Curadigm SAS 69 Receivable as of December 31, 2020 1,927 Refund of 2020 research tax credit – Nanobiotix SA (1,858) Refund of 2020 research tax credit – Curadigm SAS (69) 2021 research tax credit – Nanobiotix SA 2,272 2021 research tax credit – Curadigm SAS 218 Receivable as of December 31, 2021 2,490 |
Cash and cash equivalents
Cash and cash equivalents | 12 Months Ended |
Dec. 31, 2021 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Cash and cash equivalents | Cash and cash equivalents Accounting policy Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits. Cash equivalents are measured at amortized cost. Detail of cash and cash equivalents Cash and cash equivalent break down as follows: (in thousands of euros) As of December 31, 2021 As of December 31, 2020 Cash and bank accounts 83,921 119,151 Net cash and cash equivalents 83,921 119,151 As of December 31, 2021, cash and bank accounts decreased by €35,230 thousand as compared with December 31, 2020 mainly due to: • the non-refundable upfront payment from LianBio in June 2021 of €16.5 million ($20.0 million); • the payments made to PharmaEngine for a total of €5.4 million in 2021 pursuant to the PharmaEngine Termination Agreement; • the debt reimbursement related to the EIB loan for €3.0 million and to the Bpifrance loan for €0.5 million; and • other cash flows used in operating activities. |
Share Capital
Share Capital | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract] | |
Share Capital | Share Capital 10.1 Capital issued Accounting policies Ordinary shares are classified in shareholders’ equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders’ equity as a deduction from the proceeds of the issue. Detail of share capital transactions (in thousands or number of shares) Nature of transaction Share Capital Premiums related to share capital Number of shares December 31, 2019 672 153,139 22,415,039 March 6, 2020 Capital increase 9 0 316,083 June 24, 2020 Subscription of 2020 warrants — 1 — June 26, 2020 Subscription of 2020 warrants — 1 — June 29, 2020 Subscription of 2020 warrants — 2 — June 30, 2020 Subscription of 2020 warrants — 1 — July 27, 2020 Capital increase — — 6,000 July 28, 2020 Private placement Capital increase 99 20,030 3,300,000 July 28, 2020 Private placement Capital increase transaction costs — (1,387) — December 16, 2020 U.S. Initial public offering initial deal € - Nasdaq (€11.14) 56 20,609 1,855,000 December 16, 2020 U.S. Initial public offering initial deal $ - Nasdaq ($13.50) 163 60,494 5,445,000 December 18, 2020 U.S. Initial public offering green shoe $ - Nasdaq ($13.50) 33 12,165 1,095,000 December 18, 2020 U.S. Initial public offering costs — (9,322) — December 31, 2020 1,033 255,735 34,432,122 March 31, 2021 Capital increase AGA 2018-1 1 — 24,500 March 31, 2021 Capital increase AGA 2019-1 11 — 369,250 April 20, 2021 Warrants attribution — (11) — May 31, 2021 Warrants subscription (BSA 2021) — 43 — December 31, 2021 1,045 255,767 34,825,872 As of December 31, 2021, the share capital was €1,044,776.16 divided into 34,825,872 fully paid in ordinary shares each with a par value of €0.03, as compared with the 2020 share capital of €1,032,963.66 divided into 34,432,122 fully paid in ordinary shares, each with a par value of €0.03 and the 2019 share capital of €672,451.17 divided into 22,415,039 fully paid in ordinary shares each with a par value of €0.03. In 2021, the increase in share capital is inherent to the definitive acquisition of free shares warrants related to the AGA 2018-1 and AGA 2019-1 plans. In 2020, the increase in share capital is mainly related to the U.S. initial public offering, which closed in December 2020. In the global offering, a total of 8,395,000 ordinary shares was issued, as follows: • 5,445,000 ordinary shares in the form of ADSs were issued in the United States at $13.50 per ADS; • 1,855,000 ordinary shares were issued through a concurrent offering in certain jurisdictions outside of the United States to certain investors at €11.14 per ordinary share; and, • the underwriters for the global offering exercised in full their option to purchase 1,095,000 additional ADSs at the same public offering price of $13.50 per ADS. As of December 31, 2020, €10.7 million of transaction costs had been recorded, €9.3 million of which were related to the initial public offering in the United States, and are recognized as a reduction to premiums related to share capital. Those transaction costs were almost paid in full as of December 31, 2020. The remaining €349 thousand were paid in 2021. 10.2 Treasury shares On December 31, 2021, the Company held 15,456 treasury shares under a liquidity contract compared to 12,970 treasury shares as of December 31, 2020. This liquidity contract complies with the general regulations of, and market practices accepted by, the French Financial Markets Authority (“AMF”), entered into following the Company’s French initial public offering in 2012. These shares were deducted from IFRS equity in the amount of €202 thousand and €196 thousand as of December 31, 2021 and 2020, respectively. 10.3 Founders’ warrants, warrants, stock options and free shares Accounting policies Accounting policies for share-based payments are described in Note 17. Detail of change in founders’ warrants, warrants, stock options and free shares As of December 31, 2021 and 2020, the Company had the following type of equity plans in place: founders’ warrant (BSPCE) plans, warrant (BSA) plans, stock option (OSA) plans and free shares (AGA) plans. The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020. Founders’ warrants (BSPCE) Type Grant Exercise Outstanding Issued Exercised Forfeited Outstanding Number of BSPCE 2012-2 December 18, 2012 6.63 100,000 — — — 100,000 100,000 BSPCE 08-2013 August 28, 2013 5.92 50,000 — — — 50,000 50,000 BSPCE 09-2014 September 16, 2014 18.68 86,150 — — — 86,150 86,150 BSPCE 2015-1 February 10, 2015 18.57 68,450 — — — 68,450 68,450 BSPCE 2015-3 June 10, 2015 20.28 30,700 — — (350) 30,350 30,350 BSPCE 2016 February 2, 2016 14.46 202,617 — — (1,776) 200,841 200,841 BSPCE 2017 January 7, 2017 15.93 180,850 — — (1,350) 179,500 179,500 Total 718,767 — — (3,476) 715,291 715,291 Type Grant Exercise Outstanding Issued Exercised Forfeited Outstanding Number of BSPCE 2012-2 December 18, 2012 6.63 100,000 — — — 100,000 100,000 BSPCE 08-2013 August 28, 2013 5.92 50,000 — — — 50,000 50,000 BSPCE 09-2014 September 16, 2014 18.68 92,100 — — (5,950) 86,150 86,150 BSPCE 2015-1 February 10, 2015 18.57 70,950 — — (2,500) 68,450 68,450 BSPCE 2015-3 June 10, 2015 20.28 38,400 — — (7,700) 30,700 30,700 BSPCE 2016 February 2, 2016 14.46 212,969 — — (10,352) 202,617 202,617 BSPCE 2017 January 7, 2017 15.93 187,166 — — (6,316) 180,850 180,850 Total 751,585 — — (32,818) 718,767 718,767 By way of exception, the Executive Board decided to lift, for three former employees and for two former members of the Executive Board, the continued service condition, and, where applicable for a former Executive Board member, the performance conditions to which the exercise of certain BSPCEs was subject, notwithstanding the termination of their employment agreement and/or corporate office. The impact of share-based payments on income is detailed in Note 17. The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence, no new instrument became issuable. Warrant Plans (BSA) Type Grant date Exercise Outstanding at Issued Exercised Forfeited Outstanding Number of BSA 04-12 May 4, 2012 6.00 30,000 — — — 30,000 30,000 BSA 2013 April 10, 2013 6.37 6,000 — — — 6,000 6,000 BSA 2014 September 16, 2014 17.67 10,000 — — — 10,000 10,000 BSA 2015-1 February 10, 2015 17.67 21,000 — — — 21,000 21,000 BSA 2015-2(a) June 25, 2015 19.54 64,000 — — — 64,000 64,000 BSA 2015-2(b) June 25, 2015 19.54 — — — — — — BSA 2016 February 2, 2016 13.74 36,208 — — (36,208) — — BSA 2016-2 November 3, 2016 15.01 8,000 — — (8,000) — — BSA 2017 January 7, 2017 15.76 18,000 — — — 18,000 18,000 BSA 2018-1 March 6, 2018 13.55 28,000 — — — 28,000 28,000 BSA 2018-2 July 27, 2018 16.102 5,820 — — — 5,820 5,820 BSA 2019-1 March 29, 2019 11.66 18,000 — — — 18,000 18,000 BSA 2020 March 17, 2020 6.59 18,000 — — — 18,000 18,000 BSA 2021 (a) April 21, 2021 13.47 — 48,103 — (33,672) 14,431 14,431 BSA 2021 (b) April 21, 2021 13.64 — 30,000 — — 30,000 30,000 Total 263,028 78,103 — (77,880) 263,251 263,251 Type Grant date Exercise Outstanding at Issued Exercised Forfeited Outstanding Number of BSA 04-12 May 4, 2012 6.00 30,000 — — — 30,000 30,000 BSA 2013 April 10, 2013 6.37 6,000 — — — 6,000 6,000 BSA 2014 September 16, 2014 17.67 10,000 — — — 10,000 10,000 BSA 2015-1 February 10, 2015 17.67 21,000 — — — 21,000 21,000 BSA 2015-2(a) June 25, 2015 19.54 64,000 — — — 64,000 64,000 BSA 2015-2(b) June 25, 2015 19.54 6,000 — — (6,000) — — BSA 2016 February 2, 2016 13.74 36,208 — — — 36,208 36,208 BSA 2016-2 November 3, 2016 15.01 8,000 — — — 8,000 8,000 BSA 2017 January 7, 2017 15.76 18,000 — — — 18,000 18,000 BSA 2018-1 March 6, 2018 13.55 28,000 — — — 28,000 28,000 BSA 2018-2 July 27, 2018 16.102 5,820 — — — 5,820 5,820 BSA 2019-1 March 29, 2019 11.660 18,000 — — — 18,000 18,000 BSA 2020 March 17, 2020 6.59 — 18,000 — — 18,000 18,000 Total 251,028 18,000 — (6,000) 263,028 263,028 At a meeting on April 20, 2021, the Executive Board, acting pursuant to the delegation granted by the Company’s shareholders' meeting held on November 30, 2020 granted 48,103 warrants to members and observers of the Supervisory Board, each entitling its holder to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.47 (share premium included). The designated warrants included 18,103 warrants that were issued in replacement of certain 2016 ordinary warrants that became null on February 2, 2021. The subscription period was open from the date of the meeting of the Executive Board until September 30, 2021, inclusive. As of December 31, 2021, 14,431 warrants have been subscribed by their beneficiaries. The warrants can be exercised at any time during a 10-year period, subject to the satisfaction of the following conditions: • the subscription by the relevant beneficiary of his/her warrant; • the relevant holder has attended at least 75% of the Supervisory Board meetings held during the twelve months preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group; and • the recommended dose for two out of the three patient cohorts enrolled in the study 1100 has been determined in order to define the next steps of the immuno-oncology development plan. It is being specified that (i) the Executive Board, with the prior approval of the Supervisory Board, shall acknowledge the satisfaction of such condition and (ii) such condition shall automatically be waived in the event of a change of control. At the same meeting, the Executive Board, acting pursuant to the above mentioned delegation, also granted 30,000 warrants to a consultant of the Company, each warrant giving its holder the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.64 (share premium included) at any time during a 10-year period subject to (i) the subscription by such consultant of the warrants and (ii) the drafting by such consultant of a Chemistry, Manufacturing, Control (CMC) risk assessment report. The corresponding subscription period has been fixed from the date of the meeting of the Executive Board until July 20, 2021 inclusive. As of December 31, 2021, no warrants have been subscribed by the beneficiary. In addition, as of December 31, 2021 the report is not prepared yet. Therefore, the warrants are not vested yet. At a meeting on March 17, 2020, the Executive Board, acting pursuant to the delegation granted by the thirty-fourth resolution of the annual shareholders' meeting dated April 11, 2019 and following the approval granted by the Supervisory Board on March 13, 2020, granted 18,000 warrants to members of the Supervisory Board, each entitling the holder to subscribe to a defined number of ordinary shares with a par value of €0.03, at a price of €6.59. The holders subscribed to the warrants prior to the end of the subscription period on September 30, 2020. Stock Option Plans (OSA) Type Grant date Exercise Outstanding at Issued Exercised Forfeited Outstanding Number of OSA 2016-1 February 2, 2016 13.05 400 — — — 400 400 OSA 2016-2 November 3, 2016 14.26 4,000 — — — 4,000 4,000 OSA 2017 January 7, 2017 14.97 500 — — — 500 500 OSA 2018 March 6, 2018 12.87 52,000 — — — 52,000 52,000 OSA 2019-1 March 29, 2019 11.08 28,750 — — (500) 28,250 28,250 OSA LLY 2019 October 24, 2019 6.41 500,000 — — — 500,000 500,000 OSA 2020 March 11, 2020 6.25 400,709 — — (13,253) 387,456 387,456 OSA 2021-04 April 20, 2021 13.74 — 571,200 — (80,000) 491,200 491,200 OSA 2021-06 June 21, 2021 12.99 — 120,000 — — 120,000 120,000 Total 986,359 691,200 — (93,753) 1,583,806 1,583,806 Type Grant date Exercise Outstanding at Issued Exercised Forfeited Outstanding Number of OSA 2016-1 February 2, 2016 13.05 400 — — — 400 400 OSA 2016-2 November 3, 2016 14.26 4,000 — — — 4,000 4,000 OSA 2017 January 7, 2017 14.97 500 — — — 500 500 OSA 2018 March 6, 2018 12.87 54,000 — — (2,000) 52,000 52,000 OSA 2019-1 March 29, 2019 11.08 30,250 — — (1,500) 28,750 28,750 OSA LLY 2019 October 24, 2019 6.41 500,000 — — — 500,000 500,000 OSA 2020 March 11, 2020 6.25 — 407,972 — (7,263) 400,709 400,709 Total 589,150 407,972 — (10,763) 986,359 986,359 At a meeting on April 20, 2021, the Executive Board, acting pursuant to delegations granted by the Company’s shareholders’ meeting held on November 30, 2020, granted to certain employees of the Group and members of the Executive Board 571,200 stock options (including 143,200 stock options and 428,000 performance stock options), each giving its holder the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.74 (share premium included). Such stock options are governed by the 2020 stock option plan adopted by the Executive Board on February 9, 2021 and approved by the Company’s annual shareholders’ meeting held on April 28, 2021 (the “2020 Stock Option Plan”). The ordinary stock options are exercisable as follows: • up to one-third of the ordinary stock options as from April 20, 2022; • an additional one-third of the ordinary stock options as from April 20, 2023, • the balance, i.e., one-third of the ordinary stock options as from April 20, 2024, subject to, for each increment, a continued service condition, and in any case, • no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law. The performance stock options may be exercised under the following conditions: • 10% of the stock options may be exercised when the market price of the Company’s shares on the regulated market of Euronext in Paris reaches €24.00, • an additional 10% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches €30.00, • an additional 40% of the stock options may be exercised when the market price of the Company’s shares on the regulated market of Euronext in Paris reaches €40.00, • an additional 40% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches €60.00, and • at the latest within 10 years of the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law. It being specified that (i) among such performance stock options that may be exercised, and subject to, for each increment, a continued service condition, their holders may only exercise (x) up to 10% of such performance stock options as from April 20, 2022, (y) an additional 30% of such performance stock options as from April 20, 2023, and (z) the balance, i.e., 60% of such performance stock options as from April 20, 2024, and (ii) such additional vesting condition shall be automatically waived in the event of a change of control. The number of ordinary and performance stock options that may be exercised under the above exercise schedules would always be rounded down to the nearest whole number. At a meeting on June 21, 2021, the Executive Board, acting pursuant to the delegation granted by the shareholders’ meeting held on November 30, 2020 granted 60,000 ordinary stock options to Mr. Bart Van Rhijn following his entry into the Company and his appointment as a Member of the Executive Board. Such stock options are governed by the 2020 Stock Option Plan. Acting pursuant to a delegation granted by the Company’s annual shareholders’ meeting held on April 28, 2021, it also decided to adopt the 2021 stock option plan and to grant to Mr. Bart Van Rhijn 60,000 performance stock options governed by such plan. Each of such 120,000 stock options (whether ordinary and performance) gives it holders the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €12.99 (share premium included). The exercise conditions of the 143,200 ordinary stock options and 428,000 performance stock options granted on April 20, 2021 described above shall apply mutatis mutandis to these 60,000 ordinary stock options and 60,000 performance stock options respectively, save for the anniversary date which shall be June 30 rather than April 20. In addition, in accordance with French regulation, the exercise of the above stock options (whether ordinary and performance) are subject to an additional performance condition as soon as they are granted to a member of the Executive Board: determination of the recommended dose for two of the three patient cohorts enrolled in the NBTXR3-1100 clinical study, in order to be able to define the next stage of the development plan in immuno-oncology. At a meeting on March 11, 2020, the Executive Board adopted the 2019 Stock Option Plan and, acting pursuant to the authorization granted by the thirty-second resolution of the annual shareholders' meeting dated April 11, 2019, granted 407,972 stock options (the “OSA 2020”), 300,000 of which to members of the Executive Board and Mr. Alain Dostie and the remaining 107,972 to employees of the Company, under such 2019 Stock Option Plan. Each OSA 2020 entitles its holder to subscribe one ordinary share of the Company with a par value of €0.03, at an exercise price of €6.25 (issue premium included). The OSA 2020 may be exercised as follows: • up to one-third of the OSA 2020 as from March 11, 2021; • an additional one-third of the OSA 2020 as from March 11, 2022; and • the balance, i.e., one-third of the OSA 2020 as from March 11, 2023, subject to, for each increment, a continued service condition. In addition, the Executive Board decided that the exercise of the OSA 2020 granted to members of the Executive Board and Mr. Alain Dostie would also be subject to the achievement of positive results in the 1100 study in 2020. The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the supervisory board, on March 17, 2021. By way of exception, the Executive Board decided to lift the continued service condition of the OSA 2020 for two former Executive Board members as well as to accelerate, as from June 30, 2021, the vesting of the OSA 2020 one of these former executive board members holds, enabling him to exercise all of them, in the context of his departure from the Company. Free share plans (AGA) Type Grant date Exercise Outstanding at Issued Definitively acquired Forfeited Outstanding Number of AGA 2018-1 March 6, 2018 n.a. 24,500 — (24,500) — — — AGA 2018-2 July 27, 2018 n.a. — — — — — — AGA 2019-1 March 29, 2019 n.a. 372,000 — (369,250) (2,750) — — AGA 2020 March 11, 2020 n.a. 50,000 — — — 50,000 50,000 AGA 2021 April 20, 2021 n.a. — 362,515 — (2,003) 360,512 360,512 Total 446,500 362,515 (393,750) (4,753) 410,512 410,512 Type Grant date Exercise Outstanding at January 1, Issued Definitively acquired Forfeited Outstanding Number of AGA 2018-1 March 6, 2018 n.a. 355,250 — (316,083) (14,667) 24,500 24,500 AGA 2018-2 July 27, 2018 n.a. 6,000 — (6,000) — — — AGA 2019-1 March 29, 2019 n.a. 385,000 — — (13,000) 372,000 372,000 AGA 2020 March 11, 2020 n.a. — 50,000 — — 50,000 50,000 Total 746,250 50,000 (322,083) (27,667) 446,500 446,500 At a meeting on April 20, 2021, the Executive Board, acting pursuant to the authorization granted by Company’s shareholders’ meeting on November 30, 2020, granted 362,515 free shares, each with a par value of €0.03 to certain employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on April 20, 2023. Such free shares are governed by the 2020 free share plan adopted by the Executive Board on February 9, 2021. Furthermore, the final vesting of the free shares granted to members of the Executive Board is conditioned upon the determination of the recommended dose for two out of the three patient cohorts enrolled in the NBTXR3-1100 clinical study in order to define the next steps of the development plan in immuno-oncology. At a meeting on March 11, 2020, the Executive Board, acting pursuant to the authorization granted by the thirty-third resolution of the annual shareholders’ meeting dated April 11, 2019, granted 50,000 free shares (the “AGA 2020”) with a par value of €0.03 to Ms. Anne-Juliette Hermant, a member of the Executive Board. In addition to the acquisition and holding conditions detailed below, the acquisition of the AGA 2020 granted to Ms. Hermant is conditioned upon the achievement of positive results in Study 1100 in 2020. The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the Supervisory Board, on March 17, 2021. Free share vesting conditions The AGA 2020 and AGA 2021 are subject to, for French tax residents, a two-year acquisition period and a one-year holding period, and, for foreign tax residents, a three-year acquisition period. The free shares granted by the Company are definitively acquired at the end of the acquisition period as set by the Executive Board. At the end of such period, the beneficiary is the owner of the shares. However, during the holding period (as set by the Executive Board), if any, the shares may not be sold, transferred or pledged. Unless otherwise decided by the supervisory and executive boards of the Company, the AGA 2020 and the AGA 2021 are subject to continued service during the acquisition period (i.e., for the AGA 2020, until March 11, 2022 and for AGE 2021, until April 20, 2023), it being specified that, failing such continued service, the beneficiary definitively and irrevocably loses his or her right to acquire the relevant AGA 2020 or AGA 2021. Unless otherwise decided by the supervisory and executive boards of the Company, in the event of disability or death of a beneficiary before the end of the acquisition period, the relevant free shares shall be definitely acquired at, respectively, the date of disability or the date of the request of allocation made by his or her beneficiary in the framework of the inheritance, provided that such request is made within six months from the date of death. At a meeting on March 17, 2021, the Executive Board acknowledged the definitive acquisition of 24,500 free shares granted on March 6, 2018 following a three-year acquisition period, thus acknowledging the related share capital increase of €735. At a meeting on April 1, 2021, the Executive Board acknowledged the definitive acquisition of 369,250 free shares granted on March 29, 2019 following a two-year acquisition period, thus acknowledging the related share capital increase of €11,077.50. At a meeting on September 22, 2020, the Executive Board acknowledged the definitive acquisition of 6,000 free shares granted on July 27, 2018 following a two-year acquisition period, thus acknowledging the related share capital increase of €180. In accordance with the terms of the free shares, the Executive Board decided to lift, for seven Company’s employees and a former Executive Board member, the continued service condition to which the definitive acquisition of their free shares is subject, notwithstanding the termination of their employment agreement or corporate office. The impact of share-based payments on income is discussed in Note 17. As of December 31, 2021, the assumptions related to the estimated vesting of the founders’ warrants, the warrants and performance stock-options have been updated (see Note 17). |
Provisions
Provisions | 12 Months Ended |
Dec. 31, 2021 | |
Provisions [abstract] | |
Provisions | Provisions Accounting policies Provisions for contingencies and charges Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities. A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end. Provisions for retirement obligations Company employees receive the retirement benefits provided for by law in France: • Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and • Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan). The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method. Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee’s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity. Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate. As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used). (in thousands of euros) As of January 1, 2021 Increases Decreases As of December 31, 2021 Lump-sum retirement benefits 414 — (97) 318 Non-current provisions 414 — (97) 318 Provisions for disputes 40 54 — 94 Provision for charges — 16 — 16 Current provisions 40 70 — 110 Total provisions 454 70 (97) 428 (in thousands of euros) As of January 1, 2020 Increases Decreases (1) As of December 31, 2020 Lump-sum retirement benefits 331 83 — 414 Non-current provisions 331 83 — 414 Provisions for disputes — 40 — 40 Provision for charges 164 — (164) — Current provisions 164 40 (164) 40 Total provisions 495 123 (164) 454 (1) See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases 11.1 Current provisions Provisions for disputes comprise employee disputes in progress. The increase during 2021 and 2020 of €54 thousand and €40 thousand, respectively, were due to a new employee dispute that occurred during the respective years. In 2020, the reversal of provisions for charges of €164 thousand were related to termination costs accounted for in 2019 following an employee departure. 11.2 Non-current provisions Commitments for retirement benefits As of December 31, (in thousands of euros) 2021 2020 Provision as of beginning of period 414 331 Cost of services 84 76 Interests / discounting costs 1 3 Expense for the period 85 79 Gains or losses related to experience (133) (61) Gains or losses related to change in demographic assumptions (5) 3 Gains or losses related to change in financial assumptions (43) 62 Actuarial gains or losses recognized in other comprehensive income (182) 4 Provision as of end of period 318 414 The assumptions used to measure lump-sum retirement benefits are as follows: Measurement date December 31, 2021 December 31, 2020 Retirement assumptions Management: Age 66 Non-management: Age 64 Management: Age 66 Non-management: Age 64 Social security contribution rate 42.01 % 44 % Discount rate 0.98 % 0.33 % Mortality tables Regulatory table Regulatory table Salary increase rate (including inflation) Executive: 3% Non-Executive: 2.5% Executive: 3% Non-Executive: 2.5% Staff turnover Constant average rate of 5.86% Constant average rate of 5.86% Duration 20 years 17 years The rights granted to Company employees are defined in the Collective Agreement for the Pharmaceutical industry (manufacturing and sales of pharmaceutical products). The staff turnover rate was determined using a historical average over the 2015-2019 period. The sensitivity to the discount rate and to the salary growth is as follows: Discount rate 0.73% 0.98% 1.23% Defined Benefit Obligation as of December 31, 2021 333 318 303 The company does not expect to pay a material amount of benefits for the five |
Financial liabilities
Financial liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of financial liabilities [abstract] | |
Financial liabilities | Financial liabilities Accounting policies The Company receives assistance in the form of grants, conditional advances and interest-free loans. Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance. The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities. Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities. Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated. Financial liabilities are recognized and measured in accordance with IFRS 9 – Financial Instruments. Financial liabilities, including trade and other payables are valued at amortized cost. Financial liabilities at amortized cost Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 – Financial Instruments. They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method. Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost. Details of financial liabilities As of December 31, (in thousands of euros) 2021 2020 Lease liabilities – Short term 1,126 1,197 Repayable BPI loan advances - Short term 800 500 PGE* 1,086 141 EIB Loan – Short term 5,192 3,033 Total current financial liabilities 8,204 4,872 Lease liabilities – Long term 5,393 4,991 Repayable BPI loan advances – Long term 2,259 2,975 PGE* 8,982 9,922 EIB loan – Long term 21,182 26,218 Total non-current financial liabilities 37,816 44,107 Total financial liabilities 46,020 48,979 (*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans Bpifrance conditional advances The Company receives repayable advances from Banque Publique d’Investissement (formerly known as OSEO Innovation). Some of these advances are interest-free and are fully repayable in the event of technical and/or commercial success. In 2018, the Company was informed that the initial date of reimbursement of the Bpifrance repayable advance was deferred for 18 months. The other advances are bearing 1.56% interest. The amount to be reimbursed corresponds to the amount received to date, €2.1 million, increased by the interest amount (see Note 12.1). In June 2020, Curadigm SAS obtained a €500 thousand conditional advance from Bpifrance, €350 thousand of which was received at the signature date while the remaining amount had been scheduled to be received by Curadigm at the end of the work, expected as of March 1, 2022 at the latest, but Curadigm SAS requested an extension of the work period to Bpifrance as a result of COVID-19 which - in case of Bpifrance’s approval - could result in collectibility of the remaining €150 thousand. As of December 31, 2021, the work had not been completed and the balance, therefore, has not been paid. EIB loan In July 2018, the Company obtained a fixed rate loan from the EIB. The loan could reach a maximum amount of €40 million, divided in three tranches. The first tranche, with a nominal value of €16 million, was received in October 2018 and will be repaid in full in 2023. The accumulated fixed-rate interest related to this tranche will be paid at the same time. The second tranche, with a nominal value of €14 million, was received in March 2019 and will be repaid between 2021 and 2024. The accumulated fixed-rate interest related to this second tranche will be paid twice a year together with the principal due. The third tranche, which abides by specific conditions (NBTXR3 should obtain the European Commission trademark and reach the main performance criteria for the Phase III pivot, for head and neck cancer treatment), has not been requested by the Company. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, had been delayed by 12 months to July 31, 2021. As the conditions were not met by July 31, 2021, the Company will not be able to request the final tranche of the EIB loan. Pursuant to the terms of the loan, the Company is also required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) additional interest in the form of royalties, calculated according to the number of tranches that have been withdrawn and indexed on the annual sales turnover (see Note 4.2). Initially, the Company calculated estimated future royalties based on its forecast of future annual sales turnover, and this estimated amount was included in the amortized cost of the loan. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. Due to the delay caused by COVID-19 in clinical trials and the revision of the related sales development plan, the sales forecasts were updated resulting in a change in estimate of the accrued royalties (see Note 12 of our consolidated financial statements for details about the impact of this sales forecast update). A 10% increase of the estimated future net sales would result in an immaterial change of the EIB loan valuation recorded as of December 31, 2021. PGE loan The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for €5 million each in the form of state-guaranteed loans (“Prêts Garantis par l’Etat”, or “PGE” in France); the €5 million from HSBC (the ‘‘HSBC PGE Loan’’) was received in June 2020. This loan is booked at amortized cost for a minimum of 12 months and allows the Company to delay the reimbursement of this 12 months loan by 1 to 5 years. The Company uses this option and the reimbursement date was delayed by 1 year and will start in September 2022. The effective interest rate amounts to 0.31%. On July 10, 2020, the Company entered into the second €5 million PGE loan with Bpifrance (the ‘‘Bpifrance PGE Loan’’). The Bpifrance PGE loan has a six-year term and is 90% guaranteed by the French State. The Bpifrance PGE loan did not bear any interest for the first 12-month period but, following such 12-month period and for the subsequent 5 years, is bearing an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan will be reimbursed in 20 quarterly installments as from October 31, 2021 until July 26, 2026. 12.1 Conditional advance, bank loan and loans from government and public authorities The table below shows the detail of liabilities recognized on the statements of financial position by type of conditional advances and loans from government and public authorities. Conditional advances and loans from government and public authorities (in thousands of euros) Bpifrance advance Interest-free Bpifrance loan EIB Loan Curadigm Bpifrance advance Total As of January 1, 2020 2,165 1,210 34,746 — 38,121 Principal received — — — 350 350 Impact of discounting and accretion 19 14 (1,736) (65) (1,769) Accumulated fixed interest expense accrual 32 — 1,731 — 1,763 Accumulated variable interest expense accrual — — (4,789) — (4,789) Repayment — (250) (700) — (950) As of December 31, 2020 2,216 974 29,251 285 32,727 Principal received — — — — — Impact of discounting and accretion 17 19 (5,817) 16 (5,765) Accumulated fixed interest expense accrual 32 — 1,758 — 1,790 Accumulated variable interest expense accrual — — 4,214 — 4,214 Repayment — (500) (3,033) — (3,533) As of December 31, 2021 2,266 493 26,374 300 29,433 The impact of discounting and accretion of €5.8 million, in 2021 relates to impact from the “catch-up method” related to the variable compensation further to the royalty component in the EIB loan that is linked to future revenue expectations. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. The rest of the catch up impact is presented on the line variable interest future payments. The expected royalty payments to be made in the future, initially estimated as €17.2 million as of December 31, 2020 have been updated to €3.4 million as of December 31, 2021. Bank loan (in thousands of euros) HSBC “PGE” (1) Bpifrance “PGE” (1) Total As of January 1, 2020 — — — Principal received 5,000 5,000 10,000 Impact of discounting and accretion 14 34 47 Accumulated fixed interest expense accrual (2) 7 10 17 As of December 31, 2020 5,020 5,044 10,064 Principal received 17 (14) 3 Impact of discounting and accretion 26 120 146 Accumulated fixed interest expense accrual (3) (33) (112) (145) As of December 31, 2021 5,030 5,038 10,068 (1) ”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans (2) In 2020 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. (3) In 2021 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. 12.2 Lease liabilities The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed: (in thousands of euros) Lease liabilities As of January 1st, 2020 6,405 New lease contracts 521 Impact of discounting of the new lease contracts (94) Fixed interest expense 333 Repayment of lease (928) Early termination of lease contracts (49) As of December 31, 2020 6,188 Engagement 1,476 Impact of discounting and accretion (110) Accumulated fixed interest expense accrual 288 Repayment of lease (1,195) Early termination of lease contracts (128) As of December 31, 2021 6,519 12.3 Due dates of the financial liabilities The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows: As of December 31, 2021 (in thousands of euros) Less than 1 year Between 1 and Between 3 and More than 5 years Bpifrance 300 1,300 808 — Interest-free Bpifrance loan 500 — — — Curadigm interest-free Bpifrance advance — 200 150 — HSBC “PGE” (1) 661 2,572 1,904 — Bpifrance “PGE” (1) 425 2,662 2,237 — EIB fixed rate loan 5,192 28,762 — — Lease liabilities 1,126 2,252 2,247 1,714 Total 8,204 37,747 7,346 1,714 (1) ”The Company will reimburse the two “PGE”or (“Prêts garantis par l’Etat” or state-guaranteed loans) over 5 years with a deferral of 1 year (last reimbursement being in 2026), for the reasons mentioned in the paragraph below. The long-term debt obligations relate to the fixed rate interest and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts do not include the discounting impact, but only reflect the committed amounts under those contracts as of December 31, 2021. The outstanding balance of the EIB loan included in the table above was €33.9 million as of December 31, 2021, including €7.0 million of total fixed rate interest to be paid over the term of the loan, out of which €1.8 million was accrued as of December 31, 2021. The balance in the table above does not include €3.4 million of estimated variable rate interest, based on the consolidated forecasted sales expected to be generated by the Company during the six-year period beginning January 1, 2021 (see Notes 3.2, 4.3 and 12.1). On April 07, 2021, the Company received the approval of HSBC on its debt rescheduling request. The HSBC PGE loan will be reimbursed at the same pace as the Bpifrance loan, starting on September 2022. |
Trade payables and other curren
Trade payables and other current liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Trade payables and other current liabilities | Trade payables and other current liabilities 13.1 Trade and other payables Accounting policies Accounting policies for Trade and other payables are described in Note 12, ‘‘Financial Liabilities.’’ Accrued expenses Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date. The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date. Details of trade and other payables As of December 31, (in thousands of euros) 2021 2020 Accrued expenses - clinical trials 1,486 1,532 Trade payables & other accruals 4,996 5,574 Total trade and other payables 6,482 7,106 Trade payables are not discounted, as none of the amounts were due in more than one year. Other trade payables include €447 thousand of costs relating to the ICON contract not yet paid, as of December 31, 2021. 13.2 Other current liabilities As of December 31, (in thousands of euros) 2021 2020 Tax liabilities 258 283 Payroll tax and other payroll liabilities 4,820 6,248 Other payables 453 491 Other current liabilities 5,531 7,022 Payroll tax and other payroll liabilities consist primarily of payroll taxes, namely the employer costs to be paid on free shares, accrued bonuses, vacation days and related social charges. Payroll tax and other payroll liabilities decreased by €1.4 million from €6.2 million as of December 31, 2020 to €4.8 million as of December 31, 2021 as a result of the decrease in social charges accrual related to free shares and to bonuses. 13.3 Deferred revenues and contract liabilities As of December 31, (in thousands of euros) 2021 2020 Deferred revenues and contract liabilities 16,518 — Deferred revenues and contract liabilities 16,518 — Change in deferred revenues and contract liabilities as of December 31, 2021 consists of contract liabilities relating to the LianBio contract in the amount of €16.5 million, accounted for in accordance with IFRS 15. See Note 15 Revenues and other income for more details. |
Financial instruments included
Financial instruments included in the statement of financial position and impact on income | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [abstract] | |
Financial instruments included in the statement of financial position and impact on income | Financial instruments included in the statement of financial position and impact on income Accounting policies Accounting policies for financial instruments included in the statements of financial position and impact on income are described in Note 7, ‘‘Non-current financial assets’’, Note 8, ‘‘Trade receivables and other current assets’’, Note 9, ‘‘Cash and cash equivalents’’ and Note 12, ‘‘Financial liabilities.’’ Detail of financial instruments included in the statements of financial position and impact on income As of December 31, 2021 (in thousands of euros) Book value on Financial assets Assets and liabilities Fair value (1) Non-current financial assets Non-current financial assets 519 97 421 519 Trade receivables — — — — Cash and cash equivalents 83,921 — 83,921 83,921 Total assets 84,440 97 84,343 84,440 Financial liabilities Non-current financial liabilities 38,733 — 38,733 38,733 Current financial liabilities 7,288 — 7,288 7,288 Trade payables and other payables 6,482 — 6,482 6,482 Total liabilities 52,503 — 52,503 52,503 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. As of December 31, 2020 (in thousands of euros) Book value on the statement of financial position Financial assets carried at fair value through profit or loss Assets and liabilities carried at amortized cost Fair value (1) Non-current financial assets Non-current financial assets 505 104 401 505 Trade receivables 62 — 62 62 Cash and cash equivalents 119,151 — 119,151 119,151 Total assets 119,717 104 119,613 119,717 Financial liabilities Non-current financial liabilities 44,107 — 44,107 44,107 Current financial liabilities 4,872 — 4,872 4,872 Trade payables and other payables 7,106 — 7,106 7,106 Total liabilities 56,085 — 56,085 56,085 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. Management of financial risks The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments. The principal financial risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks. Liquidity risk Given the amount of cash and cash equivalents held by the Company as of December 31, 2021 (see Note 9), the Company does not believe that it is exposed to short-term liquidity risk. Foreign Currency Exchange Risk The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is derived almost entirely from intragroup transactions between Nanobiotix S.A. and its U.S. subsidiaries, for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone. At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity outside the euro zone could lead to a greater exposure to foreign currency exchange risk. If this occurs, the Company may implement a suitable hedging policy for these risks. The following table shows the impact of a 10% increase or decrease in the exchange rate between the euro and the U.S. dollar, calculated on the amounts of capital contributions and loans to the Company’s U.S. subsidiaries as of December 31, 2021, and 2020. For the year ended December 31, 2021 Impact Net income Equity (in thousands of euros) Increase Decrease Increase Decrease USD / Euro exchange rate 45 (45) 87 (87) Total 45 (45) 87 (87) For the year ended December 31, 2020 Impact Net income Equity (in thousands of euros) Increase Decrease Increase Decrease USD / Euro exchange rate 5 (5) 124 (124) Total 5 (5) 124 (124) Credit risk Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. The credit risk related to cash and cash equivalents and to current financial instruments is not material given the quality of the relevant financial institutions. Customer credit risk is limited, due in part to low trade receivables as of December 31, 2021 and in part to its customers’ high credit rating for other receivables. Interest rate risk The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of money market mutual funds (SICAVs). Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated. Fair value The fair value of financial instruments traded on an active market is based on the market price on the reporting date. The market prices used for the financial assets held by the Company are the bid prices in the market on the measurement date. The carrying value of receivables and current liabilities is assumed to approximate their fair value. |
Revenues and other income
Revenues and other income | 12 Months Ended |
Dec. 31, 2021 | |
Revenue [abstract] | |
Revenues and other income | Revenues and other income Accounting policies Revenue Revenue is recognized in accordance with IFRS 15. Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service). Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue. Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party e.g. : • Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered; • A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred; • A license: ◦ If the license is assessed to be a right to access the Company’s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or ◦ If the license is a right to use the Company’s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or • Product supply for which the revenue is recognized once the control over the delivered products is transferred. Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred. Application to the license and collaboration agreement with PharmaEngine Under the License and Collaboration Agreement, the Company’s and PharmaEngine’s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company’s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine. The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above: • the license of the right to use the Company’s patent and know-how; • the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine’s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and • the supply of NBTXR3 to PharmaEngine. An upfront payment of $1.0 million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012. Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $1 million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company’s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $1 million (first patient’s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine ’s territory, which had not occurred as of December 31, 2021. Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur. In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions. Application of IFRS 15 to the license and collaboration agreement with LianBio Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15. We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio: • an exclusive license, under the Company's intellectual property, to develop and market the licensed products; • the right to actively participate in global Phase III registration trials to obtain marketing approval in China; • if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals; • if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and • the requirement to purchase products under license to the Company. The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct. As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone. LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases. Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products. In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20 million and may receive up to $220 million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts. No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products. The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined. Grants Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received. Research tax credit The French tax authorities grant a research tax credit ( Crédit d’Impôt Recherche , or “CIR”), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following three years. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the “PME”, it can request immediate refund of the remaining tax credit, without application of the three-year period). The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations. Detail of revenues and other income The following table summarizes the Company’s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019. For the year ended December 31, (in thousands of euros) 2021 2020 2019 Services 5 50 40 Other sales 5 — 28 Total revenues 10 50 68 Research tax credit 2,490 1,927 2,437 Subsidies 126 526 20 Other 21 10 17 Total other income 2,637 2,462 2,473 Total revenues and other income 2,647 2,512 2,541 The Company’s revenue of €10 thousand in 2021, €50 thousand in 2020 and €68 thousand in 2019 were derived mainly from the charging-back of shared external clinical research organization costs in connection with the development support provided by the Company to PharmaEngine as part of the 2014 amendment to the Company's License and Collaboration Agreement. 100% of the revenues recognized in 2021, 2020 and 2019 were derived from the arrangement with PharmaEngine (see Note 4.1). In 2020, the Company’s other income, other than the research tax credit, mainly derives from French State subsidies of €312 thousand provided as part of the ‘‘partial unemployment measure,’’ a National plan allowing companies facing economic challenges during the COVID-19 crisis to receive from the French State approximately 84% of specific employees’ net salary, as well as the €350 thousand received by Curadigm in connection with the Bpifrance Deep Tech Funding, €187 thousand of which was recognized as revenue for the years ended December 31, 2020. |
Operating expenses
Operating expenses | 12 Months Ended |
Dec. 31, 2021 | |
Analysis of income and expense [abstract] | |
Operating expenses | Operating expenses Accounting policies Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22). Accounting policies for research and development expenses are described in Note 5. 16.1 Research and development expenses For the year ended December 31, (in thousands of euros) 2021 2020 2019 Purchases, sub-contracting and other expenses (19,562) (12,734) (16,804) Payroll costs (including share-based payments) (9,605) (10,306) (11,980) Depreciation, amortization and provision expenses (1) (1,211) (1,290) (1,627) Total research and development expenses (30,378) (24,330) (30,411) (1) see note 16.4 Depreciation, amortization and provision expenses Purchases, sub-contracting and other expenses increased by €6.9 million, or 54% for the year ended December 31, 2021 as compared with the same period in 2020. This reflects the increase of the clinical development activities, especially driven by the launch of our global Phase III clinical trial for elderly head and neck cancer patients ineligible for platinum-based (cisplatin) chemotherapy (NANORAY-312). Payroll costs decreased by €774 thousand, or 8% for the year ended December 31, 2021 as compared with the same period in 2020. This variation is mainly due to a change in the mix and in the location of our research and development staff. As of December 31, 2021, the Company’s workforce amounted to 75 research and development staff, including 9 additional positions created during the year ended December 31, 2021. As of December 31, 2020, the Company’s workforce amounted to 66 research and development staff, including a decrease of fifteen positions created during the year ended December 31, 2020 and 81 research and development staff, including 2 additional positions created during the year ended December 31, 2019. The impact of share-based payments (excluding employer’s contribution) on research and development expenses amounted to €677 thousand in 2021 as compared with €629 thousand in 2020 and €902 thousand in 2019. 16.2 Selling, General and Administrative (SG&A) expenses For the year ended December 31, (in thousands of euros) 2021 2020 2019 Purchases, fees and other expenses (9,638) (6,482) (9,435) Payroll costs (including share-based payments) (9,379) (7,789) (9,205) Depreciation, amortization and provision expenses (1) (417) (340) (270) Total SG&A expenses (19,434) (14,611) (18,909) (1) see note 16.4 Depreciation, amortization and provision expenses In 2021, purchases, fees and other expenses increased by €3,156 thousand, or 49% for the year ended December 31, 2021 as compared with the same period in 2020. This variation reflects two main impacts, first the legal expenses relating to partnership agreements as well as consulting fees, legal and compliance expenses as a result of being a U.S. public company. The second main impact relates to recruitment expenses. In 2020, wages, salaries and payroll costs, together, amounted to €15.1 million as compared with €16.8 million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer’s contribution following the exercise by beneficiaries of their right to free shares. These increases in fees and other expenses were partially offset by the decrease in rental expenses following the application of IFRS 16 for the year ended December 31, 2019. Payroll costs increased by €1.6 million or 21% in 2021, mainly due to a change in the mix and location changes of our staff in SG&A functions (more US based employees) and a one-time severance payment related to the departure of Philippe Mauberna, the prior CFO. As of December 31, 2021, the Company’s workforce amounted to 25 staff in SG&A functions in comparison with a Company’s workforce of 24 staff in SG&A functions during the year ended December 31, 2020 and a Company’s workforce of 29 staff in SG&A functions, including 6 additional positions created during the year ended December 31, 2019. The impact of share-based payments (excluding employer’s contribution) on SG&A expenses amounted to €2.5 million in 2021, as compared with €2.3 million in 2020 and €3.4 million in 2019. 16.3 Payroll costs For the year ended December 31, (in thousands of euros) 2021 2020 2019 Wages and salaries (11,391) (11,141) (11,876) Payroll taxes (4,308) (3,953) (4,913) Share-based payments (3,201) (2,924) (4,320) Retirement benefit obligations (84) (76) (76) Total payroll costs (18,984) (18,094) (21,185) Average headcount 96 97 112 End-of-period headcount 100 90 110 As of December 31, 2021, the Company’s workforce totaled 100 employees, compared with 90 December 31, 2020 and 110 as of December 31, 2019. In 2021, wages, salaries and payroll costs, together, amounted to €15.7 million as compared with €15.1 million in 2020. This is mainly due to the 10 additional positions created during the year ended December 31, 2021. In 2020, wages, salaries and payroll costs, together, amounted to €15.1 million as compared with €16.8 million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer’s contribution following the exercise by beneficiaries of their right to free shares. In 2019, wages and salaries and payroll taxes, together, reached €16.8 million due to the Company's growth and a related increase in the number of employees during the year ended December 31, 2019, together with the impact of its compensation policy. In accordance with IFRS 2 – Share-based Payment, the share-based payment amount recognized in the statements of operations reflects the expense associated with rights vesting during the fiscal year under the Company's share-based compensation plans. The share-based payment expenses amounted to €3.2 million for the year ended December 31, 2021, as compared with €2.9 million as of December 31, 2020 and €4.3 million as of December 31, 2019 (see Note 17). 16.4 Depreciation, amortization and provision expenses Depreciation, amortization and provision expenses by function are detailed as follows: For the year ended December 31, 2021 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (34) (10) (45) Amortization expense of tangible assets (1,109) (406) (1,515) Provision for charges (68) — (68) Total depreciation, amortization and provision expenses (1,211) (416) (1,628) For the year ended December 31, 2020 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (152) (23) (176) Amortization expense of tangible assets (1,250) (329) (1,579) Utilization of provision for disputes 145 — 145 Provision for charges — (40) (40) Reversal of provision for disputes — 19 19 Total depreciation, amortization and provision expenses (1,257) (373) (1,630) For the year ended December 31, 2019 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (289) (3) (292) Depreciation expense of property, plant and equipment (1,208) (270) (1,478) Utilization of provision for charges — 55 55 Provision for charges (112) (52) (164) Total depreciation, amortization and provision expenses (1,609) (270) (1,879) 16.5 OTHER OPERATING INCOME AND EXPENSES For the year ended December 31, 2021 (in thousands of euros) 2021 2020 Contract termination indemnity (PharmaEngine) (5,414) — Total Other operating income and expenses (5,414) — The Company has made payments for a cumulative amount of $6.5 million (€5.4 million converted at the exchange rate on the payment date) to PharmaEngine in accordance with the termination and release agreement signed between the parties. See Note 4.2 PharmaEngine. |
Share-based payments
Share-based payments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
Share-based payments | Share-based payments Accounting policy The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had nine (9) outstanding founders’ warrant plans, twelve (12) outstanding warrant plans, nine (9) stock option plans and two (2) outstanding free shares plans. These share-based compensation plans are settled in equity instruments. The Company has applied IFRS 2 – Share-based Payment to all equity instruments granted to employees since 2006. As required by IFRS 2 – Share-based Payment , the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders’ equity for the vesting period during which the rights with respect to the equity instruments are earned. The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below. Detail of share-based payments The Company has granted stock options (option sur actions, ‘‘OSA’’), warrants (bons de souscription d’actions, ‘‘BSA’’), founders’ warrants (bons de souscription de parts de créateur d’entreprise, ‘‘BSPCE’’) and free shares (attributions gratuites d’actions, ‘‘AGA’’) to corporate officers, employees and members of the Supervisory Board and consultants. In certain cases, exercise of the options and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash. The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below: Founders’ warrants Pre-2021 founders’ warrant plans BSPCE 2012-2 BSPCE BSPCE BSPCE BSPCE Type of underlying asset New shares New shares New shares New shares New shares Number of founder’s warrants granted 100,000 50,000 97,200 71,650 53,050 Date of shareholders' resolution approving the plan 05/04/2012 06/28/2013 06/18/2014 06/18/2014 06/18/2014 Grant date 12/18/2012 08/28/2013 09/16/2014 02/10/2015 06/10/2015 Contractual expiration date 12/18/2022 08/28/2023 09/16/2024 02/10/2025 06/10/2025 Grant price — — — — — Exercise price €6.63 €5.92 €18.68 €18.57 €20.28 Number of founders’ warrants as of Number of founders’ warrants as of December 31, 2021 100,000 50,000 86,150 68,450 30,350 Number of founders’ warrants exercised — — — — — Including founders’ warrants exercised during the period — — — — — Number of founders’ warrants lapsed or cancelled — — 11,050 3,200 22,700 Including founders’ warrants lapsed or cancelled during the period — — — — 350 Pre-2021 founders’ warrant plans BSPCE BSPCE BSPCE BSPCE Type of underlying asset New shares New shares New shares New shares Number of founder’s warrants granted 126,400 129,250 117,650 80,000 Date of shareholders' resolution approving the plan 06/25/2015 06/25/2015 06/23/2016 06/23/2016 Grant date 02/02/2016 02/02/2016 01/07/2017 01/07/2017 Contractual expiration date 02/02/2026 02/02/2026 01/08/2027 01/07/2027 Grant price — — — — Exercise price €14.46 €14.46 €15.93 €15.93 Number of founders’ warrants as of December 31, 2021 100,567 100,274 99,500 80,000 Number of founders’ warrants exercised 333 — — — Including founders’ warrants exercised during the period — — — — Number of founders’ warrants lapsed or cancelled 25,500 28,976 18,150 — Including founders’ warrants lapsed or cancelled during the period 350 1,426 1,350 — Warrants Pre-2021 warrant plans BSA 04-2012 BSA BSA BSA BSA BSA BSA Type of warrants New shares New shares New shares New shares New shares New shares New shares Number of warrants granted 52,500 10,000 14,000 26,000 64,000 6,000 18,103 Date of shareholders' resolution approving the plan 05/04/2012 05/04/2012 06/18/2014 06/18/2014 06/18/2014 06/25/2015 06/25/2015 Grant date 05/04/2012 04/10/2013 09/16/2014 02/10/2015 06/25/2015 06/25/2015 02/02/2016 Contractual expiration date 05/04/2022 04/10/2023 09/16/2024 02/10/2025 06/25/2025 06/25/2020 02/02/2021 Grant price €0.60 €2.50 €4.87 €4.87 €5.00 €2.80 €1.67 Exercise price €6.00 €6.37 €17.67 €17.67 €19.54 €19.54 €13.74 Number of warrants as of December 31, 2021 30,000 6,000 10,000 21,000 64,000 — — Number of warrants exercised 22,500 — — — — — — Including warrants exercised during the period — — — — — — — Number of warrants lapsed or cancelled — 4,000 4,000 5,000 — 6,000 18,103 Including warrants lapsed or cancelled during the period — — — — — — 18,103 Pre-2021 warrant plans BSA BSA BSA BSA BSA BSA BSA Type of warrants New shares New shares New shares New shares New shares New shares New shares Number of warrants granted 18,105 8,000 18,000 28,000 5,820 18,000 18,000 Date of shareholders' resolution approving the plan 06/25/2015 06/23/2016 06/23/2016 06/14/2017 05/23/2018 05/23/2018 04/11/2019 Grant date 02/02/2016 11/03/2016 01/07/2017 03/06/2018 07/27/2018 03/29/2019 03/17/2020 Contractual expiration date 02/02/2021 11/03/2021 01/07/2022 03/06/2023 07/27/2028 03/29/2029 03/17/2030 Grant price €1.67 €2.03 €2.26 €1.62 €2.36 €1.15 €0.29 Exercise price €13.74 €15.01 €15.76 €13.55 €16.102 €11.66 €6.59 Number of warrants as of December 31, 2021 — — 18,000 28,000 5,820 18,000 18,000 Number of warrants exercised — — — — — — — Including warrants exercised during the period — — — — — — — Number of warrants lapsed or cancelled 18,105 8,000 — — — — — Including warrants lapsed or cancelled during the period 18,105 8,000 — — — — — 2021 warrants BSA 2021 (a) BSA 2021 (b) Type of warrants New shares New shares Number of warrants granted 48,103 30,000 Date of shareholders' resolution approving the plan 11/30/2020 11/30/2020 Grant date 04/20/2021 04/20/2021 Contractual expiration date 04/20/2031 04/20/2031 Grant price €2.95 €0.68 Number of warrants as of Exercise price €13.47 €13.64 Number of warrants as of December 31, 2021 14,431 30,000 Number of warrants exercised — — Including warrants exercised during the period — — Number of warrants lapsed or cancelled 33,672 — Including warrants lapsed or cancelled during the period 33,672 — Stock options Pre-2021 stock option plans OSA OSA OSA OSA OSA OSA OSA Type of underlying asset New shares New shares New shares New shares New shares New shares New shares Number of options granted 6,400 4,000 3,500 62,000 37,500 500,000 407,972 Date of shareholders' resolution approving the plan 06/25/2015 06/23/2016 06/23/2016 06/14/2017 05/23/2018 04/11/2019 04/11/2019 Grant date 02/02/2016 11/03/2016 01/07/2017 03/06/2018 03/29/2019 10/24/2019 03/11/2020 Contractual expiration date 02/02/2026 11/03/2026 01/07/2027 03/06/2028 03/29/2029 10/24/2029 03/11/2030 Grant price — — — — — — — Exercise price €13.05 €14.26 €14.97 €12.87 €11.08 €6.41 €6.25 Number of options as of December 31, 2021 400 4,000 500 52,000 28,250 500,000 387,456 Number of options exercised — — — — — — — Number of options as of Including options exercised during the period — — — — — — — Number of options lapsed or cancelled 6,000 — 3,000 10,000 9,250 — 13,253 Including options lapsed or cancelled during the period — — — — 500 — 13,253 2021 stock option plans OSA 2021-04 OSA 2021-06 Type of underlying asset New shares New shares Number of options granted 571,200 120,000 Date of shareholders' resolution approving the plan 11/30/2020 04/28/2021 Grant date 04/20/2021 06/21/2021 Contractual expiration date 04/20/2031 06/21/2031 Grant price — — Exercise price €13.74 €12.99 Number of options as of December 31, 2021 491,200 120,000 Number of options exercised — — Number of options as of Including options exercised during the period — — Number of options lapsed or cancelled 80,000 — Including options lapsed or cancelled during the period 80,000 — Free shares Pre-2021 free shares plan not yet vested 2021 free shares plan AGA AGA AGA AGA AGA Type of underlying assets New shares New shares New shares New shares New shares Number of free shares granted 396,250 6,000 438,250 50,000 362,515 Date of shareholders' resolution approving the plan 06/14/2017 05/23/2018 05/23/2018 04/11/2019 11/30/2020 Grant date 03/06/2018 07/27/2018 03/29/2019 03/11/2020 04/20/2021 Grant price — — — — — Exercise price — — — — — Number of free shares as of December 31, 2021 — — — 50,000 360,512 Number of free shares exercised 340,583 6,000 369,250 — — Including free shares exercised during the period 24,500 — 369,250 — — Number of free shares lapsed or cancelled 55,667 — 69,000 — 2,003 Including free shares lapsed or cancelled during the period — — 2,750 — 2,003 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2021 715,291 263,251 1,583,806 410,512 2,972,860 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2020 718,767 263,028 986,359 446,500 2,414,654 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2019 751,585 251,028 589,150 746,250 2,338,013 The measurement methods used to estimate the fair value of stock options, warrants and free shares are described below: • The share price on the grant date is equal to the exercise price, except for the BSA 2014 which exercise price was set at €40, taking into account both the average share price on the 20 days preceding the grant date and the expected development perspectives of the Company; • The risk-free rate was determined based on the average life of the instruments; and • Volatility was determined based on a sample of listed companies in the biotechnology sector on the grant date and for a period equal to the life of the warrant or option. The performance conditions for all of the plans were assessed as follows: • Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and • Market-related performance conditions were directly included in the calculation of the fair value of the instruments. Except for the 2012-1 founders’ warrants, the fair value of the warrants and options was measured using the Black-Scholes model. The fair value of 2012-1 founders’ warrants was determined using the Monte Carlo valuation model to take into account the exercise conditions, which depend on the realized gain compared to the expected stock market listing price. The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence , no new instrument became issuable. BSPCE Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the year ended 2021 (in thousands of euros) Expense for the year ended 2020 (in thousands of euros) Expense for the year ended 2019 (in thousands of euros) BSPCE 2012-1 5.26 5.26 41 % 3.49 0.20 % 0.00 % 307 — — — BSPCE 2012-2 6.65 6.63 44.3% - 47.6% 5 - 7.30 0.84% - 1.22% 0.00 % 288 — — — BSPCE 04-2013 6.30 6.30 56 % 5 0.90 % 0.00 % 167 — — — BSPCE 08-2013 6.30 5.92 256 % 7 0.90 % 0.00 % 152 — — — BSPCE 09-2014 18.68 18.68 58 % 5.5/6/6.5 0.64 % 0.00 % 932 — — — BSPCE 2015-1 18.57 18.57 58% - 62% - 61% 5.5/6/6.5 0.39 % 0.00 % 50 — — — BSPCE 2015-2 18.57 18.57 58% - 62% - 61% 5.5/6/6.5 0.39 % 0.00 % 650 — — — BSPCE 2015-3 20.28 20.28 61% - 62% - 61% 5.5/6/6.5 0.56 % 0.00 % 483 — — — BSPCE 2016 Ordinary 14.46 14.46 59% - 62% - 60% 5.5/6/6.5 0.32 % 0.00 % 1,080 — — 10 BSPCE 2016 Performance 14.46 14.46 59 % 5 0.19 % 0.00 % 1,212 32 99 79 BSPCE 2017 Ordinary 15.93 15.93 58% - 61% - 59% 5.5/6/6.5 0.23 % 0.00 % 1,000 0 8 86 BSPCE 2017 Performance 15.93 15.93 59 % 5 0.11 % 0.00 % 622 — — — BSPCE 2017 15.93 15.93 59 % 5 0.11 % 0.00 % 627 — — — BSPCE 2017 Project 15.93 15.93 59 % 5 0.11 % 0.00 % 94 — — — Total BSPCE n.a. n.a. n.a. n.a. n.a. n.a. n.a. 32 107 175 BSA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the year ended 2021 (in thousands of euros) Expense for the year ended 2020 (in thousands of euros) Expense for the year ended 2019 (in thousands of euros) BSA 2012 6.00 6.00 49 % 10 0.96 % 0.00 % 183 — — — BSA 2013 6.30 6.37 156 % 6 0.90 % 0.00 % 1 — — — BSA 2014 18.68 17.67 57 % 5 0.41 % 0.00 % — — — — BSA 2015-1 17.67 17.67 58 % 5 0.26% - 0.27% 0.00 % 63 — — — BSA 2015-2 17.67 19.54 58%-58%-57%-58% 5/5.1/5.3/5.4 0.39 % 0.00 % 16 — — — BSA 2015-3 19.54 19.54 58% - 60% 4.6 – 9.6 0.25% - 0.91% 0.00 % 284 — — — BSA 2016o-1 13.74 13.74 57 % 2.4 0.00 % 0.00 % 37 — — — BSA 2016p-1 13.74 13.74 57 % 2.4 0.00 % 0.00 % 143 — — (41) BSA 2016-2 15.01 15.01 57 % 2.4 0.00 % 0.00 % — — — — BSA 2017o-1 15.76 15.76 33 % 2.4 0.00 % 0.00 % — — — — BSA 2018-1 13.55 13.55 38 % 4.8 0.7% - 0.1% 0.00 % 2 — — — BSA 2018-2 16.102 16.102 38 % 4.8 0.7% - 0.1% 0.00 % 1 — — — BSA 2019-1 11.66 11.66 37 % 9.8/9.9 0.16% - 0.50% 0.00 % 24 — — 24 BSA 2020 — 6.59 38 % 10 -0.13%/ 0.00 % 19 — 19 — BSA 2021 (a) 13.47 13.47 39.10 % 10 0.27 % 0.00 % 44 44 — — BSA 2021 (b) n.a. 13.64 n.a. 10 0.27 % 0.00 % — — — — Total BSA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 44 19 (16) OSA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the year ended 2021 (in thousands of euros) Expense for the year ended 2020 (in thousands of euros) Expense for the year ended 2019 (in thousands of euros) OSA 2016 Ordinary 13.05 13.05 59% - 62% - 60% 5.5 / 6 /6.5 0.32 % 0.00 % 117 — — — OSA 2016 Performance 13.05 13.05 59 % 5 0.19 % 0.00 % 69 — — — OSA 2016-2 14.26 14.26 58% - 62% - 59% 5.5 / 6 /6.5 0.04 % 0.00 % 27 — — 3 OSA 2017 Ordinary 15.93 14.97 58% - 61% - 59% 5.5 / 6 /6.5 0.23 % 0.00 % 31 — — 1 OSA 2017 Performance 15.93 14.97 59 % 5 0.11 % 0.00 % 35 — — — OSA 2018 12.87 12.87 35 % 5.5 / 6 /6.5 0.00 % 0.00 % 252 — 7 66 OSA 2019-1 11.08 11.08 38.1% / 37.4% 6 /6.5 0.103% / 0.149% 0.00 % 140 17 49 38 OSA 2019-2 6.41 6.41 37 % 10 0.40 % 0.00 % 252 — — 436 OSA 2020 6.25 6.25 38 % 10 0.31 % 0.00 % 939 329 453 — OSA 2021-04 O 13.60 13.74 38.9% - 37.8% - 38.3% 5.5 / 6 /6.5 -0.38%/ -0.33%/ -0.28% 0.00 % 684 188 — — OSA 2021-04 P 13.60 13.74 39.10 % 10 0.03 % 0.00 % 1,816 131 — OSA 2021-06 O 12.20 12.99 39.2% / 37.9% / 38.1% 5.5 / 6 /6.5 -0.35 %/ -0.3 %/ -0.26 % 0.00 % 246 79 — — OSA 2021-06 P 12.20 12.99 39.10 % 10 0.13 % 0.00 % 212 16 — Total OSA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 760 509 543 AGA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the year ended 2021 (in thousands of euros) Expense for the year ended 2020 (in thousands of euros) Expense for the year ended 2019 (in thousands of euros) AGA 2018-1 12.87 0.00 n.a. n.a. 0.00 % 0.00 % 4,951 16 268 2,052 AGA 2018-2 12.87 0.00 n.a. n.a. 0.00 % 0.00 % 75 — 21 37 AGA 2019-1 10.90 0.00 n.a. n.a. 0.19% / 0.141% 0.00 % 4,776 422 1,884 1,529 AGA 2020 5.90 0.00 n.a. n.a. -0.74%/-0.69% 0.00 % 287 144 116 — AGA 2021 13.60 0.00 n.a. n.a. -0.63%/ -0.59% 0.00 % 4,869 1,784 — — Total AGA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 2,366 2,289 3,618 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2021 32 44 760 2,366 3,202 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2020 107 19 509 2,289 2,924 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2019 175 (16) 543 3,618 4,320 |
Net financial income (loss)
Net financial income (loss) | 12 Months Ended |
Dec. 31, 2021 | |
Income, expense, gains or losses of financial instruments [abstract] | |
Net financial income (loss) | Net financial income (loss) For the years ended December 31, (in thousands of euros) 2021 2020 2019 Income from cash and cash equivalents — — 105 Foreign exchange gains 6,347 104 599 Other financial income 13 97 133 Total financial income 6,360 201 837 Interest cost (383) 4,676 (4,434) IFRS 16 related interests (288) (333) (359) Foreign exchange losses (109) (1,697) (176) Total financial expenses (780) 2,646 (4,970) Net financial income (loss) 5,580 2,847 (4,133) For the year ended December 31, 2021, the interest cost was a negative net amount of €383 thousands, mainly due to the EIB loan interest and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of €4.2 million in 2021 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by €1.8 million impact of EIB fixed interest cost. For the year ended December 31, 2020, the interest cost was a positive net amount of €4.7 million, substantially due to the EIB loan interests and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of €4.8 million in 2020 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by €1.7 million impact of EIB fixed interest cost. In 2021, the Company had foreign exchange gains for the total amount of €6.3 million. This impact was primarily arising from the foreign exchange gains realized by the Company related to the HSBC bank account denominated in U.S. dollars. In 2020, the Company had foreign exchange losses for the total amount of €1.7 million. This impact was first arising from retaining $113.3 million from the gross proceeds of the global offering in a US dollar bank account. |
Income tax
Income tax | 12 Months Ended |
Dec. 31, 2021 | |
Income taxes paid (refund) [abstract] | |
Income tax | Income tax Accounting policy The Company and its subsidiaries are subject to income tax in their respective jurisdictions. Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements. The main temporary differences relate to tax loss carryforwards. The prevailing income tax rates on the reporting date are used to determine deferred taxes. Deferred tax assets, which mainly arise as a result of tax loss carryforwards, are only recognized to the extent that it is probable that sufficient taxable income will be available in the future against which to offset the tax loss carryforwards or the temporary differences. Management uses its best judgment to determine such probability. Given the Company’s current stage of development and its short-term earnings outlook, the Company is unable to make sufficiently reliable forecasts of future earnings and accordingly, deferred tax assets have not been recognized and offset only to the extent of deferred tax liabilities in the same taxable entities. Detail of income tax As of December 31, 2021, in accordance with the applicable legislation, the Company has €284 million of evergreen tax losses in France, in comparison with €235 million and €184.3 million of evergreen tax losses in France as of December 31, 2020 and 2019, respectively. For fiscal years ended on or after December 31, 2018, the use of tax loss carryforwards in France is capped at €1.0 million, plus 50% of the portion of profits in excess of that limit. The cumulative tax loss carryforwards for the U.S. entities of the Company totaled $3.4 million as of December 31, 2021, $4.4 million as of December 31, 2020 and $4.8 million in the United States as of December 31, 2019. The tax loss carryforwards that were generated before January 1, 2018 will expire 20 years after they were generated; those generated after that date have an indefinite carryforward. The tax loss carryforwards in the U.S. comply with the federal and each state’s Net Operating Loss (“NOL”) rules updated by the Tax Cuts and Jobs Act (“TCJA”) of 2017. The following table reconciles the Company’s theoretical tax expense to its effective tax expense: For the year ended December 31, (in thousands of euros) 2021 2020 2019 Net loss (47,003) (33,590) (50,915) Effective tax expense 5 9 3 Recurring loss before tax (47,058) (33,581) (50,912) Theoretical tax rate (statutory rate in France) 26.50 % 28.00 % 31.00 % Theoretical tax (benefit) expense (12,470) (9,403) (15,782) Share-based payment 848 819 1,339 Other temporary differences 117 (6) (1) Other non-taxable items (644) (540) (736) Unrecognized tax losses 12,154 9,138 15,177 Effective tax expense 5 9 3 Effective tax rate 0.00 % 0.00 % 0.00 % The cumulative net unrecognized deferred tax assets amounted to €75.4 million in 2021, including €14.0 million of 2021 net operating loss carryforwards in comparison with €60.2 million in 2020, including €59.6 million of 2020 net operating loss carryforwards and €51.0 million in 2019, including €49.6 million of 2019 net operating loss carryforwards. |
Segment reporting
Segment reporting | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of operating segments [abstract] | |
Segment reporting | Segment reporting In accordance with IFRS 8 – Operating Segments , reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company’s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided. |
Loss per share
Loss per share | 12 Months Ended |
Dec. 31, 2021 | |
Earnings per share [abstract] | |
Loss per share | Loss per share Accounting policy Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17. Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share. For the year ended December 31, 2021 2020 2019 Net loss for the period (in thousands of euros) (47,063) (33,590) (50,915) Weighted average number of shares 34,733,418 24,385,827 21,631,514 Basic loss per share (in euros) (1.35) (1.38) (2.35) Diluted loss per share (in euros) (1.35) (1.38) (2.35) Instruments providing deferred access to the capital are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore, diluted loss per share is identical to basic loss per share as all equity instruments issued but not granted, representing as of December 31, 2021, 3,006,532 potential additional ordinary shares, have been considered antidilutive. |
Commitments
Commitments | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure Of Commitments [Abstract] | |
Commitments | Commitments 22.1 Obligations under the loan agreement with the EIB In the event the EIB loan is repaid early, or in the event of a change of control after repayment of the loan, the amount of royalties due will be equal to the net present value of the royalties as determined by an independent expert, such amount not to be less than €35.0 million. The EIB finance contract contains covenants that impose restrictions on the operation of the Company's business but no financial covenants that the Company is required to comply with. In certain circumstances, including any material adverse change, a change of control of the Company or if Dr. Laurent Levy, Chairman of the Executive Board, ceases to hold office, the Company may be required to pay a cancellation fee. If Dr. Laurent Levy ceases to hold a certain number of shares or ceases to be an officer, the EIB may require early repayment of the loan. 22.2 Obligations under the terms of the rental agreements part of the IFRS 16 exemptions The obligations of the Company related to the leases falling under the practical expedients (leases related to low-value assets and short-term leases) are as follow: • One short term lease for an office by Nanobiotix Corp., of which the annual rent is €140 thousand; and • Leases related to low-value assets for Nanobiotix S.A.’s printers, of which the annual rent is around €10 thousand. 22.3 Obligations related to the MD Anderson agreement In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration. The collaboration will support multiple new Phase I/II clinical trials involving around 340 patients with Nanobiotix’s first-in-class agent NBTXR3 for use in treating several cancer types – including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11 million for those clinical trials during the collaboration, and made an initial $1.0 million payment at the commencement of the collaboration and a second $1.0 million payment on February 3, 2020. Additional payments will be made in the 6 months following a patient enrollment, and expense is recorded in the statement of consolidated operations during the course of the collaboration on the basis of patients enrolled during the relevant period, with the balance payable upon enrollment of the final patient for all studies. Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $2.2 million to $16.4 million. The amount will be determined on the basis of patients enrolled in the clinical trials at the date of FDA registration. This number increases every year and varies between $2.2 million (if it had been payable in 2020) and $16.4 million (if payable in 2030). As of December 31, 2021, €1.8 million have already been invoiced since the beginning of the collaboration and €1.0 million remain in prepaid expenses. An additional payment will also occur in the event of a successful first registration of NBTXR3 with the FDA. 22.4 Obligations related to the termination of the PharmaEngine agreement In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement entered into in August 2012. During the year ended December 31, 2021, the Company paid $6.5 million to PharmaEngine (€5.4 million converted at the exchange rate on the payment date) in accordance with the termination agreement signed between the parties. PharmaEngine is eligible to receive additional payments of $1 million upon receipt by the Company of clinical study reports and of $5 million upon the second regulatory approval of NBTXR3 in any jurisdiction in the world and for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region. |
Related parties
Related parties | 12 Months Ended |
Dec. 31, 2021 | |
Related party transactions [abstract] | |
Related parties | Related parties Key management personnel compensation The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown: For the year ended December 31, (in thousands of euros) 2021 2020 2019 Salaries, wages and benefits 1,245 1,073 1,306 Share-based payments 2,018 1,723 2,066 Supervisory Board’s fees 375 70 70 Total compensation to related parties 3,638 2,866 3,442 The methods used to measure share-based payments are presented in Note 17. |
Subsequent events
Subsequent events | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of non-adjusting events after reporting period [abstract] | |
Subsequent events | Subsequent events Accounting policy The statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed. Detail of subsequent events Considerations arising from the Russia-Ukraine war Russia launched in February 2022 the invasion of Ukraine, which, in addition to creating humanitarian concerns, may also impact the health care ecosystem in the form of delayed clinical trials. Clinical trial sites originally appointed in Russia and Ukraine for the clinical trial NANORAY-312 were not actively opened at the time of such conflict and, consequently, did not recruit patients. While backup options are being identified and the replacement of such sites by sites located in other countries is actively conducted by the Company, it is currently impossible to exclude any delay in this clinical trial activity, even if no significant delay has been identified as of the date of issuance of this Annual Report. Share capital increase On March 11, 2022, the share capital of the Company was increased by a nominal amount of €1,500, through the issuance of 50,000 new ordinary shares with a nominal value of €0.03 each, increasing the Company’s share capital from €1,044,776.16 to €1,046,276.16, as a result of the definitive acquisition of 50,000 AGA 2020. Such acquisition was acknowledged by the Executive Board on March 11, 2022. |
Consolidation principles and _2
Consolidation principles and methods (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Significant Accounting Policies [Abstract] | |
General principles, Statement of Compliance and Basis of Presentation | General principles The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders’ equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management’s supervision and were approved by the Executive Board of the Company (the “Executive Board”) and reviewed by the Supervisory Board of the Company (the “Supervisory Board”) on March 30, 2022. All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items. The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (‘‘IFRS’’) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information). The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company’s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of €83,921 thousand as of December 31, 2021, as compared to €119,151 thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication. Statement of Compliance and Basis of Presentation The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union. Those are available on the European Commission website: https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002 The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021. Application of New or Amended Standards and Interpretations The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021: • Amendments to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and • Amendments to IFRS 16 - Covid-19 Related rent concession. The application of these standards had no impact on the consolidated financial statements of the Company. Application of New or Amended Standards and Interpretations early adopted by the Company The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. Application of New or Amended Standards and Interpretations not yet applied by the Company The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 : • IFRS 17 - Insurance contracts and related amendments. No impact expected on the financial statements. • Amendment to IAS 1 - Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality”. No significant impact expected on the financial statements. • Amendment to IAS 37 - Onerous Contracts - Cost of Fulfilling a Contract. No significant impact expected on the financial statements. • Amendment to IFRS 3 - Conceptual framework . No significant impact expected on the financial statements. • Amendment to IAS 8 - Definition of an accounting estimate . No significant impact expected on the financial statements. • Amendments to IAS 16 - Property, Plant and Equipment: Proceeds before Intended Use . No significant impact expected on the financial statements. |
Basis of consolidation | 3.1 Basis of consolidation Accounting policy In accordance with IFRS 10 – Consolidated Financial Statements , an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company’s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control. All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full. The accounting methods of the Company’s subsidiaries are aligned with those of the Company. The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $1.1326 as of December 31, 2021 and an average of $1.1835 for the year ended December 31, 2021 (source: Banque de France) compared with $1.2271 and $1.1413, for 2020 and $1.1234 and $1.1196 for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment. Consolidated entities As of December 31, 2021, the Company involves one parent entity, “Nanobiotix S.A.,” and five wholly owned subsidiaries: • Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014; • Nanobiotix Germany GmbH, incorporated in Germany in October 2017; • Nanobiotix Spain S.L.U., incorporated in Spain in December 2017; • Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and • Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. |
Use of judgement, estimates and assumptions | 3.2 Use of judgement, estimates and assumptions The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. Measurement of share-based payments The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants ( e.g. , vesting terms) and market data ( e.g. , expected share volatility) (see Note 17). Deferred tax assets Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19). The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position. Clinical trial accruals Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly. See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020. Revenue recognition In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio. See Note 15 for additional detail regarding the Company’s accounting policies for its additional sources of revenue. Fair value of financial assets and liabilities The fair value measurement of the loan granted by European Investment Bank (“EIB”) requires the Company to assess the amount of additional interest (“royalties”, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company’s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied). |
Intangible assets | Accounting policies In accordance with IAS 38 – Intangible Assets , intangible assets are carried at their acquisition cost. Research and Development costs Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 – Intangible Assets , development costs may only be capitalized as intangible assets if the following criteria are met: • it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale; • the Company intends to complete the development of the intangible asset and use or sell it; • the Company has the ability to use or sell the intangible asset; • it is probable that the intangible asset will generate future economic benefits; • adequate technical, financial and other resources are available to complete the development of the intangible asset; and • the Company is able to reliably measure the expenditures attributable to the development of the intangible asset. The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods. Patents Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36. Software The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license. Recoverable amount of intangible assets Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount. |
Property, plant and equipment | Accounting policies Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company’s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred. Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets. The depreciation periods used are as follows: • General fixtures and fittings, building work: 5 to 10 years; • Technical installations, equipment and industrial tooling: 3 to 10 years; and • Office and IT equipment and furniture: 1 to 10 years. Recoverable amount of property, plant and equipment Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use. |
Non-current financial assets | Accounting policies Non-current financial assets are recognized and measured in accordance with IFRS 9 – Financial Instruments. No non-current financial assets are estimated at fair value through other comprehensive income (OCI). Pursuant to IFRS 9 – Financial Instruments , financial assets are classified in three categories according to their nature and the intention of management: • Financial assets at fair value through profit and loss; • Financial assets at fair value through other comprehensive income; and • Financial assets at amortized cost. All regular way purchases and sales of financial assets are recognized at the settlement date. Financial assets at fair value through profit or loss This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable. Financial assets at amortized cost This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents. They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15. After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met: • The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired. IFRS 9 – Financial Instruments requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case–by–case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements. Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released. Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations. |
Trade receivables | Trade receivablesIn 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled. |
Cash and cash equivalents | Accounting policy Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits. Cash equivalents are measured at amortized cost. |
Capital issued | Accounting policies Ordinary shares are classified in shareholders’ equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders’ equity as a deduction from the proceeds of the issue. |
Provisions | Accounting policies Provisions for contingencies and charges Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities. A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end. Provisions for retirement obligations Company employees receive the retirement benefits provided for by law in France: • Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and • Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan). The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method. Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee’s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity. Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate. As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used). |
Financial liabilities | Accounting policies The Company receives assistance in the form of grants, conditional advances and interest-free loans. Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance. The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities. Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities. Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated. Financial liabilities are recognized and measured in accordance with IFRS 9 – Financial Instruments. Financial liabilities, including trade and other payables are valued at amortized cost. Financial liabilities at amortized cost Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 – Financial Instruments. They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method. Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost. |
Trade and other payables | Accounting policies Accounting policies for Trade and other payables are described in Note 12, ‘‘Financial Liabilities.’’ Accrued expenses Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date. The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date. |
Revenue and other income | Accounting policies Revenue Revenue is recognized in accordance with IFRS 15. Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service). Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue. Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party e.g. : • Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered; • A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred; • A license: ◦ If the license is assessed to be a right to access the Company’s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or ◦ If the license is a right to use the Company’s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or • Product supply for which the revenue is recognized once the control over the delivered products is transferred. Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred. Application to the license and collaboration agreement with PharmaEngine Under the License and Collaboration Agreement, the Company’s and PharmaEngine’s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company’s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine. The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above: • the license of the right to use the Company’s patent and know-how; • the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine’s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and • the supply of NBTXR3 to PharmaEngine. An upfront payment of $1.0 million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012. Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $1 million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company’s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $1 million (first patient’s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine ’s territory, which had not occurred as of December 31, 2021. Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur. In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions. Application of IFRS 15 to the license and collaboration agreement with LianBio Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15. We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio: • an exclusive license, under the Company's intellectual property, to develop and market the licensed products; • the right to actively participate in global Phase III registration trials to obtain marketing approval in China; • if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals; • if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and • the requirement to purchase products under license to the Company. The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct. As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone. LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases. Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products. In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20 million and may receive up to $220 million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts. No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products. The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined. Grants Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received. Research tax credit The French tax authorities grant a research tax credit ( Crédit d’Impôt Recherche , or “CIR”), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following three years. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the “PME”, it can request immediate refund of the remaining tax credit, without application of the three-year period). The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations. |
Operating expenses | Accounting policies Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22). |
Share-based payments | Accounting policy The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had nine (9) outstanding founders’ warrant plans, twelve (12) outstanding warrant plans, nine (9) stock option plans and two (2) outstanding free shares plans. These share-based compensation plans are settled in equity instruments. The Company has applied IFRS 2 – Share-based Payment to all equity instruments granted to employees since 2006. As required by IFRS 2 – Share-based Payment , the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders’ equity for the vesting period during which the rights with respect to the equity instruments are earned. The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below. |
Income tax | Accounting policy The Company and its subsidiaries are subject to income tax in their respective jurisdictions. Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements. |
Segment reporting | In accordance with IFRS 8 – Operating Segments , reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company’s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided. |
Loss per share | Accounting policy Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17. Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share. |
Subsequent events | Accounting policyThe statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed. |
Intangible assets (Tables)
Intangible assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Intangible assets other than goodwill [abstract] | |
Schedule of intangible assets | The change in intangible assets breaks down as follows: (in thousands of euros) As of As of January 1, 2021 Increases Decreases Transfer Currency As of December 31, 2021 Patents 65 — — — — 65 Software 651 5 — — — 657 Intangible assets in progress — — — — — — Gross book value of intangible assets 717 5 — — — 722 Patents (65) — — — — (65) Software (630) (22) — — — (652) Accumulated depreciation of intangible assets (1) (695) (22) — — — (717) Net book value of intangible assets 21 (17) — — — 4 (1) Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses (in thousands of euros) As of January 1, 2020 Increases Decreases Transfer Currency As of December 31, 2020 Patents 65 — — — — 65 Software 584 11 (5) 61 — 651 Intangible assets in progress 61 — — (61) — — Gross book value of intangible assets 710 11 (5) — — 717 Patents (65) — — — — (65) Software (483) (152) 5 (0) (0) (630) Accumulated depreciation of intangible assets (1) (548) (152) 5 — — (695) Net book value of intangible assets 163 (141) — (0) (0) 21 (1) Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses |
Property, plant and equipment (
Property, plant and equipment (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Property, plant and equipment [abstract] | |
Schedule of property, plant and equipment | The change in property, plant and equipment is as follows: (in thousands of euros) As of January 1, 2021 Increases Decreases Transfer Currency As of December 31, 2021 Fixtures, fittings and installations 3,313 5 — — — 3,318 Right of use – Buildings 7,171 1,362 (139) — — 8,393 Technical equipment 2,061 73 — 1 — 2,135 Office and IT equipment 988 53 (35) — 4 1,010 Transport equipment 31 — — — 3 33 Right of use – Transport equipment 65 — (38) — 1 28 Tangible assets in progress 1 97 — (0) — 98 Prepayments on tangible assets — — — (0) — — Gross book value of tangible assets 13,630 1,590 (212) — 8 15,017 Fixtures, fittings and installations (1,320) (320) — — — (1,641) Right of use – Buildings (1,739) (901) 30 — — (2,610) Technical equipment (1,466) (178) — — — (1,644) Office and IT equipment (783) (124) 34 — (3) (875) Transport equipment (31) — — — (3) (33) Right of use – Transport equipment (36) (12) 20 — (1) (28) Accumulated depreciation of tangible assets (1) (5,374) (1,534) 84 — (6) (6,831) Net book value of tangible assets 8,256 56 (129) — 3 8,186 (in thousands of euros) As of January 1, 2020 Increases Decreases Other movements & transfer. Currency As of December 31, 2020 Fixtures, fittings and installations 3,297 16 — — — 3,313 Right of use – Buildings 6,766 418 (14) — — 7,171 Technical equipment 2,019 42 — — — 2,061 Office and IT equipment 957 37 (1) — (4) 988 Transport equipment 34 — — — (3) 31 Right of use – Transport equipment 115 — (41) (5) (4) 65 Tangible assets in progress 11 1 — (11) — 1 Prepayments on tangible assets — — — — — — Gross book value of tangible assets 13,197 515 (57) (15) (11) 13,630 Fixtures, fittings and installations (1,001) (320) — — — (1,320) Right of use – Buildings (829) (911) — 2 — (1,739) Technical equipment (1,272) (194) — — — (1,466) Office and IT equipment (629) (157) 1 — 2 (783) Transport equipment (34) — — 1 3 (31) Right of use – Transport equipment (45) (35) 42 — 1 (36) Accumulated depreciation of tangible assets (1) (3,811) (1,616) 43 4 6 (5,374) Net book value of tangible assets 9,386 (1,101) (14) (12) (4) 8,256 |
Non-current financial assets (T
Non-current financial assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of financial assets [abstract] | |
Disclosure of changes in non-current financial assets | The change in non-current financial assets breaks down as follows: (in thousands of euros) Liquidity contract - Cash account (1) Other Security Total Net book value as of December 31, 2019 131 — 399 529 Additions — — 9 9 Decreases (27) — (5) (31) Currency translation adjustments — — (2) (2) Net book value as of December 31, 2020 105 — 401 505 Additions — — 9 9 Decreases (6) — — (6) Transfer — — 8 8 Currency translation adjustments — — 3 3 Net book value as of December 31, 2021 98 — 421 519 (1) See note 10.2 Treasury shares |
Trade receivables and other c_2
Trade receivables and other current assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Disclosure of break down of trade receivables | As of December 31, (in thousands of euros) 2021 2020 Trade receivables — 62 Trade receivables — 62 Trade receivables break down as follows: As of December 31, (in thousands of euros) 2021 2020 Due in 3 months or less — 62 Due between 3 and 6 months — — Due between 6 and 12 months — — Due after more than 12 months — — Trade receivables — 62 |
Disclosure of break down of other current assets | Other current assets break down as follows: As of December 31, (in thousands of euros) 2021 2020 Research tax credit receivable 2,490 1,927 VAT receivable 1,058 971 Prepaid expenses 2,213 2,217 Other receivables 3,378 920 Other current assets 9,139 6,035 |
Disclosure of changes in research tax credit receivables | The change in research tax credit receivables breaks down as follows: (in thousands of euros) Receivable as of December 31, 2019 5,688 Refund of 2018 research tax credit – Nanobiotix SA (3,251) Refund of 2019 research tax credit – Nanobiotix SA (2,374) Refund of 2019 research tax credit – Curadigm SAS (64) 2020 research tax credit – Nanobiotix SA 1,858 2020 research tax credit – Curadigm SAS 69 Receivable as of December 31, 2020 1,927 Refund of 2020 research tax credit – Nanobiotix SA (1,858) Refund of 2020 research tax credit – Curadigm SAS (69) 2021 research tax credit – Nanobiotix SA 2,272 2021 research tax credit – Curadigm SAS 218 Receivable as of December 31, 2021 2,490 |
Cash and cash equivalents (Tabl
Cash and cash equivalents (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Summary of cash and cash equivalents | Detail of cash and cash equivalents Cash and cash equivalent break down as follows: (in thousands of euros) As of December 31, 2021 As of December 31, 2020 Cash and bank accounts 83,921 119,151 Net cash and cash equivalents 83,921 119,151 |
Share Capital (Tables)
Share Capital (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract] | |
Disclosure of detail of share capital transactions | Detail of share capital transactions (in thousands or number of shares) Nature of transaction Share Capital Premiums related to share capital Number of shares December 31, 2019 672 153,139 22,415,039 March 6, 2020 Capital increase 9 0 316,083 June 24, 2020 Subscription of 2020 warrants — 1 — June 26, 2020 Subscription of 2020 warrants — 1 — June 29, 2020 Subscription of 2020 warrants — 2 — June 30, 2020 Subscription of 2020 warrants — 1 — July 27, 2020 Capital increase — — 6,000 July 28, 2020 Private placement Capital increase 99 20,030 3,300,000 July 28, 2020 Private placement Capital increase transaction costs — (1,387) — December 16, 2020 U.S. Initial public offering initial deal € - Nasdaq (€11.14) 56 20,609 1,855,000 December 16, 2020 U.S. Initial public offering initial deal $ - Nasdaq ($13.50) 163 60,494 5,445,000 December 18, 2020 U.S. Initial public offering green shoe $ - Nasdaq ($13.50) 33 12,165 1,095,000 December 18, 2020 U.S. Initial public offering costs — (9,322) — December 31, 2020 1,033 255,735 34,432,122 March 31, 2021 Capital increase AGA 2018-1 1 — 24,500 March 31, 2021 Capital increase AGA 2019-1 11 — 369,250 April 20, 2021 Warrants attribution — (11) — May 31, 2021 Warrants subscription (BSA 2021) — 43 — December 31, 2021 1,045 255,767 34,825,872 |
Disclosure of detail of change in founders' warrants, warrants and free shares | The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020. Founders’ warrants (BSPCE) Type Grant Exercise Outstanding Issued Exercised Forfeited Outstanding Number of BSPCE 2012-2 December 18, 2012 6.63 100,000 — — — 100,000 100,000 BSPCE 08-2013 August 28, 2013 5.92 50,000 — — — 50,000 50,000 BSPCE 09-2014 September 16, 2014 18.68 86,150 — — — 86,150 86,150 BSPCE 2015-1 February 10, 2015 18.57 68,450 — — — 68,450 68,450 BSPCE 2015-3 June 10, 2015 20.28 30,700 — — (350) 30,350 30,350 BSPCE 2016 February 2, 2016 14.46 202,617 — — (1,776) 200,841 200,841 BSPCE 2017 January 7, 2017 15.93 180,850 — — (1,350) 179,500 179,500 Total 718,767 — — (3,476) 715,291 715,291 Type Grant Exercise Outstanding Issued Exercised Forfeited Outstanding Number of BSPCE 2012-2 December 18, 2012 6.63 100,000 — — — 100,000 100,000 BSPCE 08-2013 August 28, 2013 5.92 50,000 — — — 50,000 50,000 BSPCE 09-2014 September 16, 2014 18.68 92,100 — — (5,950) 86,150 86,150 BSPCE 2015-1 February 10, 2015 18.57 70,950 — — (2,500) 68,450 68,450 BSPCE 2015-3 June 10, 2015 20.28 38,400 — — (7,700) 30,700 30,700 BSPCE 2016 February 2, 2016 14.46 212,969 — — (10,352) 202,617 202,617 BSPCE 2017 January 7, 2017 15.93 187,166 — — (6,316) 180,850 180,850 Total 751,585 — — (32,818) 718,767 718,767 Type Grant date Exercise Outstanding at Issued Exercised Forfeited Outstanding Number of BSA 04-12 May 4, 2012 6.00 30,000 — — — 30,000 30,000 BSA 2013 April 10, 2013 6.37 6,000 — — — 6,000 6,000 BSA 2014 September 16, 2014 17.67 10,000 — — — 10,000 10,000 BSA 2015-1 February 10, 2015 17.67 21,000 — — — 21,000 21,000 BSA 2015-2(a) June 25, 2015 19.54 64,000 — — — 64,000 64,000 BSA 2015-2(b) June 25, 2015 19.54 — — — — — — BSA 2016 February 2, 2016 13.74 36,208 — — (36,208) — — BSA 2016-2 November 3, 2016 15.01 8,000 — — (8,000) — — BSA 2017 January 7, 2017 15.76 18,000 — — — 18,000 18,000 BSA 2018-1 March 6, 2018 13.55 28,000 — — — 28,000 28,000 BSA 2018-2 July 27, 2018 16.102 5,820 — — — 5,820 5,820 BSA 2019-1 March 29, 2019 11.66 18,000 — — — 18,000 18,000 BSA 2020 March 17, 2020 6.59 18,000 — — — 18,000 18,000 BSA 2021 (a) April 21, 2021 13.47 — 48,103 — (33,672) 14,431 14,431 BSA 2021 (b) April 21, 2021 13.64 — 30,000 — — 30,000 30,000 Total 263,028 78,103 — (77,880) 263,251 263,251 Type Grant date Exercise Outstanding at Issued Exercised Forfeited Outstanding Number of BSA 04-12 May 4, 2012 6.00 30,000 — — — 30,000 30,000 BSA 2013 April 10, 2013 6.37 6,000 — — — 6,000 6,000 BSA 2014 September 16, 2014 17.67 10,000 — — — 10,000 10,000 BSA 2015-1 February 10, 2015 17.67 21,000 — — — 21,000 21,000 BSA 2015-2(a) June 25, 2015 19.54 64,000 — — — 64,000 64,000 BSA 2015-2(b) June 25, 2015 19.54 6,000 — — (6,000) — — BSA 2016 February 2, 2016 13.74 36,208 — — — 36,208 36,208 BSA 2016-2 November 3, 2016 15.01 8,000 — — — 8,000 8,000 BSA 2017 January 7, 2017 15.76 18,000 — — — 18,000 18,000 BSA 2018-1 March 6, 2018 13.55 28,000 — — — 28,000 28,000 BSA 2018-2 July 27, 2018 16.102 5,820 — — — 5,820 5,820 BSA 2019-1 March 29, 2019 11.660 18,000 — — — 18,000 18,000 BSA 2020 March 17, 2020 6.59 — 18,000 — — 18,000 18,000 Total 251,028 18,000 — (6,000) 263,028 263,028 Type Grant date Exercise Outstanding at Issued Definitively acquired Forfeited Outstanding Number of AGA 2018-1 March 6, 2018 n.a. 24,500 — (24,500) — — — AGA 2018-2 July 27, 2018 n.a. — — — — — — AGA 2019-1 March 29, 2019 n.a. 372,000 — (369,250) (2,750) — — AGA 2020 March 11, 2020 n.a. 50,000 — — — 50,000 50,000 AGA 2021 April 20, 2021 n.a. — 362,515 — (2,003) 360,512 360,512 Total 446,500 362,515 (393,750) (4,753) 410,512 410,512 Type Grant date Exercise Outstanding at January 1, Issued Definitively acquired Forfeited Outstanding Number of AGA 2018-1 March 6, 2018 n.a. 355,250 — (316,083) (14,667) 24,500 24,500 AGA 2018-2 July 27, 2018 n.a. 6,000 — (6,000) — — — AGA 2019-1 March 29, 2019 n.a. 385,000 — — (13,000) 372,000 372,000 AGA 2020 March 11, 2020 n.a. — 50,000 — — 50,000 50,000 Total 746,250 50,000 (322,083) (27,667) 446,500 446,500 |
Disclosure of detail of change in stock options | OSA) Type Grant date Exercise Outstanding at Issued Exercised Forfeited Outstanding Number of OSA 2016-1 February 2, 2016 13.05 400 — — — 400 400 OSA 2016-2 November 3, 2016 14.26 4,000 — — — 4,000 4,000 OSA 2017 January 7, 2017 14.97 500 — — — 500 500 OSA 2018 March 6, 2018 12.87 52,000 — — — 52,000 52,000 OSA 2019-1 March 29, 2019 11.08 28,750 — — (500) 28,250 28,250 OSA LLY 2019 October 24, 2019 6.41 500,000 — — — 500,000 500,000 OSA 2020 March 11, 2020 6.25 400,709 — — (13,253) 387,456 387,456 OSA 2021-04 April 20, 2021 13.74 — 571,200 — (80,000) 491,200 491,200 OSA 2021-06 June 21, 2021 12.99 — 120,000 — — 120,000 120,000 Total 986,359 691,200 — (93,753) 1,583,806 1,583,806 Type Grant date Exercise Outstanding at Issued Exercised Forfeited Outstanding Number of OSA 2016-1 February 2, 2016 13.05 400 — — — 400 400 OSA 2016-2 November 3, 2016 14.26 4,000 — — — 4,000 4,000 OSA 2017 January 7, 2017 14.97 500 — — — 500 500 OSA 2018 March 6, 2018 12.87 54,000 — — (2,000) 52,000 52,000 OSA 2019-1 March 29, 2019 11.08 30,250 — — (1,500) 28,750 28,750 OSA LLY 2019 October 24, 2019 6.41 500,000 — — — 500,000 500,000 OSA 2020 March 11, 2020 6.25 — 407,972 — (7,263) 400,709 400,709 Total 589,150 407,972 — (10,763) 986,359 986,359 |
Provisions (Tables)
Provisions (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Provisions [abstract] | |
Disclosure of changes in provisions | (in thousands of euros) As of January 1, 2021 Increases Decreases As of December 31, 2021 Lump-sum retirement benefits 414 — (97) 318 Non-current provisions 414 — (97) 318 Provisions for disputes 40 54 — 94 Provision for charges — 16 — 16 Current provisions 40 70 — 110 Total provisions 454 70 (97) 428 (in thousands of euros) As of January 1, 2020 Increases Decreases (1) As of December 31, 2020 Lump-sum retirement benefits 331 83 — 414 Non-current provisions 331 83 — 414 Provisions for disputes — 40 — 40 Provision for charges 164 — (164) — Current provisions 164 40 (164) 40 Total provisions 495 123 (164) 454 (1) See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases |
Disclosure of commitments for retirement benefits | Commitments for retirement benefits As of December 31, (in thousands of euros) 2021 2020 Provision as of beginning of period 414 331 Cost of services 84 76 Interests / discounting costs 1 3 Expense for the period 85 79 Gains or losses related to experience (133) (61) Gains or losses related to change in demographic assumptions (5) 3 Gains or losses related to change in financial assumptions (43) 62 Actuarial gains or losses recognized in other comprehensive income (182) 4 Provision as of end of period 318 414 |
Disclosure of assumptions used to measure retirement benefits | The assumptions used to measure lump-sum retirement benefits are as follows: Measurement date December 31, 2021 December 31, 2020 Retirement assumptions Management: Age 66 Non-management: Age 64 Management: Age 66 Non-management: Age 64 Social security contribution rate 42.01 % 44 % Discount rate 0.98 % 0.33 % Mortality tables Regulatory table Regulatory table Salary increase rate (including inflation) Executive: 3% Non-Executive: 2.5% Executive: 3% Non-Executive: 2.5% Staff turnover Constant average rate of 5.86% Constant average rate of 5.86% Duration 20 years 17 years |
Disclosure of sensitivity analysis for actuarial assumptions | The sensitivity to the discount rate and to the salary growth is as follows: Discount rate 0.73% 0.98% 1.23% Defined Benefit Obligation as of December 31, 2021 333 318 303 |
Financial liabilities (Tables)
Financial liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of financial liabilities [abstract] | |
Summary of changes in financial liabilities | Details of financial liabilities As of December 31, (in thousands of euros) 2021 2020 Lease liabilities – Short term 1,126 1,197 Repayable BPI loan advances - Short term 800 500 PGE* 1,086 141 EIB Loan – Short term 5,192 3,033 Total current financial liabilities 8,204 4,872 Lease liabilities – Long term 5,393 4,991 Repayable BPI loan advances – Long term 2,259 2,975 PGE* 8,982 9,922 EIB loan – Long term 21,182 26,218 Total non-current financial liabilities 37,816 44,107 Total financial liabilities 46,020 48,979 (*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans Detail of financial instruments included in the statements of financial position and impact on income As of December 31, 2021 (in thousands of euros) Book value on Financial assets Assets and liabilities Fair value (1) Non-current financial assets Non-current financial assets 519 97 421 519 Trade receivables — — — — Cash and cash equivalents 83,921 — 83,921 83,921 Total assets 84,440 97 84,343 84,440 Financial liabilities Non-current financial liabilities 38,733 — 38,733 38,733 Current financial liabilities 7,288 — 7,288 7,288 Trade payables and other payables 6,482 — 6,482 6,482 Total liabilities 52,503 — 52,503 52,503 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. As of December 31, 2020 (in thousands of euros) Book value on the statement of financial position Financial assets carried at fair value through profit or loss Assets and liabilities carried at amortized cost Fair value (1) Non-current financial assets Non-current financial assets 505 104 401 505 Trade receivables 62 — 62 62 Cash and cash equivalents 119,151 — 119,151 119,151 Total assets 119,717 104 119,613 119,717 Financial liabilities Non-current financial liabilities 44,107 — 44,107 44,107 Current financial liabilities 4,872 — 4,872 4,872 Trade payables and other payables 7,106 — 7,106 7,106 Total liabilities 56,085 — 56,085 56,085 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. |
Disclosure of detailed information about conditional advance, bank loan and loans from government and public authorities | Conditional advances and loans from government and public authorities (in thousands of euros) Bpifrance advance Interest-free Bpifrance loan EIB Loan Curadigm Bpifrance advance Total As of January 1, 2020 2,165 1,210 34,746 — 38,121 Principal received — — — 350 350 Impact of discounting and accretion 19 14 (1,736) (65) (1,769) Accumulated fixed interest expense accrual 32 — 1,731 — 1,763 Accumulated variable interest expense accrual — — (4,789) — (4,789) Repayment — (250) (700) — (950) As of December 31, 2020 2,216 974 29,251 285 32,727 Principal received — — — — — Impact of discounting and accretion 17 19 (5,817) 16 (5,765) Accumulated fixed interest expense accrual 32 — 1,758 — 1,790 Accumulated variable interest expense accrual — — 4,214 — 4,214 Repayment — (500) (3,033) — (3,533) As of December 31, 2021 2,266 493 26,374 300 29,433 Bank loan (in thousands of euros) HSBC “PGE” (1) Bpifrance “PGE” (1) Total As of January 1, 2020 — — — Principal received 5,000 5,000 10,000 Impact of discounting and accretion 14 34 47 Accumulated fixed interest expense accrual (2) 7 10 17 As of December 31, 2020 5,020 5,044 10,064 Principal received 17 (14) 3 Impact of discounting and accretion 26 120 146 Accumulated fixed interest expense accrual (3) (33) (112) (145) As of December 31, 2021 5,030 5,038 10,068 (1) ”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans (2) In 2020 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. |
Disclosure of reconciliation of changes in lease liabilities | The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed: (in thousands of euros) Lease liabilities As of January 1st, 2020 6,405 New lease contracts 521 Impact of discounting of the new lease contracts (94) Fixed interest expense 333 Repayment of lease (928) Early termination of lease contracts (49) As of December 31, 2020 6,188 Engagement 1,476 Impact of discounting and accretion (110) Accumulated fixed interest expense accrual 288 Repayment of lease (1,195) Early termination of lease contracts (128) As of December 31, 2021 6,519 |
Disclosure of maturity analysis for advances loans and lease liabilities | The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows: As of December 31, 2021 (in thousands of euros) Less than 1 year Between 1 and Between 3 and More than 5 years Bpifrance 300 1,300 808 — Interest-free Bpifrance loan 500 — — — Curadigm interest-free Bpifrance advance — 200 150 — HSBC “PGE” (1) 661 2,572 1,904 — Bpifrance “PGE” (1) 425 2,662 2,237 — EIB fixed rate loan 5,192 28,762 — — Lease liabilities 1,126 2,252 2,247 1,714 Total 8,204 37,747 7,346 1,714 |
Trade payables and other curr_2
Trade payables and other current liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Subclassifications of assets, liabilities and equities [abstract] | |
Disclosure of trade and other payables | Details of trade and other payables As of December 31, (in thousands of euros) 2021 2020 Accrued expenses - clinical trials 1,486 1,532 Trade payables & other accruals 4,996 5,574 Total trade and other payables 6,482 7,106 |
Disclosure of other current liabilities | Other current liabilities As of December 31, (in thousands of euros) 2021 2020 Tax liabilities 258 283 Payroll tax and other payroll liabilities 4,820 6,248 Other payables 453 491 Other current liabilities 5,531 7,022 |
Disclosure of deferred income and contract liabilities | Deferred revenues and contract liabilities As of December 31, (in thousands of euros) 2021 2020 Deferred revenues and contract liabilities 16,518 — Deferred revenues and contract liabilities 16,518 — |
Financial instruments include_2
Financial instruments included in the statement of financial position and impact on income (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [abstract] | |
Disclosure of details of non-current financial assets | Detail of financial instruments included in the statements of financial position and impact on income As of December 31, 2021 (in thousands of euros) Book value on Financial assets Assets and liabilities Fair value (1) Non-current financial assets Non-current financial assets 519 97 421 519 Trade receivables — — — — Cash and cash equivalents 83,921 — 83,921 83,921 Total assets 84,440 97 84,343 84,440 Financial liabilities Non-current financial liabilities 38,733 — 38,733 38,733 Current financial liabilities 7,288 — 7,288 7,288 Trade payables and other payables 6,482 — 6,482 6,482 Total liabilities 52,503 — 52,503 52,503 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. As of December 31, 2020 (in thousands of euros) Book value on the statement of financial position Financial assets carried at fair value through profit or loss Assets and liabilities carried at amortized cost Fair value (1) Non-current financial assets Non-current financial assets 505 104 401 505 Trade receivables 62 — 62 62 Cash and cash equivalents 119,151 — 119,151 119,151 Total assets 119,717 104 119,613 119,717 Financial liabilities Non-current financial liabilities 44,107 — 44,107 44,107 Current financial liabilities 4,872 — 4,872 4,872 Trade payables and other payables 7,106 — 7,106 7,106 Total liabilities 56,085 — 56,085 56,085 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. |
Disclosure of details of financial liabilities | Details of financial liabilities As of December 31, (in thousands of euros) 2021 2020 Lease liabilities – Short term 1,126 1,197 Repayable BPI loan advances - Short term 800 500 PGE* 1,086 141 EIB Loan – Short term 5,192 3,033 Total current financial liabilities 8,204 4,872 Lease liabilities – Long term 5,393 4,991 Repayable BPI loan advances – Long term 2,259 2,975 PGE* 8,982 9,922 EIB loan – Long term 21,182 26,218 Total non-current financial liabilities 37,816 44,107 Total financial liabilities 46,020 48,979 (*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans Detail of financial instruments included in the statements of financial position and impact on income As of December 31, 2021 (in thousands of euros) Book value on Financial assets Assets and liabilities Fair value (1) Non-current financial assets Non-current financial assets 519 97 421 519 Trade receivables — — — — Cash and cash equivalents 83,921 — 83,921 83,921 Total assets 84,440 97 84,343 84,440 Financial liabilities Non-current financial liabilities 38,733 — 38,733 38,733 Current financial liabilities 7,288 — 7,288 7,288 Trade payables and other payables 6,482 — 6,482 6,482 Total liabilities 52,503 — 52,503 52,503 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. As of December 31, 2020 (in thousands of euros) Book value on the statement of financial position Financial assets carried at fair value through profit or loss Assets and liabilities carried at amortized cost Fair value (1) Non-current financial assets Non-current financial assets 505 104 401 505 Trade receivables 62 — 62 62 Cash and cash equivalents 119,151 — 119,151 119,151 Total assets 119,717 104 119,613 119,717 Financial liabilities Non-current financial liabilities 44,107 — 44,107 44,107 Current financial liabilities 4,872 — 4,872 4,872 Trade payables and other payables 7,106 — 7,106 7,106 Total liabilities 56,085 — 56,085 56,085 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. |
Disclosure of effect of changes in exchange rates | The following table shows the impact of a 10% increase or decrease in the exchange rate between the euro and the U.S. dollar, calculated on the amounts of capital contributions and loans to the Company’s U.S. subsidiaries as of December 31, 2021, and 2020. For the year ended December 31, 2021 Impact Net income Equity (in thousands of euros) Increase Decrease Increase Decrease USD / Euro exchange rate 45 (45) 87 (87) Total 45 (45) 87 (87) For the year ended December 31, 2020 Impact Net income Equity (in thousands of euros) Increase Decrease Increase Decrease USD / Euro exchange rate 5 (5) 124 (124) Total 5 (5) 124 (124) |
Revenues and other income (Tabl
Revenues and other income (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Revenue [abstract] | |
Schedule of revenues and other income | The following table summarizes the Company’s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019. For the year ended December 31, (in thousands of euros) 2021 2020 2019 Services 5 50 40 Other sales 5 — 28 Total revenues 10 50 68 Research tax credit 2,490 1,927 2,437 Subsidies 126 526 20 Other 21 10 17 Total other income 2,637 2,462 2,473 Total revenues and other income 2,647 2,512 2,541 |
Operating expenses (Tables)
Operating expenses (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Analysis of income and expense [abstract] | |
Summary of research and development expense | Research and development expenses For the year ended December 31, (in thousands of euros) 2021 2020 2019 Purchases, sub-contracting and other expenses (19,562) (12,734) (16,804) Payroll costs (including share-based payments) (9,605) (10,306) (11,980) Depreciation, amortization and provision expenses (1) (1,211) (1,290) (1,627) Total research and development expenses (30,378) (24,330) (30,411) (1) see note 16.4 Depreciation, amortization and provision expenses |
Summary of selling, general and administrative expenses | Selling, General and Administrative (SG&A) expenses For the year ended December 31, (in thousands of euros) 2021 2020 2019 Purchases, fees and other expenses (9,638) (6,482) (9,435) Payroll costs (including share-based payments) (9,379) (7,789) (9,205) Depreciation, amortization and provision expenses (1) (417) (340) (270) Total SG&A expenses (19,434) (14,611) (18,909) (1) see note 16.4 Depreciation, amortization and provision expenses |
Summary of payroll costs | Payroll costs For the year ended December 31, (in thousands of euros) 2021 2020 2019 Wages and salaries (11,391) (11,141) (11,876) Payroll taxes (4,308) (3,953) (4,913) Share-based payments (3,201) (2,924) (4,320) Retirement benefit obligations (84) (76) (76) Total payroll costs (18,984) (18,094) (21,185) Average headcount 96 97 112 End-of-period headcount 100 90 110 |
Summary of depreciation, amortization and provision expenses | Depreciation, amortization and provision expenses by function are detailed as follows: For the year ended December 31, 2021 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (34) (10) (45) Amortization expense of tangible assets (1,109) (406) (1,515) Provision for charges (68) — (68) Total depreciation, amortization and provision expenses (1,211) (416) (1,628) For the year ended December 31, 2020 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (152) (23) (176) Amortization expense of tangible assets (1,250) (329) (1,579) Utilization of provision for disputes 145 — 145 Provision for charges — (40) (40) Reversal of provision for disputes — 19 19 Total depreciation, amortization and provision expenses (1,257) (373) (1,630) For the year ended December 31, 2019 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (289) (3) (292) Depreciation expense of property, plant and equipment (1,208) (270) (1,478) Utilization of provision for charges — 55 55 Provision for charges (112) (52) (164) Total depreciation, amortization and provision expenses (1,609) (270) (1,879) |
Summary of other operating income (expense) | OTHER OPERATING INCOME AND EXPENSES For the year ended December 31, 2021 (in thousands of euros) 2021 2020 Contract termination indemnity (PharmaEngine) (5,414) — Total Other operating income and expenses (5,414) — |
Share-based payments (Tables)
Share-based payments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
Disclosure of number and weighted average remaining contractual life of founders' warrants, warrants, and free shares oustanding | The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below: Founders’ warrants Pre-2021 founders’ warrant plans BSPCE 2012-2 BSPCE BSPCE BSPCE BSPCE Type of underlying asset New shares New shares New shares New shares New shares Number of founder’s warrants granted 100,000 50,000 97,200 71,650 53,050 Date of shareholders' resolution approving the plan 05/04/2012 06/28/2013 06/18/2014 06/18/2014 06/18/2014 Grant date 12/18/2012 08/28/2013 09/16/2014 02/10/2015 06/10/2015 Contractual expiration date 12/18/2022 08/28/2023 09/16/2024 02/10/2025 06/10/2025 Grant price — — — — — Exercise price €6.63 €5.92 €18.68 €18.57 €20.28 Number of founders’ warrants as of Number of founders’ warrants as of December 31, 2021 100,000 50,000 86,150 68,450 30,350 Number of founders’ warrants exercised — — — — — Including founders’ warrants exercised during the period — — — — — Number of founders’ warrants lapsed or cancelled — — 11,050 3,200 22,700 Including founders’ warrants lapsed or cancelled during the period — — — — 350 Pre-2021 founders’ warrant plans BSPCE BSPCE BSPCE BSPCE Type of underlying asset New shares New shares New shares New shares Number of founder’s warrants granted 126,400 129,250 117,650 80,000 Date of shareholders' resolution approving the plan 06/25/2015 06/25/2015 06/23/2016 06/23/2016 Grant date 02/02/2016 02/02/2016 01/07/2017 01/07/2017 Contractual expiration date 02/02/2026 02/02/2026 01/08/2027 01/07/2027 Grant price — — — — Exercise price €14.46 €14.46 €15.93 €15.93 Number of founders’ warrants as of December 31, 2021 100,567 100,274 99,500 80,000 Number of founders’ warrants exercised 333 — — — Including founders’ warrants exercised during the period — — — — Number of founders’ warrants lapsed or cancelled 25,500 28,976 18,150 — Including founders’ warrants lapsed or cancelled during the period 350 1,426 1,350 — Warrants Pre-2021 warrant plans BSA 04-2012 BSA BSA BSA BSA BSA BSA Type of warrants New shares New shares New shares New shares New shares New shares New shares Number of warrants granted 52,500 10,000 14,000 26,000 64,000 6,000 18,103 Date of shareholders' resolution approving the plan 05/04/2012 05/04/2012 06/18/2014 06/18/2014 06/18/2014 06/25/2015 06/25/2015 Grant date 05/04/2012 04/10/2013 09/16/2014 02/10/2015 06/25/2015 06/25/2015 02/02/2016 Contractual expiration date 05/04/2022 04/10/2023 09/16/2024 02/10/2025 06/25/2025 06/25/2020 02/02/2021 Grant price €0.60 €2.50 €4.87 €4.87 €5.00 €2.80 €1.67 Exercise price €6.00 €6.37 €17.67 €17.67 €19.54 €19.54 €13.74 Number of warrants as of December 31, 2021 30,000 6,000 10,000 21,000 64,000 — — Number of warrants exercised 22,500 — — — — — — Including warrants exercised during the period — — — — — — — Number of warrants lapsed or cancelled — 4,000 4,000 5,000 — 6,000 18,103 Including warrants lapsed or cancelled during the period — — — — — — 18,103 Pre-2021 warrant plans BSA BSA BSA BSA BSA BSA BSA Type of warrants New shares New shares New shares New shares New shares New shares New shares Number of warrants granted 18,105 8,000 18,000 28,000 5,820 18,000 18,000 Date of shareholders' resolution approving the plan 06/25/2015 06/23/2016 06/23/2016 06/14/2017 05/23/2018 05/23/2018 04/11/2019 Grant date 02/02/2016 11/03/2016 01/07/2017 03/06/2018 07/27/2018 03/29/2019 03/17/2020 Contractual expiration date 02/02/2021 11/03/2021 01/07/2022 03/06/2023 07/27/2028 03/29/2029 03/17/2030 Grant price €1.67 €2.03 €2.26 €1.62 €2.36 €1.15 €0.29 Exercise price €13.74 €15.01 €15.76 €13.55 €16.102 €11.66 €6.59 Number of warrants as of December 31, 2021 — — 18,000 28,000 5,820 18,000 18,000 Number of warrants exercised — — — — — — — Including warrants exercised during the period — — — — — — — Number of warrants lapsed or cancelled 18,105 8,000 — — — — — Including warrants lapsed or cancelled during the period 18,105 8,000 — — — — — 2021 warrants BSA 2021 (a) BSA 2021 (b) Type of warrants New shares New shares Number of warrants granted 48,103 30,000 Date of shareholders' resolution approving the plan 11/30/2020 11/30/2020 Grant date 04/20/2021 04/20/2021 Contractual expiration date 04/20/2031 04/20/2031 Grant price €2.95 €0.68 Number of warrants as of Exercise price €13.47 €13.64 Number of warrants as of December 31, 2021 14,431 30,000 Number of warrants exercised — — Including warrants exercised during the period — — Number of warrants lapsed or cancelled 33,672 — Including warrants lapsed or cancelled during the period 33,672 — Free shares Pre-2021 free shares plan not yet vested 2021 free shares plan AGA AGA AGA AGA AGA Type of underlying assets New shares New shares New shares New shares New shares Number of free shares granted 396,250 6,000 438,250 50,000 362,515 Date of shareholders' resolution approving the plan 06/14/2017 05/23/2018 05/23/2018 04/11/2019 11/30/2020 Grant date 03/06/2018 07/27/2018 03/29/2019 03/11/2020 04/20/2021 Grant price — — — — — Exercise price — — — — — Number of free shares as of December 31, 2021 — — — 50,000 360,512 Number of free shares exercised 340,583 6,000 369,250 — — Including free shares exercised during the period 24,500 — 369,250 — — Number of free shares lapsed or cancelled 55,667 — 69,000 — 2,003 Including free shares lapsed or cancelled during the period — — 2,750 — 2,003 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2021 715,291 263,251 1,583,806 410,512 2,972,860 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2020 718,767 263,028 986,359 446,500 2,414,654 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2019 751,585 251,028 589,150 746,250 2,338,013 |
Disclosure of number and weighted average remaining contractual life of share options outstanding | Stock options Pre-2021 stock option plans OSA OSA OSA OSA OSA OSA OSA Type of underlying asset New shares New shares New shares New shares New shares New shares New shares Number of options granted 6,400 4,000 3,500 62,000 37,500 500,000 407,972 Date of shareholders' resolution approving the plan 06/25/2015 06/23/2016 06/23/2016 06/14/2017 05/23/2018 04/11/2019 04/11/2019 Grant date 02/02/2016 11/03/2016 01/07/2017 03/06/2018 03/29/2019 10/24/2019 03/11/2020 Contractual expiration date 02/02/2026 11/03/2026 01/07/2027 03/06/2028 03/29/2029 10/24/2029 03/11/2030 Grant price — — — — — — — Exercise price €13.05 €14.26 €14.97 €12.87 €11.08 €6.41 €6.25 Number of options as of December 31, 2021 400 4,000 500 52,000 28,250 500,000 387,456 Number of options exercised — — — — — — — Number of options as of Including options exercised during the period — — — — — — — Number of options lapsed or cancelled 6,000 — 3,000 10,000 9,250 — 13,253 Including options lapsed or cancelled during the period — — — — 500 — 13,253 2021 stock option plans OSA 2021-04 OSA 2021-06 Type of underlying asset New shares New shares Number of options granted 571,200 120,000 Date of shareholders' resolution approving the plan 11/30/2020 04/28/2021 Grant date 04/20/2021 06/21/2021 Contractual expiration date 04/20/2031 06/21/2031 Grant price — — Exercise price €13.74 €12.99 Number of options as of December 31, 2021 491,200 120,000 Number of options exercised — — Number of options as of Including options exercised during the period — — Number of options lapsed or cancelled 80,000 — Including options lapsed or cancelled during the period 80,000 — BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2021 715,291 263,251 1,583,806 410,512 2,972,860 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2020 718,767 263,028 986,359 446,500 2,414,654 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of December 31, 2019 751,585 251,028 589,150 746,250 2,338,013 |
Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period | The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence , no new instrument became issuable. BSPCE Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the year ended 2021 (in thousands of euros) Expense for the year ended 2020 (in thousands of euros) Expense for the year ended 2019 (in thousands of euros) BSPCE 2012-1 5.26 5.26 41 % 3.49 0.20 % 0.00 % 307 — — — BSPCE 2012-2 6.65 6.63 44.3% - 47.6% 5 - 7.30 0.84% - 1.22% 0.00 % 288 — — — BSPCE 04-2013 6.30 6.30 56 % 5 0.90 % 0.00 % 167 — — — BSPCE 08-2013 6.30 5.92 256 % 7 0.90 % 0.00 % 152 — — — BSPCE 09-2014 18.68 18.68 58 % 5.5/6/6.5 0.64 % 0.00 % 932 — — — BSPCE 2015-1 18.57 18.57 58% - 62% - 61% 5.5/6/6.5 0.39 % 0.00 % 50 — — — BSPCE 2015-2 18.57 18.57 58% - 62% - 61% 5.5/6/6.5 0.39 % 0.00 % 650 — — — BSPCE 2015-3 20.28 20.28 61% - 62% - 61% 5.5/6/6.5 0.56 % 0.00 % 483 — — — BSPCE 2016 Ordinary 14.46 14.46 59% - 62% - 60% 5.5/6/6.5 0.32 % 0.00 % 1,080 — — 10 BSPCE 2016 Performance 14.46 14.46 59 % 5 0.19 % 0.00 % 1,212 32 99 79 BSPCE 2017 Ordinary 15.93 15.93 58% - 61% - 59% 5.5/6/6.5 0.23 % 0.00 % 1,000 0 8 86 BSPCE 2017 Performance 15.93 15.93 59 % 5 0.11 % 0.00 % 622 — — — BSPCE 2017 15.93 15.93 59 % 5 0.11 % 0.00 % 627 — — — BSPCE 2017 Project 15.93 15.93 59 % 5 0.11 % 0.00 % 94 — — — Total BSPCE n.a. n.a. n.a. n.a. n.a. n.a. n.a. 32 107 175 BSA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the year ended 2021 (in thousands of euros) Expense for the year ended 2020 (in thousands of euros) Expense for the year ended 2019 (in thousands of euros) BSA 2012 6.00 6.00 49 % 10 0.96 % 0.00 % 183 — — — BSA 2013 6.30 6.37 156 % 6 0.90 % 0.00 % 1 — — — BSA 2014 18.68 17.67 57 % 5 0.41 % 0.00 % — — — — BSA 2015-1 17.67 17.67 58 % 5 0.26% - 0.27% 0.00 % 63 — — — BSA 2015-2 17.67 19.54 58%-58%-57%-58% 5/5.1/5.3/5.4 0.39 % 0.00 % 16 — — — BSA 2015-3 19.54 19.54 58% - 60% 4.6 – 9.6 0.25% - 0.91% 0.00 % 284 — — — BSA 2016o-1 13.74 13.74 57 % 2.4 0.00 % 0.00 % 37 — — — BSA 2016p-1 13.74 13.74 57 % 2.4 0.00 % 0.00 % 143 — — (41) BSA 2016-2 15.01 15.01 57 % 2.4 0.00 % 0.00 % — — — — BSA 2017o-1 15.76 15.76 33 % 2.4 0.00 % 0.00 % — — — — BSA 2018-1 13.55 13.55 38 % 4.8 0.7% - 0.1% 0.00 % 2 — — — BSA 2018-2 16.102 16.102 38 % 4.8 0.7% - 0.1% 0.00 % 1 — — — BSA 2019-1 11.66 11.66 37 % 9.8/9.9 0.16% - 0.50% 0.00 % 24 — — 24 BSA 2020 — 6.59 38 % 10 -0.13%/ 0.00 % 19 — 19 — BSA 2021 (a) 13.47 13.47 39.10 % 10 0.27 % 0.00 % 44 44 — — BSA 2021 (b) n.a. 13.64 n.a. 10 0.27 % 0.00 % — — — — Total BSA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 44 19 (16) AGA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the year ended 2021 (in thousands of euros) Expense for the year ended 2020 (in thousands of euros) Expense for the year ended 2019 (in thousands of euros) AGA 2018-1 12.87 0.00 n.a. n.a. 0.00 % 0.00 % 4,951 16 268 2,052 AGA 2018-2 12.87 0.00 n.a. n.a. 0.00 % 0.00 % 75 — 21 37 AGA 2019-1 10.90 0.00 n.a. n.a. 0.19% / 0.141% 0.00 % 4,776 422 1,884 1,529 AGA 2020 5.90 0.00 n.a. n.a. -0.74%/-0.69% 0.00 % 287 144 116 — AGA 2021 13.60 0.00 n.a. n.a. -0.63%/ -0.59% 0.00 % 4,869 1,784 — — Total AGA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 2,366 2,289 3,618 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2021 32 44 760 2,366 3,202 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2020 107 19 509 2,289 2,924 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2019 175 (16) 543 3,618 4,320 |
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period | OSA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the year ended 2021 (in thousands of euros) Expense for the year ended 2020 (in thousands of euros) Expense for the year ended 2019 (in thousands of euros) OSA 2016 Ordinary 13.05 13.05 59% - 62% - 60% 5.5 / 6 /6.5 0.32 % 0.00 % 117 — — — OSA 2016 Performance 13.05 13.05 59 % 5 0.19 % 0.00 % 69 — — — OSA 2016-2 14.26 14.26 58% - 62% - 59% 5.5 / 6 /6.5 0.04 % 0.00 % 27 — — 3 OSA 2017 Ordinary 15.93 14.97 58% - 61% - 59% 5.5 / 6 /6.5 0.23 % 0.00 % 31 — — 1 OSA 2017 Performance 15.93 14.97 59 % 5 0.11 % 0.00 % 35 — — — OSA 2018 12.87 12.87 35 % 5.5 / 6 /6.5 0.00 % 0.00 % 252 — 7 66 OSA 2019-1 11.08 11.08 38.1% / 37.4% 6 /6.5 0.103% / 0.149% 0.00 % 140 17 49 38 OSA 2019-2 6.41 6.41 37 % 10 0.40 % 0.00 % 252 — — 436 OSA 2020 6.25 6.25 38 % 10 0.31 % 0.00 % 939 329 453 — OSA 2021-04 O 13.60 13.74 38.9% - 37.8% - 38.3% 5.5 / 6 /6.5 -0.38%/ -0.33%/ -0.28% 0.00 % 684 188 — — OSA 2021-04 P 13.60 13.74 39.10 % 10 0.03 % 0.00 % 1,816 131 — OSA 2021-06 O 12.20 12.99 39.2% / 37.9% / 38.1% 5.5 / 6 /6.5 -0.35 %/ -0.3 %/ -0.26 % 0.00 % 246 79 — — OSA 2021-06 P 12.20 12.99 39.10 % 10 0.13 % 0.00 % 212 16 — Total OSA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 760 509 543 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2021 32 44 760 2,366 3,202 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2020 107 19 509 2,289 2,924 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended December 31, 2019 175 (16) 543 3,618 4,320 |
Net financial income (loss) (Ta
Net financial income (loss) (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income, expense, gains or losses of financial instruments [abstract] | |
Summary of net financial income (loss) | For the years ended December 31, (in thousands of euros) 2021 2020 2019 Income from cash and cash equivalents — — 105 Foreign exchange gains 6,347 104 599 Other financial income 13 97 133 Total financial income 6,360 201 837 Interest cost (383) 4,676 (4,434) IFRS 16 related interests (288) (333) (359) Foreign exchange losses (109) (1,697) (176) Total financial expenses (780) 2,646 (4,970) Net financial income (loss) 5,580 2,847 (4,133) |
Income tax (Tables)
Income tax (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income taxes paid (refund) [abstract] | |
Schedule of reconciliation between statutory and effective income tax | The following table reconciles the Company’s theoretical tax expense to its effective tax expense: For the year ended December 31, (in thousands of euros) 2021 2020 2019 Net loss (47,003) (33,590) (50,915) Effective tax expense 5 9 3 Recurring loss before tax (47,058) (33,581) (50,912) Theoretical tax rate (statutory rate in France) 26.50 % 28.00 % 31.00 % Theoretical tax (benefit) expense (12,470) (9,403) (15,782) Share-based payment 848 819 1,339 Other temporary differences 117 (6) (1) Other non-taxable items (644) (540) (736) Unrecognized tax losses 12,154 9,138 15,177 Effective tax expense 5 9 3 Effective tax rate 0.00 % 0.00 % 0.00 % |
Loss per share (Tables)
Loss per share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Earnings per share [abstract] | |
Schedule of basic and diluted loss per share | For the year ended December 31, 2021 2020 2019 Net loss for the period (in thousands of euros) (47,063) (33,590) (50,915) Weighted average number of shares 34,733,418 24,385,827 21,631,514 Basic loss per share (in euros) (1.35) (1.38) (2.35) Diluted loss per share (in euros) (1.35) (1.38) (2.35) |
Related parties (Tables)
Related parties (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Related party transactions [abstract] | |
Disclosure of significant transactions | The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown: For the year ended December 31, (in thousands of euros) 2021 2020 2019 Salaries, wages and benefits 1,245 1,073 1,306 Share-based payments 2,018 1,723 2,066 Supervisory Board’s fees 375 70 70 Total compensation to related parties 3,638 2,866 3,442 |
Company information (Details)
Company information (Details) $ in Thousands, € in Millions | Jun. 15, 2021USD ($) | Jun. 30, 2021USD ($) | Jun. 30, 2021EUR (€) | May 31, 2021USD ($)study | Mar. 31, 2021USD ($) | Mar. 31, 2021USD ($) | Jun. 30, 2021EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2021EUR (€) |
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | |||||||||||
Disclosure Of Information Related To The Company [Line Items] | |||||||||||
Upfront payment | $ 4,000 | $ 2,500 | € 5.4 | $ 6,500 | $ 6,500 | € 5.4 | |||||
Milestone payment upon receipt of clinical study reports | 1,000 | $ 1,000 | |||||||||
Milestone payment upon second regulatory approval | $ 5,000 | $ 5,000 | |||||||||
Royalties agreement, period | 10 years | 10 years | |||||||||
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | Maximum | |||||||||||
Disclosure Of Information Related To The Company [Line Items] | |||||||||||
Onerous contracts provision | $ 12,500 | $ 12,500 | |||||||||
LianBio, NBTXR3 | |||||||||||
Disclosure Of Information Related To The Company [Line Items] | |||||||||||
Number of global registrational studies supported | study | 5 | ||||||||||
Upfront payment received | $ 20,000 | $ 20,000 | € 16.5 | $ 20,000 | |||||||
LianBio, NBTXR3 | Maximum | |||||||||||
Disclosure Of Information Related To The Company [Line Items] | |||||||||||
Potential development and commercial milestones payments | $ 220,000 | $ 220,000 | $ 220,000 | $ 220,000 |
General Information, Statemen_2
General Information, Statement of Compliance and Basis of Presentation (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
General Information, Statement of Compliance and Basis of Presentation [Abstract] | ||||
Cash and cash equivalents | € 83,921 | € 119,151 | € 35,094 | € 36,203 |
Consolidation principles and _3
Consolidation principles and methods (Details) | 12 Months Ended | ||
Dec. 31, 2021subsidiaryparent_entity | Dec. 31, 2020 | Dec. 31, 2019 | |
Significant Accounting Policies [Abstract] | |||
Closing foreign exchange rate | 1.1326 | 1.2271 | 1.1234 |
Average foreign exchange rate | 1.1835 | 1.1413 | 1.1196 |
Number of parent entities | parent_entity | 1 | ||
Number of subsidiaries | subsidiary | 5 |
Significant transactions (Detai
Significant transactions (Details) € in Thousands, $ in Thousands | Jun. 15, 2021USD ($) | Feb. 03, 2020USD ($) | Jun. 30, 2021EUR (€) | Jun. 30, 2021USD ($) | May 31, 2021USD ($)study | Mar. 31, 2021USD ($) | Jul. 31, 2020 | Mar. 31, 2019EUR (€) | Jan. 31, 2019USD ($)patient | Oct. 31, 2018EUR (€) | Jul. 31, 2018EUR (€) | Mar. 31, 2021USD ($) | Jun. 30, 2021EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2021EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2016USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2012USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2021USD ($) | Aug. 31, 2012USD ($) |
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Increase in loans and conditional advances | € | € 0 | € 10,350 | € 14,000 | ||||||||||||||||||||||
Prepaid expenses | € | 2,213 | 2,217 | |||||||||||||||||||||||
LianBio, NBTXR3 | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Number of global registrational studies supported | study | 5 | ||||||||||||||||||||||||
Upfront payment received | $ 20,000 | € 16,500 | $ 20,000 | $ 20,000 | |||||||||||||||||||||
LianBio, NBTXR3 | Maximum | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Potential development and commercial milestones payments | $ 220,000 | $ 220,000 | |||||||||||||||||||||||
PharmaEngine, NBTWR3 | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Upfront payment received | $ 1,000 | ||||||||||||||||||||||||
Development milestones payments received | $ 1,000 | $ 1,000 | |||||||||||||||||||||||
Total payments received under agreement | $ 3,000 | ||||||||||||||||||||||||
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Upfront payment | $ 4,000 | $ 2,500 | € 5,400 | $ 6,500 | 5,400 | $ 6,500 | |||||||||||||||||||
Milestone payment upon receipt of clinical study reports | 1,000 | $ 1,000 | |||||||||||||||||||||||
Milestone payment upon second regulatory approval | $ 5,000 | $ 5,000 | |||||||||||||||||||||||
Royalties agreement, period | 10 years | 10 years | |||||||||||||||||||||||
MD Anderson Cancer Center, NBTXR3 | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Upfront payment | $ 1,000 | $ 1,000 | |||||||||||||||||||||||
Number of patients | patient | 340 | ||||||||||||||||||||||||
Contractual capital commitments | $ 11,000 | ||||||||||||||||||||||||
Milestone payment, deferment period | 6 months | ||||||||||||||||||||||||
Prepaid expenses | € | € 1,000 | € 1,600 | |||||||||||||||||||||||
EIB fixed rate loan | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Royalties agreement, period | 6 years | ||||||||||||||||||||||||
Increase in loans and conditional advances | € | € 14,000 | € 16,000 | |||||||||||||||||||||||
Borrowings, interest rate | 5.00% | 6.00% | 4.00% | ||||||||||||||||||||||
Borrowing, maturity | 5 years | ||||||||||||||||||||||||
Undrawn borrowing facilities | € | € 10,000 | ||||||||||||||||||||||||
Borrowing, deferment period | 1 year | ||||||||||||||||||||||||
Borrowing, deferment period to request funds | 12 months | ||||||||||||||||||||||||
EIB fixed rate loan | Maximum | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Notional amount | € | € 40,000 | ||||||||||||||||||||||||
Top of range | PharmaEngine, NBTWR3 | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Potential development and commercial milestones payments | $ 56,000 | ||||||||||||||||||||||||
Top of range | MD Anderson Cancer Center, NBTXR3 | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Milestone payment increase | 16,400 | ||||||||||||||||||||||||
Top of range | EIB fixed rate loan | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Notional amount | € | € 40,000 | ||||||||||||||||||||||||
Bottom of range | MD Anderson Cancer Center, NBTXR3 | |||||||||||||||||||||||||
Disclosure of transactions between related parties [line items] | |||||||||||||||||||||||||
Milestone payment increase | $ 2,200 |
Intangible assets (Details)
Intangible assets (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets at beginning of period | € 21 | € 163 |
Increases | (17) | (141) |
Decreases | 0 | 0 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Intangible assets at end of period | 4 | 21 |
Gross book value of intangible assets | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets at beginning of period | 717 | 710 |
Increases | 5 | 11 |
Decreases | 0 | (5) |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Intangible assets at end of period | 722 | 717 |
Gross book value of intangible assets | Patents | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets at beginning of period | 65 | 65 |
Increases | 0 | 0 |
Decreases | 0 | 0 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Intangible assets at end of period | 65 | 65 |
Gross book value of intangible assets | Software | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets at beginning of period | 651 | 584 |
Increases | 5 | 11 |
Decreases | 0 | (5) |
Transfer | 0 | 61 |
Currency translation | 0 | 0 |
Intangible assets at end of period | 657 | 651 |
Gross book value of intangible assets | Intangible assets in progress | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets at beginning of period | 0 | 61 |
Increases | 0 | 0 |
Decreases | 0 | 0 |
Transfer | 0 | (61) |
Currency translation | 0 | 0 |
Intangible assets at end of period | 0 | 0 |
Accumulated depreciation of intangible assets | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets at beginning of period | (695) | (548) |
Increases | (22) | (152) |
Decreases | 0 | 5 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Intangible assets at end of period | (717) | (695) |
Accumulated depreciation of intangible assets | Patents | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets at beginning of period | (65) | (65) |
Increases | 0 | 0 |
Decreases | 0 | 0 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Intangible assets at end of period | (65) | (65) |
Accumulated depreciation of intangible assets | Software | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets at beginning of period | (630) | (483) |
Increases | (22) | (152) |
Decreases | 0 | 5 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Intangible assets at end of period | € (652) | € (630) |
Property, plant and equipment -
Property, plant and equipment - Additional Information (Details) € in Thousands | 12 Months Ended | |
Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€)lease_contract | |
Disclosure of detailed information about property, plant and equipment [line items] | ||
Increase in right-of-use assets | € 56 | € (1,101) |
Disposals, property, plant and equipment | € 129 | € 14 |
Number of new lease contracts | lease_contract | 2 | |
Lease contract, Villejuif | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Lease contract, extended period | 4 years | |
Addition to annual rent expense | € 15 | |
Lease contract, Wattignies | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Addition to annual rent expense | 35 | |
Gross book value of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Increase in right-of-use assets | € 1,590 | 515 |
Disposals, property, plant and equipment | 212 | 57 |
Fixtures, fittings and installations | Gross book value of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Increase in right-of-use assets | 5 | 16 |
Disposals, property, plant and equipment | € 0 | 0 |
Fixtures, fittings and installations | Bottom of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 5 years | |
Fixtures, fittings and installations | Top of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 10 years | |
Right of use – Buildings | Gross book value of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Increase in right-of-use assets | € 1,362 | 418 |
Disposals, property, plant and equipment | 139 | 14 |
Right of use – Buildings | Gross book value of tangible assets | Lease contract, Villejuif | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Additions to right-of-use assets | 1,390 | |
Addition to annual rent expense | € (25) | |
Right of use – Buildings | Gross book value of tangible assets | Lease contract, Oberkampf street | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Additions to right-of-use assets | 155 | |
Right of use – Buildings | Gross book value of tangible assets | Lease contract, Faubourg Saint-Antoine | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Additions to right-of-use assets | 140 | |
Right of use – Buildings | Gross book value of tangible assets | Lease contract, Alfortville | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Disposals, property, plant and equipment | 43 | |
Right of use – Buildings | Gross book value of tangible assets | Lease contract, parking Villejuif | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Additions to right-of-use assets | 30 | |
Right of use – Buildings | Bottom of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 5 years | |
Right of use – Buildings | Top of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 10 years | |
Technical equipment | Gross book value of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Increase in right-of-use assets | € 73 | 42 |
Disposals, property, plant and equipment | € 0 | 0 |
Technical equipment | Bottom of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 3 years | |
Technical equipment | Top of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 10 years | |
Office and IT equipment | Gross book value of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Increase in right-of-use assets | € 53 | 37 |
Disposals, property, plant and equipment | € 35 | 1 |
Office and IT equipment | Bottom of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 1 year | |
Office and IT equipment | Top of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 10 years | |
Transport equipment | Gross book value of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Increase in right-of-use assets | € 0 | 0 |
Disposals, property, plant and equipment | € 0 | 0 |
Transport equipment | Bottom of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 1 year | |
Transport equipment | Top of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 10 years | |
Right of use – Transport equipment | Gross book value of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Increase in right-of-use assets | € 0 | 0 |
Disposals, property, plant and equipment | € 38 | € 41 |
Right of use – Transport equipment | Bottom of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 1 year | |
Right of use – Transport equipment | Top of range | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation periods of property, plant and equipment | 10 years |
Property, plant and equipment_2
Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | € 8,256 | € 9,386 |
Increases | 56 | (1,101) |
Decreases | (129) | (14) |
Transfer | 0 | (12) |
Currency translation | 3 | (4) |
Property, plant and equipment at end of period | 8,186 | 8,256 |
Gross book value of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 13,630 | 13,197 |
Increases | 1,590 | 515 |
Decreases | (212) | (57) |
Transfer | 0 | (15) |
Currency translation | 8 | (11) |
Property, plant and equipment at end of period | 15,017 | 13,630 |
Gross book value of tangible assets | Fixtures, fittings and installations | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 3,313 | 3,297 |
Increases | 5 | 16 |
Decreases | 0 | 0 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Property, plant and equipment at end of period | 3,318 | 3,313 |
Gross book value of tangible assets | Right of use – Buildings | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 7,171 | 6,766 |
Increases | 1,362 | 418 |
Decreases | (139) | (14) |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Property, plant and equipment at end of period | 8,393 | 7,171 |
Gross book value of tangible assets | Technical equipment | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 2,061 | 2,019 |
Increases | 73 | 42 |
Decreases | 0 | 0 |
Transfer | 1 | 0 |
Currency translation | 0 | 0 |
Property, plant and equipment at end of period | 2,135 | 2,061 |
Gross book value of tangible assets | Office and IT equipment | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 988 | 957 |
Increases | 53 | 37 |
Decreases | (35) | (1) |
Transfer | 0 | 0 |
Currency translation | 4 | (4) |
Property, plant and equipment at end of period | 1,010 | 988 |
Gross book value of tangible assets | Transport equipment | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 31 | 34 |
Increases | 0 | 0 |
Decreases | 0 | 0 |
Transfer | 0 | 0 |
Currency translation | 3 | (3) |
Property, plant and equipment at end of period | 33 | 31 |
Gross book value of tangible assets | Right of use – Transport equipment | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 65 | 115 |
Increases | 0 | 0 |
Decreases | (38) | (41) |
Transfer | 0 | (5) |
Currency translation | 1 | (4) |
Property, plant and equipment at end of period | 28 | 65 |
Gross book value of tangible assets | Tangible assets in progress | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 1 | 11 |
Increases | 97 | 1 |
Decreases | 0 | 0 |
Transfer | 0 | (11) |
Currency translation | 0 | 0 |
Property, plant and equipment at end of period | 98 | 1 |
Gross book value of tangible assets | Prepayments on tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | 0 | 0 |
Increases | 0 | 0 |
Decreases | 0 | 0 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Property, plant and equipment at end of period | 0 | 0 |
Accumulated depreciation of tangible assets | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | (5,374) | (3,811) |
Increases | (1,534) | (1,616) |
Decreases | 84 | 43 |
Transfer | 0 | 4 |
Currency translation | (6) | 6 |
Property, plant and equipment at end of period | (6,831) | (5,374) |
Accumulated depreciation of tangible assets | Fixtures, fittings and installations | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | (1,320) | (1,001) |
Increases | (320) | (320) |
Decreases | 0 | 0 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Property, plant and equipment at end of period | (1,641) | (1,320) |
Accumulated depreciation of tangible assets | Right of use – Buildings | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | (1,739) | (829) |
Increases | (901) | (911) |
Decreases | 30 | 0 |
Transfer | 0 | 2 |
Currency translation | 0 | 0 |
Property, plant and equipment at end of period | (2,610) | (1,739) |
Accumulated depreciation of tangible assets | Technical equipment | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | (1,466) | (1,272) |
Increases | (178) | (194) |
Decreases | 0 | 0 |
Transfer | 0 | 0 |
Currency translation | 0 | 0 |
Property, plant and equipment at end of period | (1,644) | (1,466) |
Accumulated depreciation of tangible assets | Office and IT equipment | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | (783) | (629) |
Increases | (124) | (157) |
Decreases | 34 | 1 |
Transfer | 0 | 0 |
Currency translation | (3) | 2 |
Property, plant and equipment at end of period | (875) | (783) |
Accumulated depreciation of tangible assets | Transport equipment | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | (31) | (34) |
Increases | 0 | 0 |
Decreases | 0 | 0 |
Transfer | 0 | 1 |
Currency translation | (3) | 3 |
Property, plant and equipment at end of period | (33) | (31) |
Accumulated depreciation of tangible assets | Right of use – Transport equipment | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Property, plant and equipment at beginning of period | (36) | (45) |
Increases | (12) | (35) |
Decreases | 20 | 42 |
Transfer | 0 | 0 |
Currency translation | (1) | 1 |
Property, plant and equipment at end of period | € (28) | € (36) |
Non-current financial assets -
Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial assets [line items] | ||
Non-current financial assets at beginning of period | € 505 | € 529 |
Additions | 9 | 9 |
Decreases | (6) | (31) |
Transfer | 8 | |
Currency translation adjustments | 3 | (2) |
Non-current financial assets at end of period | 519 | 505 |
Liquidity contract - Cash account | Financial assets at fair value, class | ||
Disclosure of financial assets [line items] | ||
Non-current financial assets at beginning of period | 105 | 131 |
Additions | 0 | 0 |
Decreases | (6) | (27) |
Transfer | 0 | |
Currency translation adjustments | 0 | 0 |
Non-current financial assets at end of period | 98 | 105 |
Other long-term investments pledged as collateral | Financial assets at amortised cost, class | ||
Disclosure of financial assets [line items] | ||
Non-current financial assets at beginning of period | 0 | 0 |
Additions | 0 | 0 |
Decreases | 0 | 0 |
Transfer | 0 | |
Currency translation adjustments | 0 | 0 |
Non-current financial assets at end of period | 0 | 0 |
Security deposits paid | Financial assets at amortised cost, class | ||
Disclosure of financial assets [line items] | ||
Non-current financial assets at beginning of period | 401 | 399 |
Additions | 9 | 9 |
Decreases | 0 | (5) |
Transfer | 8 | |
Currency translation adjustments | 3 | (2) |
Non-current financial assets at end of period | € 421 | € 401 |
Non-current financial assets _2
Non-current financial assets - Additional Information (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure Of Detailed Information About Non-current Financial Assets [Line Items] | ||
Increase (decrease) in financial assets | € 14 | € (24) |
Additions | 9 | € 9 |
Security deposits paid | ||
Disclosure Of Detailed Information About Non-current Financial Assets [Line Items] | ||
Increase (decrease) in financial assets | 20 | |
Additions | € 9 |
Trade receivables and other c_3
Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Trade receivables | € 0 | € 62 |
Due in 3 months or less | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Trade receivables | 0 | 62 |
Due between 3 and 6 months | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Trade receivables | 0 | 0 |
Due between 6 and 12 months | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Trade receivables | 0 | 0 |
Due after more than 12 months | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Trade receivables | € 0 | € 0 |
Trade receivables and other c_4
Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Subclassifications of assets, liabilities and equities [abstract] | |||
Research tax credit receivable | € 2,490 | € 1,927 | € 5,688 |
VAT receivable | 1,058 | 971 | |
Prepaid expenses | 2,213 | 2,217 | |
Other receivables | 3,378 | 920 | |
Other current assets | € 9,139 | € 6,035 |
Trade receivables and other c_5
Trade receivables and other current assets - Additional Information (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Prepaid expenses | € 2,213 | € 2,217 |
Prepaid expenses related to insurance for Directors and Officers | 600 | |
Current advances to suppliers | 3,043 | 805 |
2021 Tax Year | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 2,500 | |
2020 Tax Year | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 1,900 | |
Nanobiotix S.A. | 2021 Tax Year | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 2,272 | |
Nanobiotix S.A. | 2020 Tax Year | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 1,858 | |
Curadigm SAS | 2021 Tax Year | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 218 | |
Curadigm SAS | 2020 Tax Year | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 69 | |
MD Anderson Cancer Center, NBTXR3 | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Prepaid expenses | € 1,000 | € 1,600 |
Trade receivables and other c_6
Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit receivable at beginning of period | € 1,927 | € 5,688 |
Research tax credit receivable at end of period | 2,490 | 1,927 |
2018 Tax Year | Nanobiotix S.A. | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Refund of research tax credit | (3,251) | |
2019 Tax Year | Nanobiotix S.A. | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Refund of research tax credit | (2,374) | |
2019 Tax Year | Curadigm SAS | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Refund of research tax credit | (64) | |
2020 Tax Year | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 1,900 | |
2020 Tax Year | Nanobiotix S.A. | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Refund of research tax credit | (1,858) | |
Research tax credit | 1,858 | |
2020 Tax Year | Curadigm SAS | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Refund of research tax credit | (69) | |
Research tax credit | € 69 | |
2021 Tax Year | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 2,500 | |
2021 Tax Year | Nanobiotix S.A. | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | 2,272 | |
2021 Tax Year | Curadigm SAS | ||
Disclosure of Trade Receivables and Other Current Assets [Line Items] | ||
Research tax credit | € 218 |
Cash and cash equivalents - Sum
Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Subclassifications of assets, liabilities and equities [abstract] | ||||
Cash and bank accounts | € 83,921 | € 119,151 | ||
Net cash and cash equivalents | € 83,921 | € 119,151 | € 35,094 | € 36,203 |
Cash and cash equivalents - Add
Cash and cash equivalents - Additional Information (Details) € in Thousands, $ in Millions | Jun. 15, 2021USD ($) | Jun. 30, 2021EUR (€) | Jun. 30, 2021USD ($) | May 31, 2021USD ($) | Mar. 31, 2021USD ($) | Jun. 30, 2021EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2021EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) |
Disclosure of Cash and Cash Equivalents [Line Items] | ||||||||||||
Decrease in cash and cash equivalents | € 35,230 | € (84,056) | € 1,109 | |||||||||
Loans repayments | 2,833 | € 250 | € 500 | |||||||||
EIB Loan | ||||||||||||
Disclosure of Cash and Cash Equivalents [Line Items] | ||||||||||||
Loans repayments | 3,000 | |||||||||||
BPI loan | ||||||||||||
Disclosure of Cash and Cash Equivalents [Line Items] | ||||||||||||
Loans repayments | 500 | |||||||||||
LianBio, NBTXR3 | ||||||||||||
Disclosure of Cash and Cash Equivalents [Line Items] | ||||||||||||
Upfront payment received | $ 20 | € 16,500 | $ 20 | $ 20 | ||||||||
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | ||||||||||||
Disclosure of Cash and Cash Equivalents [Line Items] | ||||||||||||
Upfront payment | $ 4 | $ 2.5 | € 5,400 | $ 6.5 | € 5,400 | $ 6.5 |
Share Capital - Disclosure of D
Share Capital - Disclosure of Detail of Share Capital Transactions (Details) | May 31, 2021EUR (€) | Apr. 20, 2021EUR (€) | Apr. 01, 2021EUR (€) | Mar. 31, 2021EUR (€)shares | Mar. 17, 2021EUR (€) | Dec. 18, 2020EUR (€)shares | Dec. 18, 2020$ / shares | Dec. 16, 2020EUR (€)€ / sharesshares | Dec. 16, 2020$ / shares | Jul. 28, 2020EUR (€)shares | Jul. 27, 2020EUR (€)shares | Jun. 30, 2020EUR (€) | Jun. 29, 2020EUR (€) | Jun. 26, 2020EUR (€) | Jun. 24, 2020EUR (€) | Mar. 06, 2020EUR (€)shares | Apr. 09, 2019€ / shares | Apr. 09, 2019$ / shares | Dec. 31, 2021EUR (€)shares | Dec. 31, 2020EUR (€)shares | Dec. 31, 2019EUR (€)shares |
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Equity at beginning of period | € 70,468,000 | € (1,908,000) | € 14,243,000 | ||||||||||||||||||
Capital increase | € 11,077.5 | € 735 | € 180 | 0 | 102,942,000 | 28,079,000 | |||||||||||||||
Subscription of warrants | 43,000 | 5,000 | 21,000 | ||||||||||||||||||
U.S. Initial public offering costs offset | (10,700,000) | 1,030,000 | |||||||||||||||||||
Equity at end of period | 26,790,000 | 70,468,000 | (1,908,000) | ||||||||||||||||||
IPO initial deal, Euro | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | € / shares | € 11.14 | ||||||||||||||||||||
IPO initial deal, US Dollar | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | $ / shares | $ 13.50 | ||||||||||||||||||||
IPO green shoe, US Dollar | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | $ / shares | $ 13.50 | ||||||||||||||||||||
Share Capital | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Equity at beginning of period | 1,032,963.66 | 672,451.17 | 589,000 | ||||||||||||||||||
Capital increase | € 99,000 | € 9,000 | 12,000 | 361,000 | 77,000 | ||||||||||||||||
Equity at end of period | € 1,044,776.16 | € 1,032,963.66 | € 672,451.17 | ||||||||||||||||||
Number of shares outstanding at beginning of period (in shares) | shares | 34,432,122 | 22,415,039 | 19,633,373 | ||||||||||||||||||
Capital increase, net (in shares) | shares | 3,300,000 | 6,000 | 316,083 | 393,750 | 12,017,083 | 2,566,666 | |||||||||||||||
Number of shares outstanding at end of period (in shares) | shares | 34,825,872 | 34,432,122 | 22,415,039 | ||||||||||||||||||
Share Capital | AGA 2018-1 | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Capital increase | € 1,000 | ||||||||||||||||||||
Capital increase, net (in shares) | shares | 24,500 | ||||||||||||||||||||
Share Capital | AGA 2018-2 | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Capital increase | € 11,000 | ||||||||||||||||||||
Capital increase, net (in shares) | shares | 369,250 | ||||||||||||||||||||
Share Capital | IPO initial deal, Euro | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Capital increase | € 56,000 | ||||||||||||||||||||
Capital increase, net (in shares) | shares | 1,855,000 | ||||||||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | € / shares | € 11.14 | ||||||||||||||||||||
Share Capital | IPO initial deal, US Dollar | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Capital increase | € 163,000 | ||||||||||||||||||||
Capital increase, net (in shares) | shares | 5,445,000 | ||||||||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | $ / shares | $ 13.50 | ||||||||||||||||||||
Share Capital | IPO green shoe, US Dollar | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Capital increase | € 33,000 | ||||||||||||||||||||
Capital increase, net (in shares) | shares | 1,095,000 | ||||||||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | $ / shares | $ 13.50 | ||||||||||||||||||||
Premiums related to share capital | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Equity at beginning of period | € 255,735,000 | € 153,139,000 | € 122,799,000 | ||||||||||||||||||
Capital increase | € 20,030,000 | € 0 | 102,591,000 | 28,002,000 | |||||||||||||||||
Subscription of warrants | € 43,000 | € (11,000) | € 1,000 | € 2,000 | € 1,000 | € 1,000 | 32,000 | 5,000 | 8,000 | ||||||||||||
U.S. Initial public offering costs offset | € (9,322,000) | € (1,387,000) | 1,030,000 | ||||||||||||||||||
Equity at end of period | € 255,767,000 | € 255,735,000 | € 153,139,000 | ||||||||||||||||||
Premiums related to share capital | IPO initial deal, Euro | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Capital increase | € 20,609,000 | ||||||||||||||||||||
Premiums related to share capital | IPO initial deal, US Dollar | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Capital increase | € 60,494,000 | ||||||||||||||||||||
Premiums related to share capital | IPO green shoe, US Dollar | |||||||||||||||||||||
Disclosure of classes of share capital [line items] | |||||||||||||||||||||
Capital increase | € 12,165,000 |
Share Capital - Capital Issued
Share Capital - Capital Issued (Details) | Dec. 18, 2020EUR (€)shares | Dec. 18, 2020$ / shares | Dec. 16, 2020€ / sharesshares | Dec. 16, 2020$ / sharesshares | Jul. 28, 2020EUR (€)shares | Jul. 27, 2020shares | Mar. 06, 2020shares | Apr. 09, 2019€ / shares | Apr. 09, 2019$ / shares | Dec. 31, 2020EUR (€)€ / sharesshares | Dec. 31, 2021EUR (€)€ / sharesshares | Dec. 31, 2020EUR (€)€ / sharesshares | Dec. 31, 2019EUR (€)€ / sharesshares | Dec. 31, 2018EUR (€)shares |
Disclosure of classes of share capital [line items] | ||||||||||||||
Equity | € 70,468,000 | € 26,790,000 | € 70,468,000 | € (1,908,000) | € 14,243,000 | |||||||||
Par value per share (euro per share) | € / shares | € 0.03 | € 0.03 | € 0.03 | € 0.03 | ||||||||||
Share issue related cost | € 10,700,000 | € (1,030,000) | ||||||||||||
Initial offering costs | € 349,000 | 10,359,000 | 1,438,000 | |||||||||||
IPO initial deal, US Dollar | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | $ / shares | $ 13.50 | |||||||||||||
IPO initial deal, Euro | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | € / shares | € 11.14 | |||||||||||||
IPO green shoe, US Dollar | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Issue of equity, price per share (in euro or dollar per share) | $ / shares | $ 13.50 | |||||||||||||
Share Capital | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Equity | € 1,032,963.66 | € 1,044,776.16 | € 1,032,963.66 | € 672,451.17 | € 589,000 | |||||||||
Number of shares outstanding | shares | 34,432,122 | 34,825,872 | 34,432,122 | 22,415,039 | 19,633,373 | |||||||||
Capital increase, net (in shares) | shares | 3,300,000 | 6,000 | 316,083 | 393,750 | 12,017,083 | 2,566,666 | ||||||||
Share Capital | Initial Public Offering | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Capital increase, net (in shares) | shares | 8,395,000 | |||||||||||||
Share Capital | IPO initial deal, US Dollar | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Capital increase, net (in shares) | shares | 5,445,000 | 5,445,000 | ||||||||||||
Issue of equity, price per share (in euro or dollar per share) | $ / shares | $ 13.50 | |||||||||||||
Share Capital | IPO initial deal, Euro | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Capital increase, net (in shares) | shares | 1,855,000 | 1,855,000 | ||||||||||||
Issue of equity, price per share (in euro or dollar per share) | € / shares | € 11.14 | |||||||||||||
Share Capital | IPO green shoe, US Dollar | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Capital increase, net (in shares) | shares | 1,095,000 | |||||||||||||
Issue of equity, price per share (in euro or dollar per share) | $ / shares | $ 13.50 | |||||||||||||
Premiums related to share capital | ||||||||||||||
Disclosure of classes of share capital [line items] | ||||||||||||||
Equity | € 255,735,000 | € 255,767,000 | € 255,735,000 | € 153,139,000 | € 122,799,000 | |||||||||
Share issue related cost | € 9,322,000 | € 1,387,000 | € (1,030,000) | |||||||||||
Initial offering costs | € 349,000 |
Share Capital - Treasury Shares
Share Capital - Treasury Shares (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of classes of share capital [line items] | ||
Treasury shares | € 202 | € 196 |
Treasury shares | ||
Disclosure of classes of share capital [line items] | ||
Number of shares outstanding | 15,456 | 12,970 |
Share Capital - Disclosure of_2
Share Capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details) | Jun. 21, 2021shares€ / shares | Apr. 20, 2021shares€ / shares | Apr. 01, 2021shares | Mar. 17, 2021shares | Jul. 27, 2020shares | Mar. 17, 2020shares€ / shares | Mar. 11, 2020shares€ / shares | Oct. 24, 2019shares€ / shares | Mar. 29, 2019shares€ / shares | Jul. 27, 2018shares€ / shares | Mar. 06, 2018shares€ / shares | Jan. 07, 2017shares€ / shares | Nov. 03, 2016shares€ / shares | Feb. 02, 2016€ / shares | Jun. 25, 2015shares€ / shares | Jun. 10, 2015shares€ / shares | Feb. 10, 2015shares€ / shares | Sep. 16, 2014shares€ / shares | Aug. 28, 2013shares€ / shares | Apr. 10, 2013shares€ / shares | Dec. 18, 2012shares€ / shares | May 04, 2012shares€ / shares | Dec. 31, 2021shares€ / shares | Dec. 31, 2020shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 2,414,654 | 2,338,013 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 2,972,860 | 2,414,654 | ||||||||||||||||||||||
BSPCE | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 718,767 | 751,585 | ||||||||||||||||||||||
Issued (in shares) | 0 | 0 | ||||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (3,476) | (32,818) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 715,291 | 718,767 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 715,291 | 718,767 | ||||||||||||||||||||||
BSPCE 2012-2 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6.63 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 100,000 | 100,000 | ||||||||||||||||||||||
Issued (in shares) | 100,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 100,000 | 100,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 100,000 | 100,000 | ||||||||||||||||||||||
BSPCE 08-2013 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 5.92 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 50,000 | 50,000 | ||||||||||||||||||||||
Issued (in shares) | 50,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 50,000 | 50,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 50,000 | 50,000 | ||||||||||||||||||||||
BSPCE 09-2014 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 18.68 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 86,150 | 92,100 | ||||||||||||||||||||||
Issued (in shares) | 97,200 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | (5,950) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 86,150 | 86,150 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 86,150 | 86,150 | ||||||||||||||||||||||
BSPCE 2015-1 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 18.57 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 68,450 | 70,950 | ||||||||||||||||||||||
Issued (in shares) | 71,650 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | (2,500) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 68,450 | 68,450 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 68,450 | 68,450 | ||||||||||||||||||||||
BSPCE 2015-3 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 20.28 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 30,700 | 38,400 | ||||||||||||||||||||||
Issued (in shares) | 53,050 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (350) | (7,700) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 30,350 | 30,700 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 30,350 | 30,700 | ||||||||||||||||||||||
BSPCE 2016 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 14.46 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 202,617 | 212,969 | ||||||||||||||||||||||
Issued (in shares) | 0 | 0 | ||||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (1,776) | (10,352) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 200,841 | 202,617 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 200,841 | 202,617 | ||||||||||||||||||||||
BSPCE 2017 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 15.93 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 180,850 | 187,166 | ||||||||||||||||||||||
Issued (in shares) | 0 | 0 | ||||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (1,350) | (6,316) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 179,500 | 180,850 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 179,500 | 180,850 | ||||||||||||||||||||||
BSA | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 263,028 | 251,028 | ||||||||||||||||||||||
Issued (in shares) | 78,103 | 18,000 | ||||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (77,880) | (6,000) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 263,251 | 263,028 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 263,251 | 263,028 | ||||||||||||||||||||||
BSA 04-12 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 30,000 | 30,000 | ||||||||||||||||||||||
Issued (in shares) | 52,500 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 30,000 | 30,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 30,000 | 30,000 | ||||||||||||||||||||||
BSA 2013 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6.37 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 6,000 | 6,000 | ||||||||||||||||||||||
Issued (in shares) | 10,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 6,000 | 6,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 6,000 | 6,000 | ||||||||||||||||||||||
BSA 2014 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 17.67 | € 40 | ||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 10,000 | 10,000 | ||||||||||||||||||||||
Issued (in shares) | 14,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 10,000 | 10,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 10,000 | 10,000 | ||||||||||||||||||||||
BSA 2015-1 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 17.67 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 21,000 | 21,000 | ||||||||||||||||||||||
Issued (in shares) | 26,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 21,000 | 21,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 21,000 | 21,000 | ||||||||||||||||||||||
BSA 2015-2(a) | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 19.54 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 64,000 | 64,000 | ||||||||||||||||||||||
Issued (in shares) | 64,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 64,000 | 64,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 64,000 | 64,000 | ||||||||||||||||||||||
BSA 2015-2(b) | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 19.54 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 0 | 6,000 | ||||||||||||||||||||||
Issued (in shares) | 6,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | (6,000) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 0 | 0 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 0 | 0 | ||||||||||||||||||||||
BSA 2016 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | 13.74 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 36,208 | 36,208 | ||||||||||||||||||||||
Issued (in shares) | 0 | 0 | ||||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (36,208) | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 0 | 36,208 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 0 | 36,208 | ||||||||||||||||||||||
BSA 2016-2 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 15.01 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 8,000 | 8,000 | ||||||||||||||||||||||
Issued (in shares) | 8,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (8,000) | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 0 | 8,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 0 | 8,000 | ||||||||||||||||||||||
BSA 2017 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 15.76 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 18,000 | 18,000 | ||||||||||||||||||||||
Issued (in shares) | 18,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 18,000 | 18,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 18,000 | 18,000 | ||||||||||||||||||||||
BSA 2018-1 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.55 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 28,000 | 28,000 | ||||||||||||||||||||||
Issued (in shares) | 28,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 28,000 | 28,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 28,000 | 28,000 | ||||||||||||||||||||||
BSA 2018-2 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 16.102 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 5,820 | 5,820 | ||||||||||||||||||||||
Issued (in shares) | 5,820 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 5,820 | 5,820 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 5,820 | 5,820 | ||||||||||||||||||||||
BSA 2019-1 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 11.66 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 18,000 | 18,000 | ||||||||||||||||||||||
Issued (in shares) | 18,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 18,000 | 18,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 18,000 | 18,000 | ||||||||||||||||||||||
BSA 2020 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6.59 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 18,000 | 0 | ||||||||||||||||||||||
Issued (in shares) | 18,000 | 0 | 18,000 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 18,000 | 18,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 18,000 | 18,000 | ||||||||||||||||||||||
BSA 2021 (a) | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.47 | € 13.47 | ||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 0 | |||||||||||||||||||||||
Issued (in shares) | 48,103 | 48,103 | ||||||||||||||||||||||
Exercised (in shares) | 0 | |||||||||||||||||||||||
Forfeited (in shares) | (33,672) | |||||||||||||||||||||||
Outstanding, end of period (in shares) | 14,431 | 0 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 14,431 | |||||||||||||||||||||||
BSA 2021 (b) | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.64 | € 13.64 | ||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 0 | |||||||||||||||||||||||
Issued (in shares) | 30,000 | 30,000 | ||||||||||||||||||||||
Exercised (in shares) | 0 | |||||||||||||||||||||||
Forfeited (in shares) | 0 | |||||||||||||||||||||||
Outstanding, end of period (in shares) | 30,000 | 0 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 30,000 | |||||||||||||||||||||||
OSA | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 986,359 | 589,150 | ||||||||||||||||||||||
Issued (in shares) | 691,200 | 407,972 | ||||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (93,753) | (10,763) | ||||||||||||||||||||||
Outstanding at end of period (in shares) | 1,583,806 | 986,359 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 1,583,806 | 986,359 | ||||||||||||||||||||||
OSA 2016-1 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.05 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 400 | 400 | ||||||||||||||||||||||
Issued (in shares) | 0 | 0 | ||||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding at end of period (in shares) | 400 | 400 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 400 | 400 | ||||||||||||||||||||||
OSA 2016-2 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 14.26 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 4,000 | 4,000 | ||||||||||||||||||||||
Issued (in shares) | 4,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding at end of period (in shares) | 4,000 | 4,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 4,000 | 4,000 | ||||||||||||||||||||||
OSA 2017 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 14.97 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 500 | 500 | ||||||||||||||||||||||
Issued (in shares) | 0 | 0 | ||||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding at end of period (in shares) | 500 | 500 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 500 | 500 | ||||||||||||||||||||||
OSA 2018 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 12.87 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 52,000 | 54,000 | ||||||||||||||||||||||
Issued (in shares) | 62,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | (2,000) | ||||||||||||||||||||||
Outstanding at end of period (in shares) | 52,000 | 52,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 52,000 | 52,000 | ||||||||||||||||||||||
OSA 2019-1 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 11.08 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 28,750 | 30,250 | ||||||||||||||||||||||
Issued (in shares) | 37,500 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (500) | (1,500) | ||||||||||||||||||||||
Outstanding at end of period (in shares) | 28,250 | 28,750 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 28,250 | 28,750 | ||||||||||||||||||||||
OSA LLY 2019 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6.41 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 500,000 | 500,000 | ||||||||||||||||||||||
Issued (in shares) | 500,000 | 0 | 0 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding at end of period (in shares) | 500,000 | 500,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 500,000 | 500,000 | ||||||||||||||||||||||
OSA 2020 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6.25 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 400,709 | 0 | ||||||||||||||||||||||
Issued (in shares) | 407,972 | 0 | 407,972 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (13,253) | (7,263) | ||||||||||||||||||||||
Outstanding at end of period (in shares) | 387,456 | 400,709 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 387,456 | 400,709 | ||||||||||||||||||||||
OSA 2021-04 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.74 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 0 | |||||||||||||||||||||||
Issued (in shares) | 571,200 | 571,200 | ||||||||||||||||||||||
Exercised (in shares) | 0 | |||||||||||||||||||||||
Forfeited (in shares) | (80,000) | |||||||||||||||||||||||
Outstanding at end of period (in shares) | 491,200 | 0 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 491,200 | |||||||||||||||||||||||
OSA 2021-06 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 12.99 | |||||||||||||||||||||||
Outstanding at beginning of period (in shares) | 0 | |||||||||||||||||||||||
Issued (in shares) | 120,000 | 120,000 | ||||||||||||||||||||||
Exercised (in shares) | 0 | |||||||||||||||||||||||
Forfeited (in shares) | 0 | |||||||||||||||||||||||
Outstanding at end of period (in shares) | 120,000 | 0 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 120,000 | |||||||||||||||||||||||
AGA | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 446,500 | 746,250 | ||||||||||||||||||||||
Issued (in shares) | 362,515 | 50,000 | ||||||||||||||||||||||
Exercised (in shares) | (393,750) | (322,083) | ||||||||||||||||||||||
Forfeited (in shares) | (4,753) | (27,667) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 410,512 | 446,500 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 410,512 | 446,500 | ||||||||||||||||||||||
AGA 2018-1 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 24,500 | 355,250 | ||||||||||||||||||||||
Issued (in shares) | 24,500 | 396,250 | 0 | 0 | ||||||||||||||||||||
Exercised (in shares) | (24,500) | (316,083) | ||||||||||||||||||||||
Forfeited (in shares) | 0 | (14,667) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 0 | 24,500 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 0 | 24,500 | ||||||||||||||||||||||
AGA 2018-2 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 0 | 6,000 | ||||||||||||||||||||||
Issued (in shares) | 6,000 | 6,000 | 0 | 0 | ||||||||||||||||||||
Exercised (in shares) | 0 | (6,000) | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 0 | 0 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 0 | 0 | ||||||||||||||||||||||
AGA 2019-1 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 372,000 | 385,000 | ||||||||||||||||||||||
Issued (in shares) | 369,250 | 438,250 | 0 | 0 | ||||||||||||||||||||
Exercised (in shares) | (369,250) | 0 | ||||||||||||||||||||||
Forfeited (in shares) | (2,750) | (13,000) | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 0 | 372,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 0 | 372,000 | ||||||||||||||||||||||
AGA 2020 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 50,000 | 0 | ||||||||||||||||||||||
Issued (in shares) | 50,000 | 0 | 50,000 | |||||||||||||||||||||
Exercised (in shares) | 0 | 0 | ||||||||||||||||||||||
Forfeited (in shares) | 0 | 0 | ||||||||||||||||||||||
Outstanding, end of period (in shares) | 50,000 | 50,000 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 50,000 | 50,000 | ||||||||||||||||||||||
AGA 2021 | ||||||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | |||||||||||||||||||||||
Outstanding, beginning of period (in shares) | 0 | |||||||||||||||||||||||
Issued (in shares) | 362,515 | 362,515 | ||||||||||||||||||||||
Exercised (in shares) | 0 | |||||||||||||||||||||||
Forfeited (in shares) | (2,003) | |||||||||||||||||||||||
Outstanding, end of period (in shares) | 360,512 | 0 | ||||||||||||||||||||||
Number of shares issuable (in shares) | 360,512 |
Share Capital - Founders_ warra
Share Capital - Founders’ warrants (Details) - BSPCE | 12 Months Ended |
Dec. 31, 2021employee | |
Former employees | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Number of employees with service conditions lifted | 3 |
Former Executive Board members | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Number of employees with service conditions lifted | 2 |
Share Capital - Warrant Plans (
Share Capital - Warrant Plans (Details) | Dec. 31, 2021sharespatient€ / shares | Apr. 20, 2021shares€ / shares | Mar. 17, 2020shares€ / shares | Mar. 29, 2019€ / shares | Dec. 31, 2021shares€ / shares | Dec. 31, 2020shares€ / shares | Dec. 31, 2019€ / shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Par value per share (euro per share) | € / shares | € 0.03 | € 0.03 | € 0.03 | € 0.03 | |||
BSA 2021 (a) | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | 48,103 | 48,103 | |||||
Exercise price (in euros per share) | € / shares | € 13.47 | € 13.47 | |||||
BSPCE exercise (in shares) | 0 | ||||||
BSA 2021 (a) | Supervisory Board | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | 48,103 | ||||||
Number of ordinary share subscribed per each BSA (in shares) | 1 | ||||||
Par value per share (euro per share) | € / shares | € 0.03 | ||||||
Exercise price (in euros per share) | € / shares | € 13.47 | ||||||
BSPCE exercise (in shares) | 14,431 | ||||||
Maximum term of other equity instruments granted for share-based payment arrangement | 10 years | ||||||
Vesting requirements, minimum attendance | 75.00% | ||||||
Vesting requirements, attendance period | 12 months | ||||||
Vesting requirements, recommended dose determination, minimum number of patients | patient | 2 | ||||||
Vesting requirements, recommended dose determination, total number of patients enrolled | patient | 3 | ||||||
BSA 2021 (a) | External Consultant | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | 30,000 | ||||||
Number of ordinary share subscribed per each BSA (in shares) | 1 | ||||||
Par value per share (euro per share) | € / shares | € 0.03 | ||||||
Exercise price (in euros per share) | € / shares | € 13.64 | ||||||
BSPCE exercise (in shares) | 0 | ||||||
Maximum term of other equity instruments granted for share-based payment arrangement | 10 years | ||||||
BSA 2021 (a) In Replacement Of BSA 2016 | Supervisory Board | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | 18,103 | ||||||
BSA 2020 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | 18,000 | 0 | 18,000 | ||||
Par value per share (euro per share) | € / shares | € 0.03 | ||||||
Exercise price (in euros per share) | € / shares | € 6.59 | ||||||
BSPCE exercise (in shares) | 0 | 0 |
Share Capital - Stock Option Pl
Share Capital - Stock Option Plans (Details) | Jun. 21, 2021sharespatient€ / shares | Apr. 20, 2021shares€ / shares | Nov. 30, 2020€ / shares | Mar. 11, 2020shares€ / shares | Dec. 31, 2021sharesemployee€ / shares | Dec. 31, 2020shares€ / shares | Dec. 31, 2019€ / shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Par value per share (euro per share) | € 0.03 | € 0.03 | € 0.03 | ||||
OSA 2021-04 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 571,200 | 571,200 | |||||
Exercise price (in euros per share) | € 13.74 | ||||||
OSA 2021-04 O | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Exercise price (in euros per share) | 13.74 | ||||||
OSA 2021-04 P | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Exercise price (in euros per share) | € 13.74 | ||||||
OSA | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 691,200 | 407,972 | |||||
Maximum term of options granted for share-based payment arrangement | 10 years | ||||||
OSA | From first year of grant date | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements, maximum percentage exercised | 10.00% | ||||||
OSA | From second year of grant date | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements, maximum percentage exercised | 30.00% | ||||||
OSA | From third year of grant date | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements, maximum percentage exercised | 60.00% | ||||||
OSA | Tranche one | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 10.00% | ||||||
Share price milestone, Euronext Paris | € 24 | ||||||
OSA | Tranche two | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 10.00% | ||||||
Share price milestone, Euronext Paris | € 30 | ||||||
OSA | Tranche three | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 40.00% | ||||||
Share price milestone, Euronext Paris | € 40 | ||||||
OSA | Tranche four | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 40.00% | ||||||
Share price milestone, Euronext Paris | € 60 | ||||||
OSA 2021-06 O | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Exercise price (in euros per share) | € 12.99 | ||||||
OSA 2021-06 P | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Exercise price (in euros per share) | € 12.99 | ||||||
OSA 2021-06 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 120,000 | 120,000 | |||||
Exercise price (in euros per share) | € 12.99 | ||||||
OSA 2020 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 407,972 | 0 | 407,972 | ||||
Number of ordinary share subscribed per each OSA | shares | 1 | ||||||
Exercise price (in euros per share) | € 6.25 | ||||||
OSA 2020 | Tranche one | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 33.33% | ||||||
OSA 2020 | Tranche two | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 33.33% | ||||||
OSA 2020 | Tranche three | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 33.33% | ||||||
Executive Board and Employees | OSA 2021-04 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 571,200 | ||||||
Number of ordinary share subscribed per each OSA | shares | 1 | ||||||
Par value per share (euro per share) | € 0.03 | ||||||
Exercise price (in euros per share) | € 13.74 | ||||||
Maximum term of options granted for share-based payment arrangement | 10 years | ||||||
Executive Board and Employees | OSA 2021-04 | Tranche one | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 33.33% | ||||||
Executive Board and Employees | OSA 2021-04 | Tranche two | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 33.33% | ||||||
Executive Board and Employees | OSA 2021-04 | Tranche three | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements for share-based payment arrangement, vesting percentage | 33.33% | ||||||
Executive Board and Employees | OSA 2021-04 O | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 143,200 | ||||||
Executive Board and Employees | OSA 2021-04 P | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 428,000 | ||||||
Bart Van Rhijn | OSA 2021-06 O | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 60,000 | ||||||
Bart Van Rhijn | OSA 2021-06 P | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 60,000 | ||||||
Bart Van Rhijn | OSA 2021-06 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 120,000 | ||||||
Number of ordinary share subscribed per each OSA | shares | 1 | ||||||
Par value per share (euro per share) | € 0.03 | ||||||
Exercise price (in euros per share) | € 12.99 | ||||||
Anne-Juliette Hermant, Laurent Levy and Bart Van Rhijn | OSA | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Vesting requirements, recommended dose determination, minimum number of patients | patient | 2 | ||||||
Vesting requirements, recommended dose determination, total number of patients enrolled | patient | 3 | ||||||
Executive Board and Alain Dostie | OSA 2020 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 300,000 | ||||||
Employees | OSA 2020 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Issued (in shares) | shares | 107,972 | ||||||
Par value per share (euro per share) | € 0.03 | ||||||
Exercise price (in euros per share) | € 6.25 | ||||||
Former Executive Board members | OSA 2020 | |||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||
Number of employees with service conditions lifted | employee | 2 | ||||||
Number of employees with vesting conditions accelerated | employee | 1 |
Share Capital - Free Share Plan
Share Capital - Free Share Plans (Details) | Apr. 20, 2021sharespatient€ / shares | Apr. 01, 2021EUR (€)shares | Mar. 17, 2021EUR (€)shares | Jul. 27, 2020EUR (€)shares | Mar. 11, 2020shares€ / shares | Oct. 24, 2019 | Mar. 29, 2019shares | Jul. 27, 2018shares | Mar. 06, 2018shares | Dec. 31, 2021EUR (€)sharesemployee€ / shares | Dec. 31, 2020EUR (€)shares€ / shares | Dec. 31, 2019EUR (€)€ / shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Par value per share (euro per share) | € / shares | € 0.03 | € 0.03 | € 0.03 | |||||||||
Capital increase, net | € | € 11,077.5 | € 735 | € 180 | € 0 | € 102,942,000 | € 28,079,000 | ||||||
AGA 2021 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Issued (in shares) | 362,515 | 362,515 | ||||||||||
AGA 2020 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Issued (in shares) | 50,000 | 0 | 50,000 | |||||||||
AGA | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Issued (in shares) | 362,515 | 50,000 | ||||||||||
Maximum term of options granted for share-based payment arrangement in the event of death or disability of optionee | 6 months | |||||||||||
AGA 2018-1 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Issued (in shares) | 24,500 | 396,250 | 0 | 0 | ||||||||
Vesting requirements for share-based payment arrangement, acquisition period | 3 years | |||||||||||
AGA 2019-1 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Issued (in shares) | 369,250 | 438,250 | 0 | 0 | ||||||||
Vesting requirements for share-based payment arrangement, acquisition period | 2 years | |||||||||||
AGA 2018-2 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Issued (in shares) | 6,000 | 6,000 | 0 | 0 | ||||||||
Vesting requirements for share-based payment arrangement, acquisition period | 2 years | |||||||||||
Executive Board and Employees | AGA 2021 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Issued (in shares) | 362,515 | |||||||||||
Par value per share (euro per share) | € / shares | € 0.03 | |||||||||||
Vesting requirements for share-based payment arrangement, holding period | 1 year | |||||||||||
Vesting requirements for share-based payment arrangement, acquisition period | 2 years | |||||||||||
Vesting requirements, recommended dose determination, minimum number of patients | patient | 2 | |||||||||||
Vesting requirements, recommended dose determination, total number of patients enrolled | patient | 3 | |||||||||||
Executive Board and Employees | AGA 2020 and AGA 2021 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Vesting requirements for share-based payment arrangement, holding period | 1 year | |||||||||||
Vesting requirements for share-based payment arrangement, acquisition period | 2 years | |||||||||||
Vesting requirements for share-based payment arrangement, acquisition period for foreign tax residents | 3 years | |||||||||||
Anne-Juliette Hermant | AGA 2020 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Issued (in shares) | 50,000 | |||||||||||
Par value per share (euro per share) | € / shares | € 0.03 | |||||||||||
Employees | AGA | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Number of employees with service conditions lifted | employee | 7 |
Provisions - Disclosure of Chan
Provisions - Disclosure of Changes in Provisions (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of other provisions [table] | ||
Other provisions at beginning of period | € 454 | € 495 |
Increases | 70 | 123 |
Decreases | (97) | (164) |
Other provisions at end of period | 428 | 454 |
Non-current provisions | ||
Disclosure of other provisions [table] | ||
Other provisions at beginning of period | 414 | 331 |
Increases | 0 | 83 |
Decreases | (97) | 0 |
Other provisions at end of period | 318 | 414 |
Lump-sum retirement benefits | ||
Disclosure of other provisions [table] | ||
Other provisions at beginning of period | 414 | 331 |
Increases | 0 | 83 |
Decreases | (97) | 0 |
Other provisions at end of period | 318 | 414 |
Current provisions | ||
Disclosure of other provisions [table] | ||
Other provisions at beginning of period | 40 | 164 |
Increases | 70 | 40 |
Decreases | 0 | (164) |
Other provisions at end of period | 110 | 40 |
Provisions for disputes | ||
Disclosure of other provisions [table] | ||
Other provisions at beginning of period | 40 | 0 |
Increases | 54 | 40 |
Decreases | 0 | 0 |
Other provisions at end of period | 94 | 40 |
Provision for charges | ||
Disclosure of other provisions [table] | ||
Other provisions at beginning of period | 0 | 164 |
Increases | 16 | 0 |
Decreases | 0 | (164) |
Other provisions at end of period | € 16 | € 0 |
Provisions - Additional Informa
Provisions - Additional Information (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of other provisions [table] | |||
Provision used | € 145 | € 55 | |
Provision reversed | € 97 | 164 | |
Payable, period | 5 years | ||
Provisions for disputes | |||
Disclosure of other provisions [table] | |||
Provision used | € 54 | 40 | |
Provision reversed | 0 | 0 | |
Provision for charges | |||
Disclosure of other provisions [table] | |||
Provision reversed | € 0 | € 164 |
Provisions - Disclosure of Comm
Provisions - Disclosure of Commitments for Retirement Benefits (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Provisions [abstract] | |||
Provisions of retirement benefits at beginning of period | € 414 | € 331 | |
Cost of services | 84 | 76 | € 76 |
Interests / discounting costs | 1 | 3 | |
Expense for the period | 85 | 79 | |
Gains or losses related to experience | (133) | (61) | |
Gains or losses related to change in demographic assumptions | (5) | 3 | |
Gains or losses related to change in financial assumptions | (43) | 62 | |
Actuarial gains or losses recognized in other comprehensive income | (182) | 4 | |
Provisions of retirement benefits at end of period | € 318 | € 414 | € 331 |
Provisions - Disclosure of Assu
Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of defined benefit plans [table] | ||
Social security contribution rate | 42.01% | 44.00% |
Discount rate | 0.98% | 0.33% |
Staff turnover | 0.0586% | 0.0586% |
Duration | 20 years | 17 years |
Management | ||
Disclosure of defined benefit plans [table] | ||
Retirement assumptions | 66 years | 66 years |
Non-management | ||
Disclosure of defined benefit plans [table] | ||
Retirement assumptions | 64 years | 64 years |
Executive | ||
Disclosure of defined benefit plans [table] | ||
Salary increase rate (including inflation) | 3.00% | 3.00% |
Non-executive | ||
Disclosure of defined benefit plans [table] | ||
Salary increase rate (including inflation) | 0.025% | 0.025% |
Provisions - Disclosure of Sens
Provisions - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of sensitivity analysis for actuarial assumptions [line items] | ||
Actuarial assumption of discount rates if rates decrease by 25% | 0.73% | |
Discount rate | 0.98% | 0.33% |
Actuarial assumption of discount rates if rates increase by 25% | 1.23% | |
Actuarial assumption of discount rates | ||
Disclosure of sensitivity analysis for actuarial assumptions [line items] | ||
Net defined benefit liability if actuarial assumption of discount rates decrease by 25% | € 333 | |
Net defined benefit liability | 318 | |
Net defined benefit liability if actuarial assumption of discount rates increase by 25% | € 303 |
Financial liabilities - Summary
Financial liabilities - Summary of Changes in Financial Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure Of Changes In Financial Liabilities [Line Items] | ||
Current financial liabilities | € 8,204 | € 4,872 |
Non-current financial liabilities | 37,816 | 44,107 |
Total financial liabilities | 46,020 | 48,979 |
Lease liabilities | ||
Disclosure Of Changes In Financial Liabilities [Line Items] | ||
Current financial liabilities | 1,126 | 1,197 |
Non-current financial liabilities | 5,393 | 4,991 |
Repayable BPI loan advances | ||
Disclosure Of Changes In Financial Liabilities [Line Items] | ||
Current financial liabilities | 800 | 500 |
Non-current financial liabilities | 2,259 | 2,975 |
PGE | Long-term borrowings | ||
Disclosure Of Changes In Financial Liabilities [Line Items] | ||
Current financial liabilities | 1,086 | 141 |
Non-current financial liabilities | 8,982 | 9,922 |
EIB Loan | Long-term borrowings | ||
Disclosure Of Changes In Financial Liabilities [Line Items] | ||
Current financial liabilities | 5,192 | 3,033 |
Non-current financial liabilities | € 21,182 | € 26,218 |
Financial liabilities - Additio
Financial liabilities - Additional Information (Details) € in Thousands | Jul. 10, 2020EUR (€)quarterly_instalment | Jul. 31, 2020 | Jun. 30, 2020EUR (€) | Mar. 31, 2019EUR (€) | Oct. 31, 2018EUR (€) | Jul. 31, 2018EUR (€)tranche | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) |
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Proceeds from borrowings | € 0 | € 10,350 | € 14,000 | |||||||
Consolidated forecasted sales, period | 6 years | |||||||||
Conditional Advances and Loans from Government and Public Authorities | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Impact of accretion and discounting | € 5,765 | 1,769 | ||||||||
Accumulated variable interest expense accrual | 4,214 | € (4,789) | ||||||||
Banque Publique d’Investissement | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Advances, deferment period | 18 months | |||||||||
Advances, interest rate | 1.56% | |||||||||
Advances received | € 2,100 | |||||||||
Bpifrance | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Advances received | € 350 | |||||||||
Authorized amount to be advanced | 500 | |||||||||
Advances, outstanding amount | 150 | |||||||||
EIB Loan | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Number of tranches | tranche | 3 | |||||||||
Proceeds from borrowings | € 14,000 | € 16,000 | ||||||||
Borrowing, deferment period to request funds | 12 months | |||||||||
Royalties agreement, period | 6 years | |||||||||
Borrowing, deferment period | 1 year | |||||||||
Borrowings, interest rate | 5.00% | 6.00% | 4.00% | |||||||
Borrowing, maturity | 5 years | |||||||||
Expected future royalty payments | 3,400 | € 17,200 | ||||||||
Accumulated variable interest expense accrual | 4,200 | 4,800 | ||||||||
Borrowings | 33,900 | |||||||||
EIB Loan | Conditional Advances and Loans from Government and Public Authorities | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Impact of accretion and discounting | 5,817 | 1,736 | ||||||||
Accumulated variable interest expense accrual | 4,214 | € (4,789) | ||||||||
EIB Loan | Fixed interest rate | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Total interest payable | 7,000 | |||||||||
Interest payable | 1,800 | |||||||||
EIB Loan | Floating interest rate | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Total interest payable | € 3,400 | |||||||||
EIB Loan | Top of range | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Notional amount | € 40,000 | |||||||||
PGE Loan, HSBC France | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Notional amount | 5,000 | |||||||||
Proceeds from borrowings | € 5,000 | |||||||||
Borrowing, initial period bearing no interest | 12 months | |||||||||
Borrowing, deferment period | 1 year | |||||||||
Borrowings, interest rate | 0.31% | |||||||||
Borrowing, guarantee fee | 0.25% | 0.25% | ||||||||
PGE Loan, HSBC France | Top of range | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Borrowing, deferment period | 5 years | |||||||||
PGE Loan, HSBC France | Bottom of range | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Borrowing, deferment period | 1 year | |||||||||
PGE Loan, BPI France | ||||||||||
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | ||||||||||
Notional amount | € 5,000 | € 350 | ||||||||
Proceeds from borrowings | € 5,000 | |||||||||
Borrowing, initial period bearing no interest | 12 months | |||||||||
Borrowings, interest rate | 2.25% | 1.36% | 1.36% | |||||||
Borrowing, maturity | 6 years | |||||||||
Percentage of State-Guaranteed loan | 0.90 | |||||||||
Borrowing, subsequent period bearing interest | 5 years | |||||||||
Borrowing, guarantee fee | 1.61% | 0.25% | 0.25% | |||||||
Number of quarterly instalments | quarterly_instalment | 20 |
Financial liabilities - Disclos
Financial liabilities - Disclosure of Detailed Information about Conditional Advances and Loans From Government and Public Authorities (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Conditional Advances and Loans from Government and Public Authorities | ||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | ||
Liabilities arising from financing activities at beginning of period | € 32,727 | € 38,121 |
Changes in liabilities arising from financing activities [abstract] | ||
Principal received | 0 | 350 |
Impact of discounting and accretion | (5,765) | (1,769) |
Accumulated fixed interest expense accrual | 1,790 | 1,763 |
Accumulated variable interest expense accrual | 4,214 | (4,789) |
Repayment | (3,533) | (950) |
Liabilities arising from financing activities at end of period | 29,433 | 32,727 |
Bpifrance advance | Conditional Advances and Loans from Government and Public Authorities | ||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | ||
Liabilities arising from financing activities at beginning of period | 2,216 | 2,165 |
Changes in liabilities arising from financing activities [abstract] | ||
Principal received | 0 | 0 |
Impact of discounting and accretion | 17 | 19 |
Accumulated fixed interest expense accrual | 32 | 32 |
Accumulated variable interest expense accrual | 0 | 0 |
Repayment | 0 | 0 |
Liabilities arising from financing activities at end of period | 2,266 | 2,216 |
Interest-free Bpifrance loan | Conditional Advances and Loans from Government and Public Authorities | ||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | ||
Liabilities arising from financing activities at beginning of period | 974 | 1,210 |
Changes in liabilities arising from financing activities [abstract] | ||
Principal received | 0 | 0 |
Impact of discounting and accretion | 19 | 14 |
Accumulated fixed interest expense accrual | 0 | 0 |
Accumulated variable interest expense accrual | 0 | 0 |
Repayment | (500) | (250) |
Liabilities arising from financing activities at end of period | 493 | 974 |
EIB Loan | ||
Changes in liabilities arising from financing activities [abstract] | ||
Accumulated variable interest expense accrual | 4,200 | 4,800 |
EIB Loan | Conditional Advances and Loans from Government and Public Authorities | ||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | ||
Liabilities arising from financing activities at beginning of period | 29,251 | 34,746 |
Changes in liabilities arising from financing activities [abstract] | ||
Principal received | 0 | 0 |
Impact of discounting and accretion | (5,817) | (1,736) |
Accumulated fixed interest expense accrual | 1,758 | 1,731 |
Accumulated variable interest expense accrual | 4,214 | (4,789) |
Repayment | (3,033) | (700) |
Liabilities arising from financing activities at end of period | 26,374 | 29,251 |
Curadigm Bpifrance advance | Conditional Advances and Loans from Government and Public Authorities | ||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | ||
Liabilities arising from financing activities at beginning of period | 285 | 0 |
Changes in liabilities arising from financing activities [abstract] | ||
Principal received | 0 | 350 |
Impact of discounting and accretion | 16 | (65) |
Accumulated fixed interest expense accrual | 0 | 0 |
Accumulated variable interest expense accrual | 0 | 0 |
Repayment | 0 | 0 |
Liabilities arising from financing activities at end of period | € 300 | € 285 |
Financial liabilities - Discl_2
Financial liabilities - Disclosure of Detailed Information about Bank Loan (Details) - EUR (€) € in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Jul. 10, 2020 | Jun. 30, 2020 | |
Long-term borrowings | ||||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | ||||
Liabilities arising from financing activities at beginning of period | € 10,064 | € 0 | ||
Changes in liabilities arising from financing activities [abstract] | ||||
Principal received | 3 | 10,000 | ||
Impact of discounting and accretion | 146 | 47 | ||
Accumulated fixed interest expense accrual | (145) | 17 | ||
Liabilities arising from financing activities at end of period | € 10,068 | € 10,064 | ||
PGE Loan, HSBC France | ||||
Changes in liabilities arising from financing activities [abstract] | ||||
Borrowing, guarantee fee | 0.25% | 0.25% | ||
Borrowings, interest rate | 0.31% | |||
PGE Loan, HSBC France | Long-term borrowings | ||||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | ||||
Liabilities arising from financing activities at beginning of period | € 5,020 | € 0 | ||
Changes in liabilities arising from financing activities [abstract] | ||||
Principal received | 17 | 5,000 | ||
Impact of discounting and accretion | 26 | 14 | ||
Accumulated fixed interest expense accrual | (33) | 7 | ||
Liabilities arising from financing activities at end of period | € 5,030 | € 5,020 | ||
PGE Loan, BPI France | ||||
Changes in liabilities arising from financing activities [abstract] | ||||
Borrowing, guarantee fee | 0.25% | 0.25% | 1.61% | |
Borrowings, interest rate | 1.36% | 1.36% | 2.25% | |
PGE Loan, BPI France | Long-term borrowings | ||||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | ||||
Liabilities arising from financing activities at beginning of period | € 5,044 | € 0 | ||
Changes in liabilities arising from financing activities [abstract] | ||||
Principal received | (14) | 5,000 | ||
Impact of discounting and accretion | 120 | 34 | ||
Accumulated fixed interest expense accrual | (112) | 10 | ||
Liabilities arising from financing activities at end of period | € 5,038 | € 5,044 |
Financial liabilities - Discl_3
Financial liabilities - Disclosure of Reconciliation of Changes in Lease Liabilities (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | |||
Fixed interest expense | € 288 | € 333 | € 359 |
Lease liabilities | |||
Summary Of Conditional Advances, Banks Loans And Loans [Line Items] | |||
Liabilities arising from financing activities at beginning of period | 6,188 | 6,405 | |
New lease contracts | 1,476 | 521 | |
Impact of discounting of the new lease contracts | (110) | (94) | |
Fixed interest expense | 288 | 333 | |
Repayment of lease | (1,195) | (928) | |
Early termination of lease contracts | (128) | (49) | |
Liabilities arising from financing activities at end of period | € 6,519 | € 6,188 | € 6,405 |
Financial liabilities - Discl_4
Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details) € in Thousands | Jul. 10, 2020 | Jun. 30, 2020 | Dec. 31, 2021EUR (€)borrowing | Dec. 31, 2020 |
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowing, number of PGE | borrowing | 2 | |||
Less than 1 year | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Lease liabilities | € 1,126 | |||
Total | 8,204 | |||
Between 1 and 3 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Lease liabilities | 2,252 | |||
Total | 37,747 | |||
Between 3 and 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Lease liabilities | 2,247 | |||
Total | 7,346 | |||
More than 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Lease liabilities | 1,714 | |||
Total | 1,714 | |||
Bpifrance | Less than 1 year | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 300 | |||
Bpifrance | Between 1 and 3 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 1,300 | |||
Bpifrance | Between 3 and 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 808 | |||
Bpifrance | More than 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
Interest-free Bpifrance loan | Less than 1 year | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 500 | |||
Interest-free Bpifrance loan | Between 1 and 3 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
Interest-free Bpifrance loan | Between 3 and 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
Interest-free Bpifrance loan | More than 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
Curadigm interest-free Bpifrance advance | Less than 1 year | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
Curadigm interest-free Bpifrance advance | Between 1 and 3 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 200 | |||
Curadigm interest-free Bpifrance advance | Between 3 and 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 150 | |||
Curadigm interest-free Bpifrance advance | More than 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
HSBC "PGE" | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowing, deferment period | 1 year | |||
HSBC "PGE" | Less than 1 year | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 661 | |||
HSBC "PGE" | Between 1 and 3 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 2,572 | |||
HSBC "PGE" | Between 3 and 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 1,904 | |||
HSBC "PGE" | More than 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
Bpifrance "PGE" | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowing, maturity | 6 years | |||
Bpifrance "PGE" | Less than 1 year | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 425 | |||
Bpifrance "PGE" | Between 1 and 3 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 2,662 | |||
Bpifrance "PGE" | Between 3 and 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 2,237 | |||
Bpifrance "PGE" | More than 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
EIB fixed rate loan | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowing, maturity | 5 years | |||
Borrowing, deferment period | 1 year | |||
EIB fixed rate loan | Less than 1 year | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 5,192 | |||
EIB fixed rate loan | Between 1 and 3 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 28,762 | |||
EIB fixed rate loan | Between 3 and 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | 0 | |||
EIB fixed rate loan | More than 5 years | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowings | € 0 | |||
HSBC "PGE" and Bpifrance "PGE" | ||||
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items] | ||||
Borrowing, maturity | 5 years | |||
Borrowing, deferment period | 1 year |
Trade payables and other curr_3
Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Subclassifications of assets, liabilities and equities [abstract] | ||
Accrued expenses - clinical trials | € 1,486 | € 1,532 |
Trade payables & other accruals | 4,996 | 5,574 |
Total trade and other payables | € 6,482 | € 7,106 |
Trade payables and other curr_4
Trade payables and other current liabilities - Additional Information (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of Trade Payables and Other Current Liabilities [Line Items] | ||
Trade payables & other accruals | € 4,996 | € 5,574 |
Decrease in payroll tax and other payroll liabilities | 1,400 | |
Payroll tax and other payroll liabilities | 4,800 | 6,200 |
Deferred revenues and contract liabilities | 16,518 | € 0 |
ICON Plc | ||
Disclosure of Trade Payables and Other Current Liabilities [Line Items] | ||
Trade payables & other accruals | 447 | |
LianBio, NBTXR3 | ||
Disclosure of Trade Payables and Other Current Liabilities [Line Items] | ||
Deferred revenues and contract liabilities | € 16,500 |
Trade payables and other curr_5
Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Subclassifications of assets, liabilities and equities [abstract] | ||
Tax liabilities | € 258 | € 283 |
Payroll tax and other payroll liabilities | 4,820 | 6,248 |
Other payables | 453 | 491 |
Other current liabilities | € 5,531 | € 7,022 |
Trade payables and other curr_6
Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Subclassifications of assets, liabilities and equities [abstract] | ||
Deferred revenues and contract liabilities | € 16,518 | € 0 |
Financial instruments include_3
Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | € 84,440 | € 119,717 |
Total financial assets, at fair value | 84,440 | 119,717 |
Total financial liabilities | 52,503 | 56,085 |
Total financial liabilities, at fair value | 52,503 | 56,085 |
Financial liabilities at amortised cost | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial liabilities | 52,503 | 56,085 |
Non-current financial liabilities | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial liabilities | 38,733 | 44,107 |
Total financial liabilities, at fair value | 38,733 | 44,107 |
Non-current financial liabilities | Financial liabilities at amortised cost | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial liabilities | 38,733 | 44,107 |
Current financial liabilities | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial liabilities | 7,288 | 4,872 |
Total financial liabilities, at fair value | 7,288 | 4,872 |
Current financial liabilities | Financial liabilities at amortised cost | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial liabilities | 7,288 | 4,872 |
Trade payables and other payables | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial liabilities | 6,482 | 7,106 |
Total financial liabilities, at fair value | 6,482 | 7,106 |
Trade payables and other payables | Financial liabilities at amortised cost | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial liabilities | 6,482 | 7,106 |
Non-current financial assets | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | 519 | 505 |
Total financial assets, at fair value | 519 | 505 |
Trade receivables | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | 0 | 62 |
Total financial assets, at fair value | 0 | 62 |
Cash and cash equivalents | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | 83,921 | 119,151 |
Total financial assets, at fair value | 83,921 | 119,151 |
Financial assets carried at fair value through profit or loss | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | 97 | 104 |
Financial assets carried at fair value through profit or loss | Non-current financial assets | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | 97 | 104 |
Financial assets at amortised cost | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | 84,343 | 119,613 |
Financial assets at amortised cost | Non-current financial assets | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | 421 | 401 |
Financial assets at amortised cost | Trade receivables | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | 0 | 62 |
Financial assets at amortised cost | Cash and cash equivalents | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total financial assets | € 83,921 | € 119,151 |
Financial instruments include_4
Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details) - Currency risk - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of detailed information about financial instruments [line items] | ||
Change in net income due to a 10% increase in exchange rate | € 45 | € 5 |
Change in net income due to a 10% decrease in exchange rate | (45) | (5) |
Change in equity due to a 10% increase in exchange rate | 87 | 124 |
Change in equity due to a 10% decrease in exchange rate | (87) | (124) |
USD / Euro exchange rate | ||
Disclosure of detailed information about financial instruments [line items] | ||
Change in net income due to a 10% increase in exchange rate | 45 | 5 |
Change in net income due to a 10% decrease in exchange rate | (45) | (5) |
Change in equity due to a 10% increase in exchange rate | 87 | 124 |
Change in equity due to a 10% decrease in exchange rate | € (87) | € (124) |
Financial instruments include_5
Financial instruments included in the statement of financial position and impact on income - Additional Information (Details) - EIB fixed rate loan € in Millions | 1 Months Ended |
Jul. 31, 2018EUR (€)tranche | |
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | |
Number of tranches | tranche | 3 |
Top of range | |
Disclosure Of Detailed Information About Financial Liabilities [Line Items] | |
Notional amount | € | € 40 |
Revenues and other income - Add
Revenues and other income - Additional Information (Details) € in Thousands, $ in Millions | Jun. 15, 2021USD ($) | Jun. 30, 2021EUR (€) | Jun. 30, 2021USD ($) | May 31, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2016USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2012USD ($) | Jun. 30, 2020EUR (€) |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||
Research tax credit utilization period | 3 years | |||||||||||
Revenues | € 10 | € 50 | € 68 | |||||||||
Subsidies | € 126 | € 526 | € 20 | |||||||||
Percentage of employees' net wages received via subsidies from French government | 84.00% | |||||||||||
PGE Loan, BPI France | ||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||
Subsidies | € 187 | |||||||||||
Notional amount | 350 | € 5,000 | ||||||||||
FRANCE | ||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||
Subsidies | € 312 | |||||||||||
PharmaEngine, NBTWR3 | ||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||
Upfront payment received | $ | $ 1 | |||||||||||
Development milestones payments received | $ | $ 1 | $ 1 | ||||||||||
PharmaEngine, NBTWR3 | Revenue by type | ||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||
Concentration risk percentage | 100.00% | 100.00% | 100.00% | |||||||||
LianBio, NBTXR3 | ||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||
Upfront payment received | $ 20 | € 16,500 | $ 20 | $ 20 | ||||||||
Minimum threshold to provide additional know-how to third party under collaboration agreement | 80.00% | |||||||||||
Milestones achievement, period | 18 months | |||||||||||
LianBio, NBTXR3 | Maximum | ||||||||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||||||
Potential development and commercial milestones payments | $ | $ 220 | $ 220 |
Revenues and other income - Sch
Revenues and other income - Schedule of Revenues and Other Income (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Revenues | € 10 | € 50 | € 68 |
Research tax credit | 2,490 | 1,927 | 2,437 |
Subsidies | 126 | 526 | 20 |
Other | 21 | 10 | 17 |
Other income | 2,637 | 2,462 | 2,473 |
Total revenues and other income | 2,647 | 2,512 | 2,541 |
Services | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Revenues | 5 | 50 | 40 |
Other sales | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Revenues | € 5 | € 0 | € 28 |
Operating expenses - Summary of
Operating expenses - Summary of Research and Development Expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Analysis of income and expense [abstract] | |||
Purchases, sub-contracting and other expenses | € (19,562) | € (12,734) | € (16,804) |
Payroll costs (including share-based payments) | (9,605) | (10,306) | (11,980) |
Depreciation, amortization, and provision expenses | (1,211) | (1,290) | (1,627) |
Research and development expenses | € (30,378) | € (24,330) | € (30,411) |
Operating expenses - Research a
Operating expenses - Research and Development, Additional Information (Details) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021EUR (€)employee | Dec. 31, 2020EUR (€)employee | Dec. 31, 2019EUR (€)employee | |
Disclosure Of Operating Expenses [Line Items] | |||
Decrease in employee benefit expense | € | € 774 | ||
Decrease in employee benefit expense, percentage | 8.00% | ||
End-of-period headcount | employee | 100 | 90 | 110 |
Increase (decrease) in number of employees | employee | 10 | ||
Share-based payments | € | € 3,201 | € 2,924 | € 4,320 |
R&D | |||
Disclosure Of Operating Expenses [Line Items] | |||
Increase in purchases, sub-contracting and other expenses | € | € 6,900 | ||
Increase in purchases, sub-contracting and other expenses, percentage | 54.00% | ||
End-of-period headcount | employee | 75 | 66 | 81 |
Increase (decrease) in number of employees | employee | 9 | (15) | 2 |
Share-based payments | € | € 677 | € 629 | € 902 |
Operating expenses - Summary _2
Operating expenses - Summary of Selling, General and Administrative Expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Analysis of income and expense [abstract] | |||
Purchases, fees and other expenses | € (9,638) | € (6,482) | € (9,435) |
Payroll costs (including share-based payments) | (9,379) | (7,789) | (9,205) |
Depreciation, amortization and provision expenses | (417) | (340) | (270) |
Total SG&A expenses | € (19,434) | € (14,611) | € (18,909) |
Operating expenses - Selling, G
Operating expenses - Selling, General and Administrative, Additional Information (Details) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021EUR (€)employeefactor | Dec. 31, 2020EUR (€)employee | Dec. 31, 2019EUR (€)employee | |
Disclosure Of Operating Expenses [Line Items] | |||
Number of impacts | factor | 2 | ||
Short-term employee benefits expense | € 15,700 | € 15,100 | € 16,800 |
Increase in employee benefit expense | € (774) | ||
Increase in employee benefit expense, percentage | (8.00%) | ||
End-of-period headcount | employee | 100 | 90 | 110 |
Increase in number of employees | employee | 10 | ||
Share-based payments | € 3,201 | € 2,924 | € 4,320 |
Selling, general and administrative expense | |||
Disclosure Of Operating Expenses [Line Items] | |||
Increase in rent, fees, and other expenses | € 3,156 | ||
Increase in rent, fees, and other expenses, percentage | 49.00% | ||
Increase in employee benefit expense | € 1,600 | ||
Increase in employee benefit expense, percentage | 21.00% | ||
End-of-period headcount | employee | 25 | 24 | 29 |
Increase in number of employees | employee | 6 | ||
Share-based payments | € 2,500 | € 2,300 | € 3,400 |
Operating expenses - Summary _3
Operating expenses - Summary of Payroll Costs (Details) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021EUR (€)employee | Dec. 31, 2020EUR (€)employee | Dec. 31, 2019EUR (€)employee | |
Analysis of income and expense [abstract] | |||
Wages and salaries | € (11,391) | € (11,141) | € (11,876) |
Payroll taxes | (4,308) | (3,953) | (4,913) |
Share-based payments | (3,201) | (2,924) | (4,320) |
Retirement benefit obligations | (84) | (76) | (76) |
Total payroll costs | € (18,984) | € (18,094) | € (21,185) |
Average headcount | employee | 96 | 97 | 112 |
End-of-period headcount | employee | 100 | 90 | 110 |
Operating expenses - Payroll Co
Operating expenses - Payroll Costs, Additional Information (Details) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021EUR (€)employee | Dec. 31, 2020EUR (€)employee | Dec. 31, 2019EUR (€)employee | |
Analysis of income and expense [abstract] | |||
End-of-period headcount | employee | 100 | 90 | 110 |
Increase in number of employees | employee | 10 | ||
Short-term employee benefits expense | € | € 15,700 | € 15,100 | € 16,800 |
Share-based payments | € | € 3,201 | € 2,924 | € 4,320 |
Operating expenses - Summary _4
Operating expenses - Summary of Depreciation, Amortization and Provision Expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure Of Operating Expenses [Line Items] | |||
Amortization expense of intangible assets | € (45) | € (176) | € (292) |
Amortization expense of tangible assets | (1,515) | (1,579) | (1,478) |
Utilization of provisions | 145 | 55 | |
Provision for charges | (68) | (40) | (164) |
Reversal of provision for disputes | 19 | ||
Total depreciation, amortization and provision expenses | (1,628) | (1,630) | (1,879) |
R&D | |||
Disclosure Of Operating Expenses [Line Items] | |||
Amortization expense of intangible assets | (34) | (152) | (289) |
Amortization expense of tangible assets | (1,109) | (1,250) | (1,208) |
Utilization of provisions | 145 | 0 | |
Provision for charges | (68) | 0 | (112) |
Reversal of provision for disputes | 0 | ||
Total depreciation, amortization and provision expenses | (1,211) | (1,257) | (1,609) |
SG&A | |||
Disclosure Of Operating Expenses [Line Items] | |||
Amortization expense of intangible assets | (10) | (23) | (3) |
Amortization expense of tangible assets | (406) | (329) | (270) |
Utilization of provisions | 0 | 55 | |
Provision for charges | 0 | (40) | (52) |
Reversal of provision for disputes | 19 | ||
Total depreciation, amortization and provision expenses | € (416) | € (373) | € (270) |
Operating expenses - Summary _5
Operating expenses - Summary of Other Operating Income (Expense) (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Analysis of income and expense [abstract] | |||
Contract termination indemnity (PharmaEngine) | € (5,414) | € 0 | |
Total Other operating income and expenses | € (5,414) | € 0 | € 0 |
Operating expenses - Other Oper
Operating expenses - Other Operating Income (Expense), Additional Information (Details) € in Thousands, $ in Millions | 12 Months Ended | ||
Dec. 31, 2021EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2020EUR (€) | |
Disclosure Of Operating Expenses [Line Items] | |||
Contract termination indemnities | € 5,414 | € 0 | |
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | |||
Disclosure Of Operating Expenses [Line Items] | |||
Contract termination indemnities | € 5,400 | $ 6.5 |
Share-based payments - Addition
Share-based payments - Additional Information (Details) | Sep. 16, 2014€ / shares | Dec. 31, 2021plan€ / shares |
Disclosure Of Detailed Information About Share-based Payments [Line Items] | ||
Number of preceding trading days taken into account in the determination of the share price on the grant date | 20 days | |
BSPCE | ||
Disclosure Of Detailed Information About Share-based Payments [Line Items] | ||
Number of share-based payment arrangement plans | 9 | |
BSA | ||
Disclosure Of Detailed Information About Share-based Payments [Line Items] | ||
Number of share-based payment arrangement plans | 12 | |
OSA | ||
Disclosure Of Detailed Information About Share-based Payments [Line Items] | ||
Number of share-based payment arrangement plans | 9 | |
AGA | ||
Disclosure Of Detailed Information About Share-based Payments [Line Items] | ||
Number of share-based payment arrangement plans | 2 | |
BSA 2014 | ||
Disclosure Of Detailed Information About Share-based Payments [Line Items] | ||
Exercise price (in euros per share) | € / shares | € 17.67 | € 40 |
Share-based payments - Disclosu
Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Oustanding (Details) | Apr. 20, 2021shares€ / shares | Apr. 01, 2021shares | Mar. 17, 2021shares | Jul. 27, 2020shares | Mar. 17, 2020shares€ / shares | Mar. 11, 2020shares€ / shares | Mar. 29, 2019shares€ / shares | Jul. 27, 2018shares€ / shares | Mar. 06, 2018shares€ / shares | Jan. 07, 2017shares€ / shares | Nov. 03, 2016shares€ / shares | Feb. 02, 2016shares€ / shares | Jun. 25, 2015shares€ / shares | Jun. 10, 2015shares€ / shares | Feb. 10, 2015shares€ / shares | Sep. 16, 2014shares€ / shares | Aug. 28, 2013shares€ / shares | Apr. 10, 2013shares€ / shares | Dec. 18, 2012shares€ / shares | May 04, 2012shares€ / shares | Dec. 31, 2021shares€ / shares | Dec. 31, 2020shares | Dec. 31, 2019shares |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards outstanding (in shares) | 2,972,860 | 2,414,654 | 2,338,013 | ||||||||||||||||||||
BSPCE | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards outstanding (in shares) | 715,291 | 718,767 | 751,585 | ||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 3,476 | 32,818 | |||||||||||||||||||||
BSPCE 2012-2 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 100,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6.63 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 100,000 | 100,000 | 100,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSPCE 08-2013 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 50,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 5.92 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 50,000 | 50,000 | 50,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSPCE 09-2014 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 97,200 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 18.68 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 86,150 | 86,150 | 92,100 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 11,050 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 5,950 | |||||||||||||||||||||
BSPCE 2015-1 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 71,650 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 18.57 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 68,450 | 68,450 | 70,950 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 3,200 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 2,500 | |||||||||||||||||||||
BSPCE 2015-3 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 53,050 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 20.28 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 30,350 | 30,700 | 38,400 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 22,700 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 350 | 7,700 | |||||||||||||||||||||
BSPCE 2016 Ordinary | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 126,400 | ||||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 14.46 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 100,567 | ||||||||||||||||||||||
Number of awards, exercised (in shares) | 333 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 25,500 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 350 | ||||||||||||||||||||||
BSPCE 2016 Performance | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 129,250 | ||||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 14.46 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 100,274 | ||||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 28,976 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 1,426 | ||||||||||||||||||||||
BSPCE 2017 Ordinary | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 117,650 | ||||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 15.93 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 99,500 | ||||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 18,150 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 1,350 | ||||||||||||||||||||||
BSPCE 2017 Performance | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 80,000 | ||||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 15.93 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 80,000 | ||||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | ||||||||||||||||||||||
BSA | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 78,103 | 18,000 | |||||||||||||||||||||
Number of awards outstanding (in shares) | 263,251 | 263,028 | 251,028 | ||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 77,880 | 6,000 | |||||||||||||||||||||
BSA 04-12 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 52,500 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0.60 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 30,000 | 30,000 | 30,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 22,500 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2013 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 10,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 2.50 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 6.37 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 6,000 | 6,000 | 6,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 4,000 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2014 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 14,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 4.87 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 17.67 | € 40 | |||||||||||||||||||||
Number of awards outstanding (in shares) | 10,000 | 10,000 | 10,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 4,000 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2015-1 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 26,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 4.87 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 17.67 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 21,000 | 21,000 | 21,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 5,000 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2015-2(a) | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 64,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 5 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 19.54 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 64,000 | 64,000 | 64,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2015-2(b) | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 6,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 2.80 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 19.54 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 0 | 0 | 6,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 6,000 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 6,000 | |||||||||||||||||||||
BSA 2016 ordinary | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 18,103 | ||||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 1.67 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.74 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 0 | ||||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 18,103 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 18,103 | ||||||||||||||||||||||
BSA 2016 performance | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 18,105 | ||||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 1.67 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.74 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 0 | ||||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 18,105 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 18,105 | ||||||||||||||||||||||
BSA 2016-2 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 8,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 2.03 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 15.01 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 0 | 8,000 | 8,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 8,000 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 8,000 | 0 | |||||||||||||||||||||
BSA 2017 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 18,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 2.26 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 15.76 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 18,000 | 18,000 | 18,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2018-1 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 28,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 1.62 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.55 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 28,000 | 28,000 | 28,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2018-2 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 5,820 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 2.36 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 16.102 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 5,820 | 5,820 | 5,820 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2019-1 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 18,000 | 0 | 0 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 1.15 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | 11.66 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 18,000 | 18,000 | 18,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2020 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 18,000 | 0 | 18,000 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0.29 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | 6.59 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 18,000 | 18,000 | 0 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
BSA 2021 (a) | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 48,103 | 48,103 | |||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 2.95 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.47 | € 13.47 | |||||||||||||||||||||
Number of awards outstanding (in shares) | 14,431 | 0 | |||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 33,672 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 33,672 | ||||||||||||||||||||||
BSA 2021 (b) | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 30,000 | 30,000 | |||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0.68 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 13.64 | € 13.64 | |||||||||||||||||||||
Number of awards outstanding (in shares) | 30,000 | 0 | |||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | ||||||||||||||||||||||
AGA | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 362,515 | 50,000 | |||||||||||||||||||||
Number of awards outstanding (in shares) | 410,512 | 446,500 | 746,250 | ||||||||||||||||||||
Awards exercised during the period (in shares) | 393,750 | 322,083 | |||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 4,753 | 27,667 | |||||||||||||||||||||
AGA 2018-1 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 24,500 | 396,250 | 0 | 0 | |||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 0 | 24,500 | 355,250 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 340,583 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 24,500 | 316,083 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 55,667 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 14,667 | |||||||||||||||||||||
AGA 2018-2 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 6,000 | 6,000 | 0 | 0 | |||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 0 | 0 | 6,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 6,000 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 6,000 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
AGA 2019-1 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 369,250 | 438,250 | 0 | 0 | |||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 0 | 372,000 | 385,000 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 369,250 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 369,250 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 69,000 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 2,750 | 13,000 | |||||||||||||||||||||
AGA 2020 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 50,000 | 0 | 50,000 | ||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 50,000 | 50,000 | 0 | ||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | 0 | |||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 0 | 0 | |||||||||||||||||||||
AGA 2021 | |||||||||||||||||||||||
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding | |||||||||||||||||||||||
Number of awards issued (in shares) | 362,515 | 362,515 | |||||||||||||||||||||
Grant price (in euro per share) | € / shares | € 0 | ||||||||||||||||||||||
Exercise price (in euros per share) | € / shares | € 0 | ||||||||||||||||||||||
Number of awards outstanding (in shares) | 360,512 | 0 | |||||||||||||||||||||
Number of awards, exercised (in shares) | 0 | ||||||||||||||||||||||
Awards exercised during the period (in shares) | 0 | ||||||||||||||||||||||
Number of awards lapsed or cancelled (in shares) | 2,003 | ||||||||||||||||||||||
Number of awards lapsed or cancelled during the period (in shares) | 2,003 |
Share-based payments - Disclo_2
Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Oustanding (Details) | Jun. 21, 2021shares€ / shares | Apr. 20, 2021shares€ / shares | Mar. 11, 2020shares€ / shares | Oct. 24, 2019shares€ / shares | Mar. 29, 2019shares€ / shares | Mar. 06, 2018shares€ / shares | Jan. 07, 2017shares€ / shares | Nov. 03, 2016shares€ / shares | Feb. 02, 2016shares€ / shares | Dec. 31, 2021shares | Dec. 31, 2020shares | Dec. 31, 2019shares |
OSA | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 691,200 | 407,972 | ||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 1,583,806 | 986,359 | 589,150 | |||||||||
Number of options as of including options exercised during the period (in shares) | 0 | 0 | ||||||||||
Options lapsed or cancelled during the period (in shares) | 93,753 | 10,763 | ||||||||||
OSA 2016-1 Performance | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 6,400 | |||||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 13.05 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 400 | |||||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | |||||||||||
Number of options lapsed or cancelled (in shares) | 6,000 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 0 | |||||||||||
OSA 2016-2 | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 4,000 | 0 | 0 | |||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 14.26 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 4,000 | 4,000 | 4,000 | |||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | 0 | ||||||||||
Number of options lapsed or cancelled (in shares) | 0 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 0 | 0 | ||||||||||
OSA 2017 Ordinary | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 3,500 | |||||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 14.97 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 500 | |||||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | |||||||||||
Number of options lapsed or cancelled (in shares) | 3,000 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 0 | |||||||||||
OSA 2018 | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 62,000 | 0 | 0 | |||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 12.87 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 52,000 | 52,000 | 54,000 | |||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | 0 | ||||||||||
Number of options lapsed or cancelled (in shares) | 10,000 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 0 | 2,000 | ||||||||||
OSA 2019-1 | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 37,500 | 0 | 0 | |||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 11.08 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 28,250 | 28,750 | 30,250 | |||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | 0 | ||||||||||
Number of options lapsed or cancelled (in shares) | 9,250 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 500 | 1,500 | ||||||||||
OSA LLY 2019 | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 500,000 | 0 | 0 | |||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 6.41 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 500,000 | 500,000 | 500,000 | |||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | 0 | ||||||||||
Number of options lapsed or cancelled (in shares) | 0 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 0 | 0 | ||||||||||
OSA 2020 | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 407,972 | 0 | 407,972 | |||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 6.25 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 387,456 | 400,709 | 0 | |||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | 0 | ||||||||||
Number of options lapsed or cancelled (in shares) | 13,253 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 13,253 | 7,263 | ||||||||||
OSA 2021-04 | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 571,200 | 571,200 | ||||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 13.74 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 491,200 | 0 | ||||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | |||||||||||
Number of options lapsed or cancelled (in shares) | 80,000 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 80,000 | |||||||||||
OSA 2021-06 | ||||||||||||
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] | ||||||||||||
Number of options granted (in shares) | 120,000 | 120,000 | ||||||||||
Exercise price (euro per share) | € / shares | € 0 | |||||||||||
Exercise price (in euros per share) | € / shares | € 12.99 | |||||||||||
Number of share options outstanding in share-based payment arrangement (in shares) | 120,000 | 0 | ||||||||||
Number of options, exercised (in shares) | 0 | |||||||||||
Number of options as of including options exercised during the period (in shares) | 0 | |||||||||||
Number of options lapsed or cancelled (in shares) | 0 | |||||||||||
Options lapsed or cancelled during the period (in shares) | 0 |
Share-based payments - Disclo_3
Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details) - EUR (€) € / shares in Units, € in Thousands | Jun. 21, 2021 | Apr. 20, 2021 | Mar. 17, 2020 | Mar. 11, 2020 | Mar. 29, 2019 | Jul. 27, 2018 | Mar. 06, 2018 | Jan. 07, 2017 | Nov. 03, 2016 | Feb. 02, 2016 | Jun. 25, 2015 | Jun. 10, 2015 | Feb. 10, 2015 | Sep. 16, 2014 | Aug. 28, 2013 | Apr. 10, 2013 | Dec. 18, 2012 | May 04, 2012 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Expense for the year | € 3,202 | € 2,924 | € 4,320 | ||||||||||||||||||
BSPCE | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Expense for the year | 32 | 107 | 175 | ||||||||||||||||||
BSPCE 2012-2 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 5.26 | ||||||||||||||||||||
Exercise price (in euro per share) | € 5.26 | ||||||||||||||||||||
Volatility | 41.00% | ||||||||||||||||||||
Maturity (in years) | 3 years 5 months 26 days | ||||||||||||||||||||
Risk-free rate | 0.20% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 307 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 2012-2 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 6.65 | ||||||||||||||||||||
Exercise price (in euro per share) | € 6.63 | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 288 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 2012-2 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 44.30% | ||||||||||||||||||||
Risk-free rate | 0.84% | ||||||||||||||||||||
BSPCE 2012-2 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 47.60% | ||||||||||||||||||||
Risk-free rate | 1.22% | ||||||||||||||||||||
BSPCE 2012-2 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
BSPCE 2012-2 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 7 years 3 months 18 days | ||||||||||||||||||||
BSPCE 09-2014 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 6.30 | ||||||||||||||||||||
Exercise price (in euro per share) | € 6.30 | ||||||||||||||||||||
Volatility | 56.00% | ||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
Risk-free rate | 0.90% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 167 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 08-2013 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 6.30 | ||||||||||||||||||||
Exercise price (in euro per share) | € 5.92 | ||||||||||||||||||||
Volatility | 256.00% | ||||||||||||||||||||
Maturity (in years) | 7 years | ||||||||||||||||||||
Risk-free rate | 0.90% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 152 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 09-2014 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 18.68 | ||||||||||||||||||||
Exercise price (in euro per share) | € 18.68 | ||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
Risk-free rate | 0.64% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 932 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 09-2014 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 6 months | ||||||||||||||||||||
BSPCE 09-2014 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years | ||||||||||||||||||||
BSPCE 09-2014 | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years 6 months | ||||||||||||||||||||
BSPCE 2015-1 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 18.57 | ||||||||||||||||||||
Exercise price (in euro per share) | € 18.57 | ||||||||||||||||||||
Risk-free rate | 0.39% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 50 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 2015-1 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
BSPCE 2015-1 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 62.00% | ||||||||||||||||||||
BSPCE 2015-1 | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 61.00% | ||||||||||||||||||||
BSPCE 2015-1 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 6 months | ||||||||||||||||||||
BSPCE 2015-1 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years | ||||||||||||||||||||
BSPCE 2015-1 | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years 6 months | ||||||||||||||||||||
BSPCE 2015-2 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 18.57 | ||||||||||||||||||||
Exercise price (in euro per share) | € 18.57 | ||||||||||||||||||||
Risk-free rate | 0.39% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 650 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 2015-2 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
BSPCE 2015-2 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 62.00% | ||||||||||||||||||||
BSPCE 2015-2 | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 61.00% | ||||||||||||||||||||
BSPCE 2015-2 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 6 months | ||||||||||||||||||||
BSPCE 2015-2 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years | ||||||||||||||||||||
BSPCE 2015-2 | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years 6 months | ||||||||||||||||||||
BSPCE 2015-3 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 20.28 | ||||||||||||||||||||
Exercise price (in euro per share) | € 20.28 | ||||||||||||||||||||
Risk-free rate | 0.56% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 483 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 2015-3 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 61.00% | ||||||||||||||||||||
BSPCE 2015-3 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 62.00% | ||||||||||||||||||||
BSPCE 2015-3 | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 61.00% | ||||||||||||||||||||
BSPCE 2015-3 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 6 months | ||||||||||||||||||||
BSPCE 2015-3 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years | ||||||||||||||||||||
BSPCE 2015-3 | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years 6 months | ||||||||||||||||||||
BSPCE 2016 Ordinary | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 14.46 | ||||||||||||||||||||
Exercise price (in euro per share) | € 14.46 | ||||||||||||||||||||
Risk-free rate | 0.32% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 1,080 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 10 | ||||||||||||||||||
BSPCE 2016 Ordinary | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 59.00% | ||||||||||||||||||||
BSPCE 2016 Ordinary | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 62.00% | ||||||||||||||||||||
BSPCE 2016 Ordinary | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 60.00% | ||||||||||||||||||||
BSPCE 2016 Ordinary | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 6 months | ||||||||||||||||||||
BSPCE 2016 Ordinary | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years | ||||||||||||||||||||
BSPCE 2016 Ordinary | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years 6 months | ||||||||||||||||||||
BSPCE 2016 Performance | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 14.46 | ||||||||||||||||||||
Exercise price (in euro per share) | € 14.46 | ||||||||||||||||||||
Volatility | 59.00% | ||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
Risk-free rate | 0.19% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 1,212 | ||||||||||||||||||||
Expense for the year | 32 | 99 | 79 | ||||||||||||||||||
BSPCE 2017 Ordinary | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 15.93 | ||||||||||||||||||||
Exercise price (in euro per share) | € 15.93 | ||||||||||||||||||||
Risk-free rate | 0.23% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 1,000 | ||||||||||||||||||||
Expense for the year | 0 | 8 | 86 | ||||||||||||||||||
BSPCE 2017 Ordinary | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
BSPCE 2017 Ordinary | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 61.00% | ||||||||||||||||||||
BSPCE 2017 Ordinary | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 59.00% | ||||||||||||||||||||
BSPCE 2017 Ordinary | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 6 months | ||||||||||||||||||||
BSPCE 2017 Ordinary | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years | ||||||||||||||||||||
BSPCE 2017 Ordinary | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 6 years 6 months | ||||||||||||||||||||
BSPCE 2017 Performance | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 15.93 | ||||||||||||||||||||
Exercise price (in euro per share) | € 15.93 | ||||||||||||||||||||
Volatility | 59.00% | ||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
Risk-free rate | 0.11% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 622 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 2017 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 15.93 | ||||||||||||||||||||
Exercise price (in euro per share) | € 15.93 | ||||||||||||||||||||
Volatility | 59.00% | ||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
Risk-free rate | 0.11% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 627 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSPCE 2017 Project | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 15.93 | ||||||||||||||||||||
Exercise price (in euro per share) | € 15.93 | ||||||||||||||||||||
Volatility | 59.00% | ||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
Risk-free rate | 0.11% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 94 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Expense for the year | 44 | 19 | (16) | ||||||||||||||||||
BSA 04-12 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 6 | ||||||||||||||||||||
Exercise price (in euro per share) | € 6 | ||||||||||||||||||||
Volatility | 49.00% | ||||||||||||||||||||
Maturity (in years) | 10 years | ||||||||||||||||||||
Risk-free rate | 0.96% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 183 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2013 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 6.30 | ||||||||||||||||||||
Exercise price (in euro per share) | € 6.37 | ||||||||||||||||||||
Volatility | 156.00% | ||||||||||||||||||||
Maturity (in years) | 6 years | ||||||||||||||||||||
Risk-free rate | 0.90% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 1 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2014 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 18.68 | ||||||||||||||||||||
Exercise price (in euro per share) | € 17.67 | ||||||||||||||||||||
Volatility | 57.00% | ||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
Risk-free rate | 0.41% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 0 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2015-1 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 17.67 | ||||||||||||||||||||
Exercise price (in euro per share) | € 17.67 | ||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 63 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2015-1 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.26% | ||||||||||||||||||||
BSA 2015-1 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.27% | ||||||||||||||||||||
BSA 2015-2(a) | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 17.67 | ||||||||||||||||||||
Exercise price (in euro per share) | € 19.54 | ||||||||||||||||||||
Risk-free rate | 0.39% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 16 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2015-2(a) | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
BSA 2015-2(a) | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
BSA 2015-2(a) | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 57.00% | ||||||||||||||||||||
BSA 2015-2(a) | Tranche four | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
BSA 2015-2(a) | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years | ||||||||||||||||||||
BSA 2015-2(a) | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 1 month 6 days | ||||||||||||||||||||
BSA 2015-2(a) | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 3 months 18 days | ||||||||||||||||||||
BSA 2015-2(a) | Tranche four | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 5 years 4 months 24 days | ||||||||||||||||||||
BSA 2015-2(b) | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 19.54 | ||||||||||||||||||||
Exercise price (in euro per share) | € 19.54 | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 284 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2015-2(b) | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 58.00% | ||||||||||||||||||||
Risk-free rate | 0.25% | ||||||||||||||||||||
BSA 2015-2(b) | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Volatility | 60.00% | ||||||||||||||||||||
Risk-free rate | 0.91% | ||||||||||||||||||||
BSA 2015-2(b) | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 4 years 7 months 6 days | ||||||||||||||||||||
BSA 2015-2(b) | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 9 years 7 months 6 days | ||||||||||||||||||||
BSA 2016 ordinary | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 13.74 | ||||||||||||||||||||
Exercise price (in euro per share) | € 13.74 | ||||||||||||||||||||
Volatility | 57.00% | ||||||||||||||||||||
Maturity (in years) | 2 years 4 months 24 days | ||||||||||||||||||||
Risk-free rate | 0.00% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 37 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2016 performance | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 13.74 | ||||||||||||||||||||
Exercise price (in euro per share) | € 13.74 | ||||||||||||||||||||
Volatility | 57.00% | ||||||||||||||||||||
Maturity (in years) | 2 years 4 months 24 days | ||||||||||||||||||||
Risk-free rate | 0.00% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 143 | ||||||||||||||||||||
Expense for the year | 0 | 0 | (41) | ||||||||||||||||||
BSA 2016-2 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 15.01 | ||||||||||||||||||||
Exercise price (in euro per share) | € 15.01 | ||||||||||||||||||||
Volatility | 57.00% | ||||||||||||||||||||
Maturity (in years) | 2 years 4 months 24 days | ||||||||||||||||||||
Risk-free rate | 0.00% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 0 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2017 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 15.76 | ||||||||||||||||||||
Exercise price (in euro per share) | € 15.76 | ||||||||||||||||||||
Volatility | 33.00% | ||||||||||||||||||||
Maturity (in years) | 2 years 4 months 24 days | ||||||||||||||||||||
Risk-free rate | 0.00% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 0 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2018-1 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 13.55 | ||||||||||||||||||||
Exercise price (in euro per share) | € 13.55 | ||||||||||||||||||||
Volatility | 38.00% | ||||||||||||||||||||
Maturity (in years) | 4 years 9 months 18 days | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 2 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2018-1 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.70% | ||||||||||||||||||||
BSA 2018-1 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.10% | ||||||||||||||||||||
BSA 2018-2 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 16.102 | ||||||||||||||||||||
Exercise price (in euro per share) | € 16.102 | ||||||||||||||||||||
Volatility | 38.00% | ||||||||||||||||||||
Maturity (in years) | 4 years 9 months 18 days | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 1 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
BSA 2018-2 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.70% | ||||||||||||||||||||
BSA 2018-2 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.10% | ||||||||||||||||||||
BSA 2019-1 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 11.66 | ||||||||||||||||||||
Exercise price (in euro per share) | € 11.66 | ||||||||||||||||||||
Volatility | 37.00% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 24 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 24 | ||||||||||||||||||
BSA 2019-1 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.16% | ||||||||||||||||||||
BSA 2019-1 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.50% | ||||||||||||||||||||
BSA 2019-1 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 9 years 9 months 18 days | ||||||||||||||||||||
BSA 2019-1 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Maturity (in years) | 9 years 10 months 24 days | ||||||||||||||||||||
BSA 2020 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 0 | ||||||||||||||||||||
Exercise price (in euro per share) | € 6.59 | ||||||||||||||||||||
Volatility | 38.00% | ||||||||||||||||||||
Maturity (in years) | 10 years | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 19 | ||||||||||||||||||||
Expense for the year | 0 | 19 | 0 | ||||||||||||||||||
BSA 2020 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.13%) | ||||||||||||||||||||
BSA 2020 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.07%) | ||||||||||||||||||||
BSA 2021 (a) | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 13.47 | ||||||||||||||||||||
Exercise price (in euro per share) | € 13.47 | ||||||||||||||||||||
Volatility | 39.10% | ||||||||||||||||||||
Maturity (in years) | 10 years | ||||||||||||||||||||
Risk-free rate | 0.27% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 44 | ||||||||||||||||||||
Expense for the year | 44 | 0 | 0 | ||||||||||||||||||
BSA 2021 (b) | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Exercise price (in euro per share) | € 13.64 | ||||||||||||||||||||
Maturity (in years) | 10 years | ||||||||||||||||||||
Risk-free rate | 0.27% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 0 | ||||||||||||||||||||
Expense for the year | 0 | 0 | 0 | ||||||||||||||||||
AGA | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Expense for the year | 2,366 | 2,289 | 3,618 | ||||||||||||||||||
AGA 2018-1 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 12.87 | ||||||||||||||||||||
Exercise price (in euro per share) | € 0 | ||||||||||||||||||||
Risk-free rate | 0.00% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 4,951 | ||||||||||||||||||||
Expense for the year | 16 | 268 | 2,052 | ||||||||||||||||||
AGA 2018-2 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 12.87 | ||||||||||||||||||||
Exercise price (in euro per share) | € 0 | ||||||||||||||||||||
Risk-free rate | 0.00% | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 75 | ||||||||||||||||||||
Expense for the year | 0 | 21 | 37 | ||||||||||||||||||
AGA 2019-1 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 10.90 | ||||||||||||||||||||
Exercise price (in euro per share) | € 0 | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 4,776 | ||||||||||||||||||||
Expense for the year | 422 | 1,884 | 1,529 | ||||||||||||||||||
AGA 2019-1 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.19% | ||||||||||||||||||||
AGA 2019-1 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | 0.141% | ||||||||||||||||||||
AGA 2020 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 5.90 | ||||||||||||||||||||
Exercise price (in euro per share) | € 0 | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 287 | ||||||||||||||||||||
Expense for the year | 144 | 116 | 0 | ||||||||||||||||||
AGA 2020 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.74%) | ||||||||||||||||||||
AGA 2020 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.69%) | ||||||||||||||||||||
AGA 2021 | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Share price (in euros) | € 13.60 | ||||||||||||||||||||
Exercise price (in euro per share) | € 0 | ||||||||||||||||||||
Yield | 0.00% | ||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 4,869 | ||||||||||||||||||||
Expense for the year | 1,784 | 0 | 0 | ||||||||||||||||||
AGA 2021 | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.63%) | ||||||||||||||||||||
AGA 2021 | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.59%) | ||||||||||||||||||||
OSA 2021-04 O | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 684 | ||||||||||||||||||||
Expense for the year | 188 | 0 | 0 | ||||||||||||||||||
OSA 2021-04 O | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.38%) | ||||||||||||||||||||
OSA 2021-04 O | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.33%) | ||||||||||||||||||||
OSA 2021-04 O | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.28%) | ||||||||||||||||||||
OSA 2021-06 O | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Value of initial plan (in thousands of euros) | € 246 | ||||||||||||||||||||
Expense for the year | € 79 | € 0 | € 0 | ||||||||||||||||||
OSA 2021-06 O | Tranche one | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.35%) | ||||||||||||||||||||
OSA 2021-06 O | Tranche two | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.30%) | ||||||||||||||||||||
OSA 2021-06 O | Tranche three | |||||||||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||||||||||
Risk-free rate | (0.26%) |
Share-based payments - Disclo_4
Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details) € / shares in Units, € in Thousands | Jun. 21, 2021EUR (€)yr€ / shares | Apr. 20, 2021EUR (€)yr€ / shares | Mar. 11, 2020EUR (€)yr€ / shares | Oct. 24, 2019EUR (€)yr€ / shares | Mar. 29, 2019EUR (€)yr€ / shares | Mar. 06, 2018EUR (€)yr€ / shares | Jan. 07, 2017EUR (€)yr€ / shares | Nov. 03, 2016EUR (€)yr€ / shares | Feb. 02, 2016EUR (€)yr€ / shares | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Expense for the year | € 3,202 | € 2,924 | € 4,320 | |||||||||
OSA | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Expense for the year | 760 | 509 | 543 | |||||||||
OSA 2016 Ordinary | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 13.05 | |||||||||||
Exercise price (in euros per share) | € / shares | € 13.05 | |||||||||||
Risk-free rate | 0.32% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 117 | |||||||||||
Expense for the year | 0 | 0 | 0 | |||||||||
OSA 2016 Ordinary | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 59.00% | |||||||||||
OSA 2016 Ordinary | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 62.00% | |||||||||||
OSA 2016 Ordinary | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 60.00% | |||||||||||
OSA 2016 Ordinary | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 5.5 | |||||||||||
OSA 2016 Ordinary | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6 | |||||||||||
OSA 2016 Ordinary | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6.5 | |||||||||||
OSA 2016-1 Performance | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 13.05 | |||||||||||
Exercise price (in euros per share) | € / shares | € 13.05 | |||||||||||
Volatility | 59.00% | |||||||||||
Maturity (in years) | yr | 5,000 | |||||||||||
Risk-free rate | 0.19% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 69 | |||||||||||
Expense for the year | 0 | 0 | 0 | |||||||||
OSA 2016-2 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 14.26 | |||||||||||
Exercise price (in euros per share) | € / shares | € 14.26 | |||||||||||
Risk-free rate | 0.04% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 27 | |||||||||||
Expense for the year | 0 | 0 | 3 | |||||||||
OSA 2016-2 | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 58.00% | |||||||||||
OSA 2016-2 | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 62.00% | |||||||||||
OSA 2016-2 | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 59.00% | |||||||||||
OSA 2016-2 | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 5.5 | |||||||||||
OSA 2016-2 | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6 | |||||||||||
OSA 2016-2 | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6.5 | |||||||||||
OSA 2017 Ordinary | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 15.93 | |||||||||||
Exercise price (in euros per share) | € / shares | € 14.97 | |||||||||||
Risk-free rate | 0.23% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 31 | |||||||||||
Expense for the year | 0 | 0 | 1 | |||||||||
OSA 2017 Ordinary | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 58.00% | |||||||||||
OSA 2017 Ordinary | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 61.00% | |||||||||||
OSA 2017 Ordinary | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 59.00% | |||||||||||
OSA 2017 Ordinary | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 5.5 | |||||||||||
OSA 2017 Ordinary | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6 | |||||||||||
OSA 2017 Ordinary | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6.5 | |||||||||||
OSA 2017 Performance | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 15.93 | |||||||||||
Exercise price (in euros per share) | € / shares | € 14.97 | |||||||||||
Volatility | 59.00% | |||||||||||
Maturity (in years) | yr | 5,000 | |||||||||||
Risk-free rate | 0.11% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 35 | |||||||||||
Expense for the year | 0 | 0 | 0 | |||||||||
OSA 2018 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 12.87 | |||||||||||
Exercise price (in euros per share) | € / shares | € 12.87 | |||||||||||
Volatility | 35.00% | |||||||||||
Risk-free rate | 0.00% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 252 | |||||||||||
Expense for the year | 0 | 7 | 66 | |||||||||
OSA 2018 | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 5.5 | |||||||||||
OSA 2018 | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6 | |||||||||||
OSA 2018 | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6.5 | |||||||||||
OSA 2019-1 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 11.08 | |||||||||||
Exercise price (in euros per share) | € / shares | € 11.08 | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 140 | |||||||||||
Expense for the year | 17 | 49 | 38 | |||||||||
OSA 2019-1 | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 38.10% | |||||||||||
Risk-free rate | 0.103% | |||||||||||
OSA 2019-1 | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 37.40% | |||||||||||
Risk-free rate | 0.149% | |||||||||||
OSA 2019-1 | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6 | |||||||||||
OSA 2019-1 | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6.5 | |||||||||||
OSA LLY 2019 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 6.41 | |||||||||||
Exercise price (in euros per share) | € / shares | € 6.41 | |||||||||||
Volatility | 37.00% | |||||||||||
Maturity (in years) | yr | 10,000 | |||||||||||
Risk-free rate | 0.40% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 252 | |||||||||||
Expense for the year | 0 | 0 | 436 | |||||||||
OSA 2020 | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 6.25 | |||||||||||
Exercise price (in euros per share) | € / shares | € 6.25 | |||||||||||
Volatility | 38.00% | |||||||||||
Maturity (in years) | yr | 10,000 | |||||||||||
Risk-free rate | 0.31% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 939 | |||||||||||
Expense for the year | 329 | 453 | 0 | |||||||||
OSA 2021-04 O | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 13.60 | |||||||||||
Exercise price (in euros per share) | € / shares | € 13.74 | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 684 | |||||||||||
Expense for the year | 188 | 0 | 0 | |||||||||
OSA 2021-04 O | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 38.90% | |||||||||||
OSA 2021-04 O | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 37.80% | |||||||||||
OSA 2021-04 O | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 38.30% | |||||||||||
OSA 2021-04 O | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 5.5 | |||||||||||
OSA 2021-04 O | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6 | |||||||||||
OSA 2021-04 O | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6.5 | |||||||||||
OSA 2021-04 P | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 13.60 | |||||||||||
Exercise price (in euros per share) | € / shares | € 13.74 | |||||||||||
Volatility | 39.10% | |||||||||||
Maturity (in years) | yr | 10,000 | |||||||||||
Risk-free rate | 0.03% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 1,816 | |||||||||||
Expense for the year | 131 | 0 | ||||||||||
OSA 2021-06 O | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 12.20 | |||||||||||
Exercise price (in euros per share) | € / shares | € 12.99 | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 246 | |||||||||||
Expense for the year | 79 | 0 | 0 | |||||||||
OSA 2021-06 O | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 39.20% | |||||||||||
OSA 2021-06 O | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 37.90% | |||||||||||
OSA 2021-06 O | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Volatility | 38.10% | |||||||||||
OSA 2021-06 O | Tranche one | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 5.5 | |||||||||||
OSA 2021-06 O | Tranche two | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6 | |||||||||||
OSA 2021-06 O | Tranche three | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Maturity (in years) | yr | 6.5 | |||||||||||
OSA 2021-06 P | ||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||
Share price (in euros) | € / shares | € 12.20 | |||||||||||
Exercise price (in euros per share) | € / shares | € 12.99 | |||||||||||
Volatility | 39.10% | |||||||||||
Maturity (in years) | yr | 10,000 | |||||||||||
Risk-free rate | 0.13% | |||||||||||
Yield | 0.00% | |||||||||||
Value of initial plan (in thousands of euros) | € 212 | |||||||||||
Expense for the year | € 16 | € 0 |
Net financial income (loss) - S
Net financial income (loss) - Summary of Net Financial Income (Loss) (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income, expense, gains or losses of financial instruments [abstract] | |||
Income from cash and cash equivalents | € 0 | € 0 | € 105 |
Foreign exchange gains | 6,347 | 104 | 599 |
Other financial income | 13 | 97 | 133 |
Total financial income | 6,360 | 201 | 837 |
Interest cost | (383) | 4,676 | (4,434) |
IFRS 16 related interests | (288) | (333) | (359) |
Foreign exchange losses | (109) | (1,697) | (176) |
Total financial expenses | (780) | 2,646 | (4,970) |
Financial income (loss) | € 5,580 | € 2,847 | € (4,133) |
Net financial income (loss) - A
Net financial income (loss) - Additional Information (Details) € in Thousands, $ in Millions | 12 Months Ended | |||
Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2020USD ($) | Dec. 31, 2019EUR (€) | |
Disclosure of financial instruments by type of interest rate [line items] | ||||
Interest cost | € (383) | € 4,676 | € (4,434) | |
Foreign exchange gains | 6,347 | 104 | € 599 | |
Foreign exchange losses | 1,700 | |||
Proceeds from issuing shares | $ | $ 113.3 | |||
EIB fixed rate loan | ||||
Disclosure of financial instruments by type of interest rate [line items] | ||||
Accumulated variable interest expense accrual | 4,200 | 4,800 | ||
Fixed interest rate | EIB fixed rate loan | ||||
Disclosure of financial instruments by type of interest rate [line items] | ||||
Interest expense on borrowings | € 1,800 | € 1,700 |
Income tax - Additional Informa
Income tax - Additional Information (Details) € in Millions, $ in Millions | 12 Months Ended | ||||||
Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2017 | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||||||
Unused tax losses | € 75.4 | € 60.2 | € 51 | ||||
Deferred tax rate | 25.80% | 26.50% | 25.49% | ||||
Unused tax losses | |||||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||||||
Unused tax losses | € 14 | € 59.6 | € 49.6 | ||||
FRANCE | Unused tax losses | |||||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||||||
Deferred tax liability (asset) | € 284 | € 235 | € 184.3 | ||||
UNITED STATES | Unused tax losses | |||||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||||||
Deferred tax liability (asset) | $ | $ 3.4 | $ 4.4 | $ 4.8 | ||||
Expiration period | 20 years |
Income tax - Schedule of Reconc
Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income taxes paid (refund) [abstract] | |||
Net loss | € (47,003) | € (33,590) | € (50,915) |
Effective tax expense | 5 | 9 | 3 |
Recurring loss before tax | € (47,058) | € (33,581) | € (50,912) |
Theoretical tax rate (statutory rate in France) | 26.50% | 28.00% | 31.00% |
Theoretical tax (benefit) expense | € (12,470) | € (9,403) | € (15,782) |
Share-based payment | 848 | 819 | 1,339 |
Other temporary differences | 117 | (6) | (1) |
Other non-taxable items | (644) | (540) | (736) |
Unrecognized tax losses | 12,154 | 9,138 | 15,177 |
Effective tax expense | € (5) | € (9) | € (3) |
Effective tax rate | 0.00% | 0.00% | 0.00% |
Loss per share - Schedule of Ba
Loss per share - Schedule of Basic and Diluted Loss Per Share (Details) - EUR (€) € / shares in Units, € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Earnings per share [abstract] | |||
Net loss for the period (in thousands of euros) | € (47,063) | € (33,590) | € (50,915) |
Weighted average number of shares (in shares) | 34,733,418,000 | 24,385,827,000 | 21,631,514,000 |
Basic loss per share (in euro per share) | € (1.35) | € (1.38) | € (2.35) |
Diluted loss per share (in euro per share) | € (1.35) | € (1.38) | € (2.35) |
Loss per share - Additional Inf
Loss per share - Additional Information (Details) | 12 Months Ended |
Dec. 31, 2021shares | |
Earnings per share [abstract] | |
Potential additional ordinary shares that are considered antidilutive (in shares) | 3,006,532 |
Commitments (Details)
Commitments (Details) € in Thousands, $ in Thousands | Feb. 03, 2020USD ($) | May 31, 2021USD ($) | Mar. 31, 2021USD ($) | Jan. 31, 2019USD ($)patient | Jul. 31, 2018 | Mar. 31, 2021USD ($) | Jun. 30, 2021EUR (€) | Dec. 31, 2021USD ($) | Dec. 31, 2021USD ($)lease_contract | Dec. 31, 2021EUR (€)lease_contract | Dec. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) |
Disclosure of contingent liabilities [line items] | ||||||||||||
Number of short term leases | lease_contract | 1 | 1 | ||||||||||
Annual short term lease expense | € | € 140 | |||||||||||
Annual lease expense | € | 10 | |||||||||||
Prepaid expenses | € | 2,213 | € 2,213 | € 2,217 | |||||||||
MD Anderson Cancer Center, NBTXR3 | ||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||
Number of patients | patient | 340 | |||||||||||
Contractual capital commitments | $ | $ 11,000 | |||||||||||
Upfront payment | $ | $ 1,000 | $ 1,000 | ||||||||||
Milestone payment, deferment period | 6 months | |||||||||||
Research expense since start of collaboration | € | 1,800 | |||||||||||
Prepaid expenses | € | 1,000 | 1,000 | € 1,600 | |||||||||
MD Anderson Cancer Center, NBTXR3 | Bottom of range | ||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||
Milestone payment increase | $ | $ 2,200 | |||||||||||
MD Anderson Cancer Center, NBTXR3 | Top of range | ||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||
Milestone payment increase | $ | 16,400 | |||||||||||
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | ||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||
Upfront payment | $ 4,000 | $ 2,500 | € 5,400 | $ 6,500 | $ 6,500 | 5,400 | ||||||
Milestone payment upon receipt of clinical study reports | $ | 1,000 | $ 1,000 | ||||||||||
Milestone payment upon second regulatory approval | $ | $ 5,000 | $ 5,000 | ||||||||||
Royalties agreement, period | 10 years | 10 years | ||||||||||
EIB fixed rate loan | ||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||
Royalties agreement, period | 6 years | |||||||||||
Minimum | EIB fixed rate loan | ||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||
Estimated financial effect of contingent liabilities | € | € 35,000 | € 35,000 |
Related parties (Details)
Related parties (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Related party transactions [abstract] | |||
Salaries, wages and benefits | € 1,245 | € 1,073 | € 1,306 |
Share-based payments | 2,018 | 1,723 | 2,066 |
Supervisory Board’s fees | 375 | 70 | 70 |
Total compensation to related parties | € 3,638 | € 2,866 | € 3,442 |
Subsequent events (Details)
Subsequent events (Details) - EUR (€) | Mar. 11, 2022 | Apr. 01, 2021 | Mar. 17, 2021 | Jul. 28, 2020 | Jul. 27, 2020 | Mar. 06, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Disclosure of non-adjusting events after reporting period [line items] | ||||||||||
Capital increase, net | € 11,077.5 | € 735 | € 180 | € 0 | € 102,942,000 | € 28,079,000 | ||||
Par value per share (euro per share) | € 0.03 | € 0.03 | € 0.03 | |||||||
Equity | € 26,790,000 | € 70,468,000 | € (1,908,000) | € 14,243,000 | ||||||
Major ordinary share transactions | ||||||||||
Disclosure of non-adjusting events after reporting period [line items] | ||||||||||
Par value per share (euro per share) | € 0.03 | |||||||||
Share capital Ordinary shares | ||||||||||
Disclosure of non-adjusting events after reporting period [line items] | ||||||||||
Capital increase, net | € 99,000 | € 9,000 | € 12,000 | € 361,000 | € 77,000 | |||||
Capital increase, net (in shares) | 3,300,000 | 6,000 | 316,083 | 393,750 | 12,017,083 | 2,566,666 | ||||
Equity | € 1,044,776.16 | € 1,032,963.66 | € 672,451.17 | € 589,000 | ||||||
Share capital Ordinary shares | Major ordinary share transactions | ||||||||||
Disclosure of non-adjusting events after reporting period [line items] | ||||||||||
Capital increase, net | € 1,500 | |||||||||
Capital increase, net (in shares) | 50,000 | |||||||||
Equity | € 1,046,276.16 | |||||||||
Share capital Ordinary shares | Major ordinary share transactions | AGA 2020 | ||||||||||
Disclosure of non-adjusting events after reporting period [line items] | ||||||||||
Capital increase, net (in shares) | 50,000 |